

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

| | | | |
|---|--|--|---|
| (51) International Patent Classification ⁶ : C07K 14/47, 14/00, 7/00, C12N 5/10, 15/10, 15/11, 15/12, 15/63, A61K 38/00 | | A1 | (11) International Publication Number: WO 99/26972 (43) International Publication Date: 3 June 1999 (03.06.99) |
| (21) International Application Number: PCT/US98/24614 | | (81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). | |
| (22) International Filing Date: 17 November 1998 (17.11.98) | | | |
| (30) Priority Data: 08/976,110 21 November 1997 (21.11.97) US 09/080,478 18 May 1998 (18.05.98) US 09/175,928 20 October 1998 (20.10.98) US | | | |
| (71) Applicant: GENETICS INSTITUTE, INC. [US/US]; 87 CambridgePark Drive, Cambridge, MA 02140 (US). | | | |
| (72) Inventors: JACOBS, Kenneth; 151 Beaumont Avenue, Newton, MA 02160 (US). MCCOY, John, M.; 56 Howard Street, Reading, MA 01867 (US). LAVALLIE, Edward, R.; 113 Ann Lee Road, Harvard, MA 01451 (US). COLLINS-RACIE, Lisa, A.; 124 School Street, Acton, MA 01720 (US). EVANS, Cheryl; 307 Brighton Drive, Beverly, MA 01915 (US). MERBERG, David; 2 Orchard Drive, Acton, MA 01720 (US). TREACY, Maurice; 93 Walcott Road, Chestnut Hill, MA 02167 (US). | | | |
| (74) Agent: SPRUNGER, Suzanne, A.; American Home Products Corporation, Patent & Trademark Dept. – 2B, One Campus Drive, Parsippany, NJ 07054 (US). | | | |

(54) Title: SECRETED PROTEINS AND POLYNUCLEOTIDES ENCODING THEM**(57) Abstract**

Novel polynucleotides and the proteins encoded thereby are disclosed.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

| | | | | | | | |
|----|--------------------------|----|---------------------------------------|----|---|----|--------------------------|
| AL | Albania | ES | Spain | LS | Lesotho | SI | Slovenia |
| AM | Armenia | FI | Finland | LT | Lithuania | SK | Slovakia |
| AT | Austria | FR | France | LU | Luxembourg | SN | Senegal |
| AU | Australia | GA | Gabon | LV | Latvia | SZ | Swaziland |
| AZ | Azerbaijan | GB | United Kingdom | MC | Monaco | TD | Chad |
| BA | Bosnia and Herzegovina | GE | Georgia | MD | Republic of Moldova | TG | Togo |
| BB | Barbados | GH | Ghana | MG | Madagascar | TJ | Tajikistan |
| BE | Belgium | GN | Guinea | MK | The former Yugoslav Republic of Macedonia | TM | Turkmenistan |
| BF | Burkina Faso | GR | Greece | ML | Mali | TR | Turkey |
| BG | Bulgaria | HU | Hungary | MN | Mongolia | TT | Trinidad and Tobago |
| BJ | Benin | IE | Ireland | MR | Mauritania | UA | Ukraine |
| BR | Brazil | IL | Israel | MW | Malawi | UG | Uganda |
| BY | Belarus | IS | Iceland | MX | Mexico | US | United States of America |
| CA | Canada | IT | Italy | NE | Niger | UZ | Uzbekistan |
| CF | Central African Republic | JP | Japan | NL | Netherlands | VN | Viet Nam |
| CG | Congo | KE | Kenya | NO | Norway | YU | Yugoslavia |
| CH | Switzerland | KG | Kyrgyzstan | NZ | New Zealand | ZW | Zimbabwe |
| CI | Côte d'Ivoire | KP | Democratic People's Republic of Korea | PL | Poland | | |
| CM | Cameroon | KR | Republic of Korea | PT | Portugal | | |
| CN | China | KZ | Kazakhstan | RO | Romania | | |
| CU | Cuba | LC | Saint Lucia | RU | Russian Federation | | |
| CZ | Czech Republic | LI | Liechtenstein | SD | Sudan | | |
| DE | Germany | LK | Sri Lanka | SE | Sweden | | |
| DK | Denmark | LR | Liberia | SG | Singapore | | |
| EE | Estonia | | | | | | |

5

SECRETED PROTEINS AND POLYNUCLEOTIDES ENCODING THEM

This application is a continuation-in-part of the following applications: Ser. No. 08/686,878, filed July 26, 1996; Ser. No. 08/702,081, filed August 23, 1996, which is a 10 continuation-in-part of Ser. No. 08/686,878; Ser. No. 08/721,489, filed September 27, 1996, which is a continuation-in-part of Ser. No. 08/686,878; and 08/721,924, filed September 27, 1996, which is a continuation-in-part of Ser. No. 08/686,878; all of which are incorporated by reference herein.

15

FIELD OF THE INVENTION

The present invention provides novel polynucleotides and proteins encoded by such polynucleotides, along with therapeutic, diagnostic and research utilities for these polynucleotides and proteins.

20

BACKGROUND OF THE INVENTION

Technology aimed at the discovery of protein factors (including e.g., cytokines, such as lymphokines, interferons, CSFs and interleukins) has matured rapidly over the past decade. The now routine hybridization cloning and expression cloning techniques 25 clone novel polynucleotides "directly" in the sense that they rely on information directly related to the discovered protein (i.e., partial DNA/amino acid sequence of the protein in the case of hybridization cloning; activity of the protein in the case of expression cloning). More recent "indirect" cloning techniques such as signal sequence cloning, which isolates DNA sequences based on the presence of a now well-recognized secretory leader 30 sequence motif, as well as various PCR-based or low stringency hybridization cloning techniques, have advanced the state of the art by making available large numbers of DNA/amino acid sequences for proteins that are known to have biological activity by virtue of their secreted nature in the case of leader sequence cloning, or by virtue of the cell or tissue source in the case of PCR-based techniques. It is to these proteins and the 35 polynucleotides encoding them that the present invention is directed.

SUMMARY OF THE INVENTION

In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:1;
- 5 (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:1 from nucleotide 44 to nucleotide 1204;
- (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:1 from nucleotide 1 to nucleotide 403;
- 10 (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone AJ26_3 deposited under accession number ATCC 98115;
- (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone AJ26_3 deposited under accession number ATCC 98115;
- 15 (f) a polynucleotide comprising the nucleotide sequence of the mature protein coding sequence of clone AJ26_3 deposited under accession number ATCC 98115;
- (g) a polynucleotide encoding the mature protein encoded by the cDNA insert of clone AJ26_3 deposited under accession number ATCC 98115;
- 20 (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:2;
- (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:2 having biological activity;
- 25 (j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;
- (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ; and
- (l) a polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides specified in (a)-(i).

30 Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:1 from nucleotide 44 to nucleotide 1204; the nucleotide sequence of SEQ ID NO:1 from nucleotide 1 to nucleotide 403; the nucleotide sequence of the full-length protein coding sequence of clone AJ26_3 deposited under accession number ATCC 98115; or the nucleotide sequence of the mature protein coding sequence of clone AJ26_3 deposited

under accession number ATCC 98115. In other preferred embodiments, the polynucleotide encodes the full-length or mature protein encoded by the cDNA insert of clone AJ26_3 deposited under accession number ATCC 98115. In yet other preferred embodiments, the present invention provides a polynucleotide encoding a protein 5 comprising the amino acid sequence of SEQ ID NO:2 from amino acid 1 to amino acid 120.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:1.

In other embodiments, the present invention provides a composition comprising 10 a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:2;
- (b) the amino acid sequence of SEQ ID NO:2 from amino acid 1 to amino acid 120;
- (c) fragments of the amino acid sequence of SEQ ID NO:2; and
- (d) the amino acid sequence encoded by the cDNA insert of clone AJ26_3 deposited under accession number ATCC 98115;

the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:2 or the amino acid sequence of SEQ ID NO:2 from amino acid 1 to amino acid 120.

20 In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:3;
- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:3 from nucleotide 928 to nucleotide 2541;
- (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:3 from nucleotide 988 to nucleotide 2541;
- (d) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:3 from nucleotide 684 to nucleotide 1128;
- (e) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone AJ172_2 deposited under accession number ATCC 98115;
- (f) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone AJ172_2 deposited under accession number ATCC 98115;

(g) a polynucleotide comprising the nucleotide sequence of the mature protein coding sequence of clone AJ172_2 deposited under accession number ATCC 98115;

5 (h) a polynucleotide encoding the mature protein encoded by the cDNA insert of clone AJ172_2 deposited under accession number ATCC 98115;

(i) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:4;

10 (j) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:4 having biological activity;

(k) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(h) above;

(l) a polynucleotide which encodes a species homologue of the protein of (i) or (j) above ; and

15 (m) a polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides specified in (a)-(j).

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:3 from nucleotide 928 to nucleotide 2541; the nucleotide sequence of SEQ ID NO:3 from nucleotide 988 to nucleotide 2541; the nucleotide sequence of SEQ ID NO:3 from nucleotide 684 to nucleotide 1128; the nucleotide sequence of the full-length protein coding sequence of clone AJ172_2 deposited under accession number ATCC 98115; or the nucleotide sequence of the mature protein coding sequence of clone AJ172_2 deposited under accession number ATCC 98115. In other preferred embodiments, the polynucleotide encodes the full-length or mature protein encoded by the cDNA insert of clone AJ172_2 deposited under accession number ATCC 98115. In yet other preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:4 from amino acid 1 to amino acid 67.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:3.

In other embodiments, the present invention provides a composition comprising 30 a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

(a) the amino acid sequence of SEQ ID NO:4;

(b) the amino acid sequence of SEQ ID NO:4 from amino acid 1 to amino acid 67;

(c) fragments of the amino acid sequence of SEQ ID NO:4; and
(d) the amino acid sequence encoded by the cDNA insert of clone AJ172_2 deposited under accession number ATCC 98115;
the protein being substantially free from other mammalian proteins. Preferably such 5 protein comprises the amino acid sequence of SEQ ID NO:4 or the amino acid sequence of SEQ ID NO:4 from amino acid 1 to amino acid 67.

In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

(a) a polynucleotide comprising the nucleotide sequence of SEQ ID 10 NO:6;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:6 from nucleotide 185 to nucleotide 385;
(c) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone AP224_2 deposited under accession 15 number ATCC 98115;
(d) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone AP224_2 deposited under accession number ATCC 98115;
(e) a polynucleotide comprising the nucleotide sequence of the mature protein coding sequence of clone AP224_2 deposited under accession number 20 ATCC 98115;
(f) a polynucleotide encoding the mature protein encoded by the cDNA insert of clone AP224_2 deposited under accession number ATCC 98115;
(g) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:7;
25 (h) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:7 having biological activity;
(i) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(f) above;
(j) a polynucleotide which encodes a species homologue of the protein 30 of (g) or (h) above ; and
(k) a polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides specified in (a)-(h).

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:6 from nucleotide 185 to nucleotide 385; the nucleotide sequence of the full-length

protein coding sequence of clone AP224_2 deposited under accession number ATCC 98115; or the nucleotide sequence of the mature protein coding sequence of clone AP224_2 deposited under accession number ATCC 98115. In other preferred embodiments, the polynucleotide encodes the full-length or mature protein encoded by the cDNA insert of 5 clone AP224_2 deposited under accession number ATCC 98115. In yet other preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:7 from amino acid 1 to amino acid 28.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:6, SEQ ID NO:5 or SEQ ID NO:8 .

10 In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:7;
- (b) the amino acid sequence of SEQ ID NO:7 from amino acid 1 to 15 amino acid 28;
- (c) fragments of the amino acid sequence of SEQ ID NO:7; and
- (d) the amino acid sequence encoded by the cDNA insert of clone AP224_2 deposited under accession number ATCC 98115;

the protein being substantially free from other mammalian proteins. Preferably such 20 protein comprises the amino acid sequence of SEQ ID NO:7 or the amino acid sequence of SEQ ID NO:7 from amino acid 1 to amino acid 28.

In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID 25 NO:9;
- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:9 from nucleotide 6 to nucleotide 2408;
- (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:9 from nucleotide 1295 to nucleotide 1705;
- (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone BL89_13 deposited under accession 30 number ATCC 98153;
- (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone BL89_13 deposited under accession number ATCC 98153;

- (f) a polynucleotide comprising the nucleotide sequence of the mature protein coding sequence of clone BL89_13 deposited under accession number ATCC 98153;
- 5 (g) a polynucleotide encoding the mature protein encoded by the cDNA insert of clone BL89_13 deposited under accession number ATCC 98153;
- (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:10;
- 10 (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:10 having biological activity;
- (j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;
- (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ; and
- 15 (l) a polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides specified in (a)-(i).

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:9 from nucleotide 6 to nucleotide 2408; the nucleotide sequence of SEQ ID NO:9 from nucleotide 1295 to nucleotide 1705; the nucleotide sequence of the full-length protein coding sequence of clone BL89_13 deposited under accession number ATCC 98153; or the nucleotide sequence of the mature protein coding sequence of clone BL89_13 deposited under accession number ATCC 98153. In other preferred embodiments, the polynucleotide encodes the full-length or mature protein encoded by the cDNA insert of clone BL89_13 deposited under accession number ATCC 98153. In yet other preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:10 from amino acid 431 to amino acid 567.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:9.

In other embodiments, the present invention provides a composition comprising 30 a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:10;
- (b) the amino acid sequence of SEQ ID NO:10 from amino acid 431 to amino acid 567;

(c) fragments of the amino acid sequence of SEQ ID NO:10; and
(d) the amino acid sequence encoded by the cDNA insert of clone BL89_13 deposited under accession number ATCC 98153;
the protein being substantially free from other mammalian proteins. Preferably such 5 protein comprises the amino acid sequence of SEQ ID NO:10 or the amino acid sequence of SEQ ID NO:10 from amino acid 431 to amino acid 567.

In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

10 (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:11;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:11 from nucleotide 2113 to nucleotide 2337;
(c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:11 from nucleotide 2036 to nucleotide 2316;
15 (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone BL341_4 deposited under accession number ATCC 98115;
(e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone BL341_4 deposited under accession number ATCC 98115;
20 (f) a polynucleotide comprising the nucleotide sequence of the mature protein coding sequence of clone BL341_4 deposited under accession number ATCC 98115;
(g) a polynucleotide encoding the mature protein encoded by the cDNA insert of clone BL341_4 deposited under accession number ATCC 98115;
25 (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:12;
(i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:12 having biological activity;
(j) a polynucleotide which is an allelic variant of a polynucleotide of
30 (a)-(g) above;
(k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ; and
(l) a polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides specified in (a)-(i).

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:11 from nucleotide 2113 to nucleotide 2337; the nucleotide sequence of SEQ ID NO:11 from nucleotide 2036 to nucleotide 2316; the nucleotide sequence of the full-length protein coding sequence of clone BL341_4 deposited under accession number ATCC 98115; or the 5 nucleotide sequence of the mature protein coding sequence of clone BL341_4 deposited under accession number ATCC 98115. In other preferred embodiments, the polynucleotide encodes the full-length or mature protein encoded by the cDNA insert of clone BL341_4 deposited under accession number ATCC 98115. In yet other preferred embodiments, the present invention provides a polynucleotide encoding a protein 10 comprising the amino acid sequence of SEQ ID NO:12 from amino acid 1 to amino acid 68.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:11.

In other embodiments, the present invention provides a composition comprising 15 a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:12;
- (b) the amino acid sequence of SEQ ID NO:12 from amino acid 1 to amino acid 68;
- 20 (c) fragments of the amino acid sequence of SEQ ID NO:12; and
- (d) the amino acid sequence encoded by the cDNA insert of clone BL341_4 deposited under accession number ATCC 98115;

the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:12 or the amino acid sequence 25 of SEQ ID NO:12 from amino acid 1 to amino acid 68.

In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:13;
- 30 (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:13 from nucleotide 1 to nucleotide 390;
- (c) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone BV239_3 deposited under accession number ATCC 98153;

- (d) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone BV239_3 deposited under accession number ATCC 98153;
- 5 (e) a polynucleotide comprising the nucleotide sequence of the mature protein coding sequence of clone BV239_3 deposited under accession number ATCC 98153;
- (f) a polynucleotide encoding the mature protein encoded by the cDNA insert of clone BV239_3 deposited under accession number ATCC 98153;
- 10 (g) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:14;
- (h) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:14 having biological activity;
- (i) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(f) above;
- 15 (j) a polynucleotide which encodes a species homologue of the protein of (g) or (h) above ; and
- (k) a polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides specified in (a)-(h).

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:13 from nucleotide 1 to nucleotide 390; the nucleotide sequence of the full-length protein coding sequence of clone BV239_3 deposited under accession number ATCC 98153; or the nucleotide sequence of the mature protein coding sequence of clone BV239_3 deposited under accession number ATCC 98153. In other preferred embodiments, the polynucleotide encodes the full-length or mature protein encoded by the cDNA insert of clone BV239_3 deposited under accession number ATCC 98153. In yet other preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:14 from amino acid 50 to amino acid 130.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:13.

30 In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:14;

(b) the amino acid sequence of SEQ ID NO:14 from amino acid 50 to amino acid 130;

(c) fragments of the amino acid sequence of SEQ ID NO:14; and

(d) the amino acid sequence encoded by the cDNA insert of clone

5 BV239_3 deposited under accession number ATCC 98153;

the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:14 or the amino acid sequence of SEQ ID NO:14 from amino acid 50 to amino acid 130.

In one embodiment, the present invention provides a composition comprising an 10 isolated polynucleotide selected from the group consisting of:

(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:15;

(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:15 from nucleotide 144 to nucleotide 257;

15 (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:15 from nucleotide 30 to nucleotide 271;

(d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone CC25_17 deposited under accession number ATCC 98153;

20 (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone CC25_17 deposited under accession number ATCC 98153;

(f) a polynucleotide comprising the nucleotide sequence of the mature protein coding sequence of clone CC25_17 deposited under accession number ATCC 98153;

(g) a polynucleotide encoding the mature protein encoded by the cDNA insert of clone CC25_17 deposited under accession number ATCC 98153;

(h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:16;

30 (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:16 having biological activity;

(j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;

(k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ; and

(l) a polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides specified in (a)-(i).

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:15 from nucleotide 144 to nucleotide 257; the nucleotide sequence of SEQ ID NO:15 from nucleotide 30 to nucleotide 271; the nucleotide sequence of the full-length protein coding sequence of clone CC25_17 deposited under accession number ATCC 98153; or the nucleotide sequence of the mature protein coding sequence of clone CC25_17 deposited under accession number ATCC 98153. In other preferred embodiments, the polynucleotide encodes the full-length or mature protein encoded by the cDNA insert of clone CC25_17 deposited under accession number ATCC 98153.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:15.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:16;
- (b) fragments of the amino acid sequence of SEQ ID NO:16; and
- (c) the amino acid sequence encoded by the cDNA insert of clone CC25_17 deposited under accession number ATCC 98153;

the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:16.

In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:17;
- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:17 from nucleotide 431 to nucleotide 520;
- (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:17 from nucleotide 266 to nucleotide 511;
- (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone CC397_19 deposited under accession number ATCC 98153;
- (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone CC397_19 deposited under accession number ATCC 98153;

- (f) a polynucleotide comprising the nucleotide sequence of the mature protein coding sequence of clone CC397_19 deposited under accession number ATCC 98153;
- 5 (g) a polynucleotide encoding the mature protein encoded by the cDNA insert of clone CC397_19 deposited under accession number ATCC 98153;
- (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:18;
- 10 (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:18 having biological activity;
- (j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;
- (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ; and
- 15 (l) a polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides specified in (a)-(i).

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:17 from nucleotide 431 to nucleotide 520; the nucleotide sequence of SEQ ID NO:17 from nucleotide 266 to nucleotide 511; the nucleotide sequence of the full-length protein coding sequence of clone CC397_19 deposited under accession number ATCC 98153; or
20 the nucleotide sequence of the mature protein coding sequence of clone CC397_19 deposited under accession number ATCC 98153. In other preferred embodiments, the polynucleotide encodes the full-length or mature protein encoded by the cDNA insert of clone CC397_19 deposited under accession number ATCC 98153. In yet other preferred embodiments, the present invention provides a polynucleotide encoding a protein
25 comprising the amino acid sequence of SEQ ID NO:18 from amino acid 1 to amino acid 27.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:17.

In other embodiments, the present invention provides a composition comprising
30 a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:18;
- (b) the amino acid sequence of SEQ ID NO:18 from amino acid 1 to amino acid 27;

(c) fragments of the amino acid sequence of SEQ ID NO:18; and
(d) the amino acid sequence encoded by the cDNA insert of clone CC397_19 deposited under accession number ATCC 98153;
the protein being substantially free from other mammalian proteins. Preferably such
5 protein comprises the amino acid sequence of SEQ ID NO:18 or the amino acid sequence
of SEQ ID NO:18 from amino acid 1 to amino acid 27.

In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

(a) a polynucleotide comprising the nucleotide sequence of SEQ ID
10 NO:20;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:20 from nucleotide 253 to nucleotide 519;
(c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:20 from nucleotide 298 to nucleotide 519;
15 (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone D305_2 deposited under accession number ATCC 98115;
(e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone D305_2 deposited under accession number ATCC 98115;
20 (f) a polynucleotide comprising the nucleotide sequence of the mature protein coding sequence of clone D305_2 deposited under accession number ATCC 98115;
(g) a polynucleotide encoding the mature protein encoded by the cDNA insert of clone D305_2 deposited under accession number ATCC 98115;
25 (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:21;
(i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:21 having biological activity;
(j) a polynucleotide which is an allelic variant of a polynucleotide of
30 (a)-(g) above;
(k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ; and
(l) a polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides specified in (a)-(i).

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:20 from nucleotide 253 to nucleotide 519; the nucleotide sequence of SEQ ID NO:20 from nucleotide 298 to nucleotide 519; the nucleotide sequence of the full-length protein coding sequence of clone D305_2 deposited under accession number ATCC 98115; or the

5 nucleotide sequence of the mature protein coding sequence of clone D305_2 deposited under accession number ATCC 98115. In other preferred embodiments, the polynucleotide encodes the full-length or mature protein encoded by the cDNA insert of clone D305_2 deposited under accession number ATCC 98115.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
10 ID NO:20, SEQ ID NO:19 or SEQ ID NO:22.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:21;
- 15 (b) fragments of the amino acid sequence of SEQ ID NO:21; and
- (c) the amino acid sequence encoded by the cDNA insert of clone D305_2 deposited under accession number ATCC 98115;

the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:21.

20 In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:23;
- 25 (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:23 from nucleotide 194 to nucleotide 622;
- (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:23 from nucleotide 524 to nucleotide 622;
- (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone G55_1 deposited under accession number ATCC 98115;
- 30 (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone G55_1 deposited under accession number ATCC 98115;

- (f) a polynucleotide comprising the nucleotide sequence of the mature protein coding sequence of clone G55_1 deposited under accession number ATCC 98115;
- 5 (g) a polynucleotide encoding the mature protein encoded by the cDNA insert of clone G55_1 deposited under accession number ATCC 98115;
- (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:24;
- (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:24 having biological activity;
- 10 (j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;
- (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ; and
- 15 (l) a polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides specified in (a)-(i).

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:23 from nucleotide 194 to nucleotide 622; the nucleotide sequence of SEQ ID NO:23 from nucleotide 524 to nucleotide 622; the nucleotide sequence of the full-length protein coding sequence of clone G55_1 deposited under accession number ATCC 98115; or the nucleotide sequence of the mature protein coding sequence of clone G55_1 deposited under accession number ATCC 98115. In other preferred embodiments, the polynucleotide encodes the full-length or mature protein encoded by the cDNA insert of clone G55_1 deposited under accession number ATCC 98115. In yet other preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:24 from amino acid 1 to amino acid 32.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:23 or SEQ ID NO:25.

In other embodiments, the present invention provides a composition comprising

30 a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:24;
- (b) the amino acid sequence of SEQ ID NO:24 from amino acid 1 to amino acid 32;

(c) fragments of the amino acid sequence of SEQ ID NO:24; and
(d) the amino acid sequence encoded by the cDNA insert of clone G55_1 deposited under accession number ATCC 98115;
the protein being substantially free from other mammalian proteins. Preferably such 5 protein comprises the amino acid sequence of SEQ ID NO:24 or the amino acid sequence of SEQ ID NO:24 from amino acid 1 to amino acid 32.

In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID 10 NO:26;
- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:26 from nucleotide 402 to nucleotide 533;
- (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:26 from nucleotide 447 to nucleotide 533;
- 15 (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone K39_7 deposited under accession number ATCC 98115;
- (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone K39_7 deposited under accession number ATCC 98115;
- 20 (f) a polynucleotide comprising the nucleotide sequence of the mature protein coding sequence of clone K39_7 deposited under accession number ATCC 98115;
- (g) a polynucleotide encoding the mature protein encoded by the cDNA insert of clone K39_7 deposited under accession number ATCC 98115;
- 25 (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:27;
- (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:27 having biological activity;
- (j) a polynucleotide which is an allelic variant of a polynucleotide of 30 (a)-(g) above;
- (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ; and
- (l) a polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides specified in (a)-(i).

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:26 from nucleotide 402 to nucleotide 533; the nucleotide sequence of SEQ ID NO:26 from nucleotide 447 to nucleotide 533; the nucleotide sequence of the full-length protein coding sequence of clone K39_7 deposited under accession number ATCC 98115; or the 5 nucleotide sequence of the mature protein coding sequence of clone K39_7 deposited under accession number ATCC 98115. In other preferred embodiments, the polynucleotide encodes the full-length or mature protein encoded by the cDNA insert of clone K39_7 deposited under accession number ATCC 98115.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ 10 ID NO:26 or SEQ ID NO:28.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:27;
- 15 (b) fragments of the amino acid sequence of SEQ ID NO:27; and
- (c) the amino acid sequence encoded by the cDNA insert of clone K39_7 deposited under accession number ATCC 98115;

the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:27.

20 In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:29;
- 25 (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:29 from nucleotide 241 to nucleotide 525;
- (c) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone K330_3 deposited under accession number ATCC 98115;
- (d) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone K330_3 deposited under accession number ATCC 98115;
- 30 (e) a polynucleotide comprising the nucleotide sequence of the mature protein coding sequence of clone K330_3 deposited under accession number ATCC 98115;

- (f) a polynucleotide encoding the mature protein encoded by the cDNA insert of clone K330_3 deposited under accession number ATCC 98115;
- (g) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:30;
- 5 (h) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:30 having biological activity;
- (i) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(f) above;
- 10 (j) a polynucleotide which encodes a species homologue of the protein of (g) or (h) above ; and
- (k) a polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides specified in (a)-(h).

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:29 from nucleotide 241 to nucleotide 525; the nucleotide sequence of the full-length 15 protein coding sequence of clone K330_3 deposited under accession number ATCC 98115; or the nucleotide sequence of the mature protein coding sequence of clone K330_3 deposited under accession number ATCC 98115. In other preferred embodiments, the polynucleotide encodes the full-length or mature protein encoded by the cDNA insert of clone K330_3 deposited under accession number ATCC 98115. In yet other preferred 20 embodiments, the present invention provides a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:30 from amino acid 1 to amino acid 35.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:29 or SEQ ID NO:31.

25 In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:30;
- (b) the amino acid sequence of SEQ ID NO:30 from amino acid 1 to 30 amino acid 35;
- (c) fragments of the amino acid sequence of SEQ ID NO:30; and
- (d) the amino acid sequence encoded by the cDNA insert of clone K330_3 deposited under accession number ATCC 98115;

the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:30 or the amino acid sequence of SEQ ID NO:30 from amino acid 1 to amino acid 35.

In one embodiment, the present invention provides a composition comprising an
5 isolated polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:32;
- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:32 from nucleotide 158 to nucleotide 571;
- 10 (c) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone K363_3 deposited under accession number ATCC 98115;
- (d) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone K363_3 deposited under accession number ATCC 98115;
- 15 (e) a polynucleotide comprising the nucleotide sequence of the mature protein coding sequence of clone K363_3 deposited under accession number ATCC 98115;
- (f) a polynucleotide encoding the mature protein encoded by the cDNA insert of clone K363_3 deposited under accession number ATCC 98115;
- 20 (g) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:33;
- (h) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:33 having biological activity;
- 25 (i) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(f) above;
- (j) a polynucleotide which encodes a species homologue of the protein of (g) or (h) above ; and
- (k) a polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides specified in (a)-(h).

30 Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:32 from nucleotide 158 to nucleotide 571; the nucleotide sequence of the full-length protein coding sequence of clone K363_3 deposited under accession number ATCC 98115; or the nucleotide sequence of the mature protein coding sequence of clone K363_3 deposited under accession number ATCC 98115. In other preferred embodiments, the

polynucleotide encodes the full-length or mature protein encoded by the cDNA insert of clone K363_3 deposited under accession number ATCC 98115. In yet other preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:33 from amino acid 24 to amino acid 5 96.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:32 or SEQ ID NO:34.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group 10 consisting of:

- (a) the amino acid sequence of SEQ ID NO:33;
- (b) the amino acid sequence of SEQ ID NO:33 from amino acid 24 to amino acid 96;
- (c) fragments of the amino acid sequence of SEQ ID NO:33; and
- (d) the amino acid sequence encoded by the cDNA insert of clone 15 K363_3 deposited under accession number ATCC 98115;

the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:33 or the amino acid sequence of SEQ ID NO:33 from amino acid 24 to amino acid 96.

20 In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:35;
- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID 25 NO:35 from nucleotide 401 to nucleotide 526;
- (c) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone K446_3 deposited under accession number ATCC 98115;
- (d) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone K446_3 deposited under accession number ATCC 98115;
- (e) a polynucleotide comprising the nucleotide sequence of the mature protein coding sequence of clone K446_3 deposited under accession number ATCC 98115;

- (f) a polynucleotide encoding the mature protein encoded by the cDNA insert of clone K446_3 deposited under accession number ATCC 98115;
- (g) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:36;
- 5 (h) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:36 having biological activity;
- (i) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(f) above;
- 10 (j) a polynucleotide which encodes a species homologue of the protein of (g) or (h) above ; and
- (k) a polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides specified in (a)-(h).

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:35 from nucleotide 401 to nucleotide 526; the nucleotide sequence of the full-length protein coding sequence of clone K446_3 deposited under accession number ATCC 98115; or the nucleotide sequence of the mature protein coding sequence of clone K446_3 deposited under accession number ATCC 98115. In other preferred embodiments, the polynucleotide encodes the full-length or mature protein encoded by the cDNA insert of clone K446_3 deposited under accession number ATCC 98115.

20 Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:35 or SEQ ID NO:37.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

25

- (a) the amino acid sequence of SEQ ID NO:36;
- (b) fragments of the amino acid sequence of SEQ ID NO:36; and
- (c) the amino acid sequence encoded by the cDNA insert of clone K446_3 deposited under accession number ATCC 98115;

the protein being substantially free from other mammalian proteins. Preferably such 30 protein comprises the amino acid sequence of SEQ ID NO:36.

In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:38;

- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:38 from nucleotide 380 to nucleotide 535;
- (c) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone K464_4 deposited under accession number ATCC 98115;
- 5 (d) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone K464_4 deposited under accession number ATCC 98115;
- (e) a polynucleotide comprising the nucleotide sequence of the mature protein coding sequence of clone K464_4 deposited under accession number ATCC 98115;
- 10 (f) a polynucleotide encoding the mature protein encoded by the cDNA insert of clone K464_4 deposited under accession number ATCC 98115;
- (g) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:39;
- 15 (h) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:39 having biological activity;
- (i) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(f) above;
- (j) a polynucleotide which encodes a species homologue of the protein of (g) or (h) above ; and
- 20 (k) a polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides specified in (a)-(h).

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:38 from nucleotide 380 to nucleotide 535; the nucleotide sequence of the full-length protein coding sequence of clone K464_4 deposited under accession number ATCC 98115; or the nucleotide sequence of the mature protein coding sequence of clone K464_4 deposited under accession number ATCC 98115. In other preferred embodiments, the polynucleotide encodes the full-length or mature protein encoded by the cDNA insert of clone K464_4 deposited under accession number ATCC 98115.

30 Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:38 or SEQ ID NO:40.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:39;
- (b) fragments of the amino acid sequence of SEQ ID NO:39; and
- (c) the amino acid sequence encoded by the cDNA insert of clone K464_4 deposited under accession number ATCC 98115;

5 the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:39.

In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:41;
- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:41 from nucleotide 218 to nucleotide 1159;
- (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:41 from nucleotide 806 to nucleotide 1159;
- 10 (d) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:41 from nucleotide 217 to nucleotide 517;
- (e) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone K483_1 deposited under accession number ATCC 98115;
- 15 (f) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone K483_1 deposited under accession number ATCC 98115;
- (g) a polynucleotide comprising the nucleotide sequence of the mature protein coding sequence of clone K483_1 deposited under accession number ATCC 98115;
- 20 (h) a polynucleotide encoding the mature protein encoded by the cDNA insert of clone K483_1 deposited under accession number ATCC 98115;
- (i) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:42;
- 25 (j) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:42 having biological activity;
- (k) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(h) above;
- 30 (l) a polynucleotide which encodes a species homologue of the protein of (i) or (j) above ; and

(m) a polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides specified in (a)-(j).

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:41 from nucleotide 218 to nucleotide 1159; the nucleotide sequence of SEQ ID NO:41 from nucleotide 806 to nucleotide 1159; the nucleotide sequence of SEQ ID NO:41 from nucleotide 217 to nucleotide 517; the nucleotide sequence of the full-length protein coding sequence of clone K483_1 deposited under accession number ATCC 98115; or the nucleotide sequence of the mature protein coding sequence of clone K483_1 deposited under accession number ATCC 98115. In other preferred embodiments, the polynucleotide encodes the full-length or mature protein encoded by the cDNA insert of clone K483_1 deposited under accession number ATCC 98115. In yet other preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:42 from amino acid 1 to amino acid 100.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:41.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

(a) the amino acid sequence of SEQ ID NO:42;
(b) the amino acid sequence of SEQ ID NO:42 from amino acid 1 to amino acid 100;
(c) fragments of the amino acid sequence of SEQ ID NO:42; and
(d) the amino acid sequence encoded by the cDNA insert of clone K483_1 deposited under accession number ATCC 98115;

the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:42 or the amino acid sequence of SEQ ID NO:42 from amino acid 1 to amino acid 100.

In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:43;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:43 from nucleotide 446 to nucleotide 835;

(c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:43 from nucleotide 503 to nucleotide 835;

5 (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone L69_3 deposited under accession number ATCC 98115;

(e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone L69_3 deposited under accession number ATCC 98115;

10 (f) a polynucleotide comprising the nucleotide sequence of the mature protein coding sequence of clone L69_3 deposited under accession number ATCC 98115;

(g) a polynucleotide encoding the mature protein encoded by the cDNA insert of clone L69_3 deposited under accession number ATCC 98115;

(h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:44;

15 (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:44 having biological activity;

(j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;

20 (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ; and

(l) a polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides specified in (a)-(i).

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:43 from nucleotide 446 to nucleotide 835; the nucleotide sequence of SEQ ID NO:43 from nucleotide 503 to nucleotide 835; the nucleotide sequence of the full-length protein coding sequence of clone L69_3 deposited under accession number ATCC 98115; or the nucleotide sequence of the mature protein coding sequence of clone L69_3 deposited under accession number ATCC 98115. In other preferred embodiments, the polynucleotide encodes the full-length or mature protein encoded by the cDNA insert of clone L69_3 deposited under accession number ATCC 98115. In yet other preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:44 from amino acid 1 to amino acid 93.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:43 or SEQ ID NO:45.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group

5 consisting of:

- (a) the amino acid sequence of SEQ ID NO:44;
- (b) the amino acid sequence of SEQ ID NO:44 from amino acid 1 to amino acid 93;
- (c) fragments of the amino acid sequence of SEQ ID NO:44; and
- 10 (d) the amino acid sequence encoded by the cDNA insert of clone L69_3 deposited under accession number ATCC 98115;

the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:44 or the amino acid sequence of SEQ ID NO:44 from amino acid 1 to amino acid 93.

15 In certain preferred embodiments, the polynucleotide is operably linked to an expression control sequence. The invention also provides a host cell, including bacterial, yeast, insect and mammalian cells, transformed with such polynucleotide compositions.

Processes are also provided for producing a protein, which comprise:

- 20 (a) growing a culture of the host cell transformed with such polynucleotide compositions in a suitable culture medium; and
- (b) purifying the protein from the culture.

The protein produced according to such methods is also provided by the present invention. Preferred embodiments include those in which the protein produced by such process is a mature form of the protein.

25 Protein compositions of the present invention may further comprise a pharmaceutically acceptable carrier. Compositions comprising an antibody which specifically reacts with such protein are also provided by the present invention.

Methods are also provided for preventing, treating or ameliorating a medical condition which comprises administering to a mammalian subject a therapeutically 30 effective amount of a composition comprising a protein of the present invention and a pharmaceutically acceptable carrier.

BRIEF DESCRIPTION OF THE DRAWINGS

Figures 1A and 1B are schematic representations of the pED6 and pNOTs vectors, respectively, used for deposit of clones disclosed herein.

5

DETAILED DESCRIPTIONISOLATED PROTEINS AND POLYNUCLEOTIDES

Nucleotide and amino acid sequences, as presently determined, are reported below for each clone and protein disclosed in the present application. The nucleotide sequence of each clone can readily be determined by sequencing of the deposited clone
10 in accordance with known methods. The predicted amino acid sequence (both full-length and mature) can then be determined from such nucleotide sequence. The amino acid sequence of the protein encoded by a particular clone can also be determined by expression of the clone in a suitable host cell, collecting the protein and determining its sequence. For each disclosed protein applicants have identified what they have
15 determined to be the reading frame best identifiable with sequence information available at the time of filing.

As used herein a "secreted" protein is one which, when expressed in a suitable host cell, is transported across or through a membrane, including transport as a result of signal sequences in its amino acid sequence. "Secreted" proteins include without limitation
20 proteins secreted wholly (e.g., soluble proteins) or partially (e.g., receptors) from the cell in which they are expressed. "Secreted" proteins also include without limitation proteins which are transported across the membrane of the endoplasmic reticulum.

Clone "AJ26_3"

25 A polynucleotide of the present invention has been identified as clone "AJ26_3". AJ26_3 was isolated from a human adult testes cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. AJ26_3 is a full-length clone,
30 including the entire coding sequence of a secreted protein (also referred to herein as "AJ26_3 protein").

The nucleotide sequence of AJ26_3 as presently determined is reported in SEQ ID NO:1. What applicants presently believe to be the proper reading frame and the predicted

amino acid sequence of the AJ26_3 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:2.

The EcoRI/NotI restriction fragment obtainable from the deposit containing clone AJ26_3 should be approximately 2100 bp.

5 The nucleotide sequence disclosed herein for AJ26_3 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. AJ26_3 demonstrated at least some similarity with sequences identified as U46493 (Cloning vector pFlp recombinase gene, complete cds). The predicted amino acid sequence disclosed herein for AJ26_3 was searched against the
10 GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted AJ26_3 protein demonstrated at least some similarity to sequences identified as J01917 (DNA polymerase [Human adenovirus type 2]), J01969 (DNA polymerase [Human adenovirus type 5]), L24893 (HUMAAC02_1 myelin protein zero [Homo sapiens]), U43330 (CTX [Xenopus laevis]), and U43394 (CTX [Xenopus laevis]).
15 Based upon sequence similarity, AJ26_3 proteins and each similar protein or peptide may share at least some activity. The TopPredII computer program predicts four potential transmembrane domains within the AJ26_3 protein sequence, centered around amino acids 11, 41, 163, and 246 of SEQ ID NO:2. The AJ26_3 protein also has a possible signal sequence that could be cleaved to produce a mature protein starting at amino acid 17 of
20 SEQ ID NO:2.

Clone "AJ172_2"

A polynucleotide of the present invention has been identified as clone "AJ172_2". AJ172_2 was isolated from a human adult testes cDNA library using methods which are
25 selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. AJ172_2 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "AJ172_2 protein").
30 The nucleotide sequence of AJ172_2 as presently determined is reported in SEQ ID NO:3. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the AJ172_2 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:4. Amino acids 8 to 20 are a predicted

leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 21, or are a transmembrane domain.

The EcoRI/NotI restriction fragment obtainable from the deposit containing clone AJ172_2 should be approximately 3000 bp.

5 The nucleotide sequence disclosed herein for AJ172_2 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. AJ172_2 demonstrated at least some similarity with sequences identified as AA077794 (7H01C09 Chromosome 7 HeLa cDNA Library Homo sapiens cDNA clone 7H01C09), AC000064 (Human BAC clone RG083M05 from 7q21-7q22, complete sequence), D78692 (Human placenta cDNA 5'-end GEN-503H08), H12439 (yJ11h10.r1 Homo sapiens cDNA clone 148483 5'), R27389 (yh46a09.s1 Homo sapiens cDNA clone 132760 3'), and T09280 (Novel AMP/MCF virus clone 24 genome). The predicted amino acid sequence disclosed herein for AJ172_2 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol.

10 The predicted AJ172_2 protein demonstrated at least some similarity to sequences identified as M26927 (pol polyprotein [Gibbon leukemia virus]), M93134 (pol protein [Friend murine leukemia virus]), and R75189 (Osteoinductive retrovirus RFB-14 pol gene product). AJ172_2 protein is similar to a number of viral env proteins, including those of baboon endogenous virus and many leukemia viruses, which associate with the membrane portion of the viral envelope. Based upon sequence similarity, AJ172_2 proteins and each similar protein or peptide may share at least some activity. The TopPredII computer program predicts five potential transmembrane domains within the AJ172_2 protein sequence, centered around amino acids 104, 267, 292, 328, and 457 of SEQ ID NO:4.

15

20

25

Clone "AP224_2"

A polynucleotide of the present invention has been identified as clone "AP224_2". AP224_2 was isolated from a human adult placenta cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. AP224_2 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "AP224_2 protein").

The nucleotide sequence of the 5' portion of AP224_2 as presently determined is reported in SEQ ID NO:5. An additional internal nucleotide sequence from AP224_2 as presently determined is reported in SEQ ID NO:6. What applicants believe is the proper reading frame and the predicted amino acid sequence encoded by such internal sequence 5 is reported in SEQ ID NO:7. Additional nucleotide sequence from the 3' portion of AP224_2, including the polyA tail, is reported in SEQ ID NO:8.

The EcoRI/NotI restriction fragment obtainable from the deposit containing clone AP224_2 should be approximately 2100 bp.

The nucleotide sequence disclosed herein for AP224_2 was searched against the 10 GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. AP224_2 demonstrated at least some similarity with sequences identified as R37675 (yf61f08.s1 Homo sapiens cDNA clone 26687 3'). Based upon sequence similarity, AP224_2 proteins and each similar protein or peptide may share at least some activity.

15

Clone "BL89_13"

A polynucleotide of the present invention has been identified as clone "BL89_13". BL89_13 was isolated from a human adult testes cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was 20 identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. BL89_13 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "BL89_13 protein").

The nucleotide sequence of BL89_13 as presently determined is reported in SEQ 25 ID NO:9. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the BL89_13 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:10.

The EcoRI/NotI restriction fragment obtainable from the deposit containing clone BL89_13 should be approximately 3200 bp.

30 The nucleotide sequence disclosed herein for BL89_13 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. No hits were found in the database. The TopPredII computer program predicts a potential transmembrane domain within the BL89_13 protein sequence centered around amino acid 625 of SEQ ID NO:10.

Clone "BL341_4"

A polynucleotide of the present invention has been identified as clone "BL341_4". BL341_4 was isolated from a human adult testes cDNA library using methods which are

5 selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. BL341_4 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "BL341_4 protein").

10 The nucleotide sequence of BL341_4 as presently determined is reported in SEQ ID NO:11. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the BL341_4 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:12.

15 The EcoRI/NotI restriction fragment obtainable from the deposit containing clone BL341_4 should be approximately 2600 bp.

The nucleotide sequence disclosed herein for BL341_4 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. BL341_4 demonstrated at least some similarity with sequences identified as AA460103 (zx50a12.r1 Soares testis NHT Homo sapiens cDNA clone) and

20 Z63359 (H.sapiens CpG island DNA genomic Mse1 fragment, clone 81e7, reverse read cpq81e7.rt1a). Based upon sequence similarity, BL341_4 proteins and each similar protein or peptide may share at least some activity.

Clone "BV239_3"

25 A polynucleotide of the present invention has been identified as clone "BV239_3". BV239_3 was isolated from a human adult brain cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. BV239_3 is a full-length

30 clone, including the entire coding sequence of a secreted protein (also referred to herein as "BV239_3 protein").

The nucleotide sequence of BV239_3 as presently determined is reported in SEQ ID NO:13. What applicants presently believe to be the proper reading frame and the

predicted amino acid sequence of the BV239_3 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:14.

The EcoRI/NotI restriction fragment obtainable from the deposit containing clone BV239_3 should be approximately 310 bp.

5 The nucleotide sequence disclosed herein for BV239_3 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. BV239_3 demonstrated at least some similarity with sequences identified as U46493 (Cloning vector pFlp recombinase gene, complete cds). Based upon sequence similarity, BV239_3 proteins and each similar protein or peptide may share at
10 least some activity.

Clone "CC25_17"

A polynucleotide of the present invention has been identified as clone "CC25_17". CC25_17 was isolated from a human adult brain cDNA library using methods which are
15 selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. CC25_17 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "CC25_17 protein").

20 The nucleotide sequence of CC25_17 as presently determined is reported in SEQ ID NO:15. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the CC25_17 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:16.

The EcoRI/NotI restriction fragment obtainable from the deposit containing clone
25 CC25_17 should be approximately 300 bp.

The nucleotide sequence disclosed herein for CC25_17 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. CC25_17 demonstrated at least some similarity with sequences identified as U46493 (Cloning vector pFlp recombinase gene, complete cds). Based upon
30 sequence similarity, CC25_17 proteins and each similar protein or peptide may share at least some activity.

Clone "CC397_19"

A polynucleotide of the present invention has been identified as clone "CC397_19". CC397_19 was isolated from a human adult brain cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was 5 identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. CC397_19 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "CC397_19 protein").

The nucleotide sequence of CC397_19 as presently determined is reported in SEQ 10 ID NO:17. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the CC397_19 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:18.

The EcoRI/NotI restriction fragment obtainable from the deposit containing clone CC397_19 should be approximately 1700 bp.

15 The nucleotide sequence disclosed herein for CC397_19 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. CC397_19 demonstrated at least some similarity with sequences identified as AC002129 (Human DNA from chromosome 19 cosmid R33743, genomic sequence, complete sequence), D82019 (Mouse gene for basigin precursor, basigin signal 20 precursor), G08688 (human STS CHLC.GATA29D08.P14592 clone GATA29D08), M68516 (Human protein C inhibitor gene, complete cds), and Z68756 (Human DNA sequence from cosmid L191F1, Huntington's Disease Region, chromosome 4p16.3 contains Huntington Disease (HD) gene, CpG island ESTs and U7 small nuclear RNA). The predicted amino acid sequence disclosed herein for CC397_19 was searched against the 25 GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted CC397_19 protein demonstrated at least some similarity to sequences identified as X52164 (Q300 protein (AA 1-77) [Mus musculus]). Based upon sequence similarity, CC397_19 proteins and each similar protein or peptide may share at least some activity. The nucleotide sequence of CC397_19 indicates that it may contain an Alu 30 repetitive element.

Clone "D305_2"

A polynucleotide of the present invention has been identified as clone "D305_2". D305_2 was isolated from a human adult blood (peripheral blood mononuclear cells

treated with concanavalin A and phorbol myristate acetate) cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. D305_2 is a full-length clone,
5 including the entire coding sequence of a secreted protein (also referred to herein as "D305_2 protein").

The nucleotide sequence of the 5' portion of D305_2 as presently determined is reported in SEQ ID NO:19. An additional internal nucleotide sequence from D305_2 as presently determined is reported in SEQ ID NO:20. What applicants believe is the proper
10 reading frame and the predicted amino acid sequence encoded by such internal sequence is reported in SEQ ID NO:21. Amino acids 3 to 15 of SEQ ID NO:21 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 16, or are a transmembrane domain. Additional nucleotide sequence from the 3' portion of D305_2, including the polyA tail, is reported in SEQ ID NO:22.

15 The EcoRI/NotI restriction fragment obtainable from the deposit containing clone D305_2 should be approximately 2400 bp.

The nucleotide sequence disclosed herein for D305_2 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. D305_2 demonstrated at least some similarity with sequences
20 identified as AA055703 (zJ75d04.r1 Stratagene colon (#937204) Homo sapiens cDNA clone 510439 5'), N49593 (yy58d05.s1 Homo sapiens cDNA clone 277737 3'), R66646 (yi35b08.r1 Homo sapiens cDNA clone 141207 5' similar to SP P24A_YEAST P32802 P24A PROTEIN), U81006 (Human p76 mRNA, complete cds), and Z48758 (S.cerevisiae chromosome IV cosmid 9727). The predicted amino acid sequence disclosed herein for D305_2 was
25 searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted D305_2 protein demonstrated at least some similarity to sequences identified as U53880 (P24A protein (unknown function) (Swiss Prot. accession number P32802) [Saccharomyces cerevisiae]), U81006 (p76 [Homo sapiens]), X67316 (SCEMP70_1 p24a 70 kDa precursor [Saccharomyces cerevisiae]), and
30 Z48758 (unknown [Saccharomyces cerevisiae]). Based upon sequence similarity, D305_2 proteins and each similar protein or peptide may share at least some activity.

Clone "G55_1"

A polynucleotide of the present invention has been identified as clone "G55_1". G55_1 was isolated from a human adult blood (peripheral blood mononuclear cells treated with concanavalin A and phorbol myristate acetate) cDNA library using methods which

5 are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. G55_1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "G55_1 protein").

10 The nucleotide sequence of the 5' portion of G55_1 as presently determined is reported in SEQ ID NO:23. What applicants presently believe is the proper reading frame for the coding region is indicated in SEQ ID NO:24. The predicted amino acid sequence of the G55_1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:24. Amino acids 98 to 110 are a predicted leader/signal sequence, with the

15 predicted mature amino acid sequence beginning at amino acid 111, or are a transmembrane domain. Additional nucleotide sequence from the 3' portion of G55_1, including the polyA tail, is reported in SEQ ID NO:25.

The EcoRI/NotI restriction fragment obtainable from the deposit containing clone G55_1 should be approximately 2000 bp.

20 The nucleotide sequence disclosed herein for G55_1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. G55_1 demonstrated at least some similarity with sequences identified as R83586 (yp16a07.r1 Homo sapiens cDNA clone 187572 5'). Based upon sequence similarity, G55_1 proteins and each similar protein or peptide may share at least

25 some activity.

Clone "K39_7"

A polynucleotide of the present invention has been identified as clone "K39_7". K39_7 was referred to as K39_2 in previous applications. K39_7 was isolated from a

30 murine adult bone marrow (stromal cell line FCM-4) cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. K39_7 is a full-length clone,

including the entire coding sequence of a secreted protein (also referred to herein as "K39_7 protein").

The nucleotide sequence of the 5' portion of K39_7 as presently determined is reported in SEQ ID NO:26. What applicants presently believe is the proper reading frame 5 for the coding region is indicated in SEQ ID NO:27. The predicted amino acid sequence of the K39_7 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:27. Amino acids 3 to 15 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 16, or are a transmembrane domain. Additional nucleotide sequence from the 3' portion of K39_7, 10 including the polyA tail, is reported in SEQ ID NO:28.

The EcoRI/NotI restriction fragment obtainable from the deposit containing clone K39_7 should be approximately 1675 bp.

The nucleotide sequence disclosed herein for K39_7 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and 15 FASTA search protocols. K39_7 demonstrated at least some similarity with sequences identified as AA254326 (va15d06.r1 Soares mouse lymph node NbMLN Mus musculus cDNA clone 722987 5' similar to WP:C09G4.1 CE03978), D18935 (Mouse 3'-directed cDNA, MUSGS01125, clone mc0564), H14129 (ym65b04.r1 Homo sapiens cDNA clone 163759 5'), and R20230 (hUOG-1, DNA segment encoding a mammalian GDF-1 protein). The 20 predicted amino acid sequence disclosed herein for K39_7 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted K39_7 protein demonstrated at least some similarity to sequences identified as R86811 (Saccharomyces cerevisiae mutant LAG1 protein) and U42438 (similar to S. cerevisiae longevity-assurance protein 1 (SP P38703) [Caenorhabditis elegans]). Based 25 upon sequence similarity, K39_7 proteins and each similar protein or peptide may share at least some activity.

Clone "K330_3"

A polynucleotide of the present invention has been identified as clone "K330_3".
30 K330_3 was referred to as K330_2 in previous applications. K330_3 was isolated from a murine adult bone marrow (stromal cell line FCM-4) cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. K330_3 is a full-length clone,

including the entire coding sequence of a secreted protein (also referred to herein as "K330_3 protein").

The nucleotide sequence of the 5' portion of K330_3 as presently determined is reported in SEQ ID NO:29. What applicants presently believe is the proper reading frame 5 for the coding region is indicated in SEQ ID NO:30. The predicted amino acid sequence of the K330_3 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:30. Additional nucleotide sequence from the 3' portion of K330_3, including the polyA tail, is reported in SEQ ID NO:31.

The EcoRI/NotI restriction fragment obtainable from the deposit containing clone 10 K330_3 should be approximately 1300 bp.

The nucleotide sequence disclosed herein for K330_3 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. K330_3 demonstrated at least some similarity with sequences identified as A03900 (H.sapiens HuV(NP) gene), AA038010 (mi80a11.r1 Soares mouse 15 p3NMF19.5 Mus musculus cDNA clone 472892 5'), M30775 (Mouse thymidylate synthase pseudogene, 3' flank), R40824 (yf82c07.s1 Homo sapiens cDNA clone 28939 3'), T23245 (Human gene signature HUMGS05046), and U23512 (Caenorhabditis elegans cosmid M01G4). Based upon sequence similarity, K330_3 proteins and each similar protein or peptide may share at least some activity.

20

Clone "K363_3"

A polynucleotide of the present invention has been identified as clone "K363_3". K363_3 was referred to as K363_2 in previous applications. K363_3 was isolated from a murine adult bone marrow (stromal cell line FCM-4) cDNA library using methods which 25 are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. K363_3 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "K363_3 protein").

30 The nucleotide sequence of the 5' portion of K363_3 as presently determined is reported in SEQ ID NO:32. What applicants presently believe is the proper reading frame for the coding region is indicated in SEQ ID NO:33. The predicted amino acid sequence of the K363_3 protein corresponding to the foregoing nucleotide sequence is reported in

SEQ ID NO:33. Additional nucleotide sequence from the 3' portion of K363_3, including the polyA tail, is reported in SEQ ID NO:34.

The EcoRI/NotI restriction fragment obtainable from the deposit containing clone K363_3 should be approximately 2690 bp.

5 The nucleotide sequence disclosed herein for K363_3 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. K363_3 demonstrated at least some similarity with sequences identified as AA437876 (vd20h06.s1 Knowles Solter mouse 2 cell Mus musculus cDNA clone 793115 5'), D21554 (Mouse embryonal carcinoma F9 cell cDNA, 67F09), and Y08460
10 (Mus musculus mRNA for Mdes transmembrane protein). The predicted amino acid sequence disclosed herein for K363_3 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted K363_3 protein demonstrated at least some similarity to sequences identified as Y08460 (Mdes protein [Mus musculus]). Based upon sequence similarity, K363_3 proteins and each
15 similar protein or peptide may share at least some activity.

Clone "K446_3"

A polynucleotide of the present invention has been identified as clone "K446_3". K446_3 was referred to as K446_2 in previous applications. K446_3 was isolated from a
20 murine adult bone marrow (stromal cell line FCM-4) cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. K446_3 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as
25 "K446_3 protein").

The nucleotide sequence of the 5' portion of K446_3 as presently determined is reported in SEQ ID NO:35. What applicants presently believe is the proper reading frame for the coding region is indicated in SEQ ID NO:36. The predicted amino acid sequence of the K446_3 protein corresponding to the foregoing nucleotide sequence is reported in
30 SEQ ID NO:36. Additional nucleotide sequence from the 3' portion of K446_3, including the polyA tail, is reported in SEQ ID NO:37.

The EcoRI/NotI restriction fragment obtainable from the deposit containing clone K446_3 should be approximately 2150 bp.

The nucleotide sequence disclosed herein for K446_3 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. No hits were found in the database.

5 Clone "K464_4"

A polynucleotide of the present invention has been identified as clone "K464_4". K464_4 was referred to as K464_3 in previous applications. K464_4 was isolated from a murine adult bone marrow (stromal cell line FCM-4) cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was 10 identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. K464_4 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "K464_4 protein").

15 The nucleotide sequence of the 5' portion of K464_4 as presently determined is reported in SEQ ID NO:38. What applicants presently believe is the proper reading frame for the coding region is indicated in SEQ ID NO:39. The predicted amino acid sequence of the K464_4 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:39. Additional nucleotide sequence from the 3' portion of K464_4, including the polyA tail, is reported in SEQ ID NO:40.

20 The EcoRI/NotI restriction fragment obtainable from the deposit containing clone K464_4 should be approximately 1250 bp.

The nucleotide sequence disclosed herein for K464_4 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. K464_4 demonstrated at least some similarity with sequences 25 identified as AA260484 (va95a09.r1 Soares mouse NML Mus musculus cDNA clone 747160 5'), AA419864 (vf49b08.r1 Soares mouse NbM), L25338 (Mus musculus folate-binding protein gene, 5' end), M22527 (Mouse cytotoxic T lymphocyte-specific serine protease), T01176 (P815A antigen precursor gene P1A), T21224 (Human gene signature HUMGS02538), T41900 (Vector pAPEX-3p), U46493 (Cloning vector pFlp 30 recombinase gene, complete cds), U89673 (Cloning vector pIRES1neo, complete plasmid sequence), W32699 (zc06b11.s1 Soares parathyroid tumor NbHPA Homo sapiens cDNA clone 321501 3'), and W36926 (mb82b10.r1 Soares mouse p3NMF19.5 Mus musculus cDNA clone 335899 5'). The predicted amino acid sequence disclosed herein for K464_4 was searched against the GenPept and GeneSeq amino acid sequence databases using the

BLASTX search protocol. The predicted K464_4 protein demonstrated at least some similarity to sequences identified as L33768 (JAK3 [Mus musculus]) and X16213 (MHC T7 class I antigen (64 AA) (119 is 2nd base in codon) [Mus musculus]). Based upon sequence similarity, K464_4 proteins and each similar protein or peptide may share at least some activity.

5 Clone "K483_1"

A polynucleotide of the present invention has been identified as clone "K483_1". K483_1 was isolated from a murine adult bone marrow (stromal cell line FCM-4) cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. K483_1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "K483_1 protein").

10 The nucleotide sequence of K483_1 as presently determined is reported in SEQ ID NO:41. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the K483_1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:42. Amino acids 184 to 196 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 197, or are a transmembrane domain.

15 The EcoRI/NotI restriction fragment obtainable from the deposit containing clone K483_1 should be approximately 1500 bp.

The nucleotide sequence disclosed herein for K483_1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. K483_1 demonstrated at least some similarity with sequences identified as AA110914 (mm02c03.r1 Stratagene mouse kidney (#937315) Mus musculus cDNA clone 520324 5'), AA318160 (EST20431 Retina II Homo sapiens cDNA 5' end), AA500150 (vi97c09.r1 Barstead mouse pooled organs MPLRB4 Mus musculus cDNA clone 920176 5'), and N41895 (yw86b03.r1 Homo sapiens cDNA clone 259085 5'). Based upon sequence similarity, K483_1 proteins and each similar protein or peptide may share at least some activity. The TopPredII computer program predicts three potential transmembrane domains within the K483_1 protein sequence, centered around amino acids 18, 179, and 270 of SEQ ID NO:42. The K483_1 protein also has a possible signal

sequence that could be cleaved to produce a mature protein starting at amino acid 34 of SEQ ID NO:42.

Clone "L69_3"

5 A polynucleotide of the present invention has been identified as clone "L69_3". L69_3 was referred to as L69_2 in previous applications. L69_3 was isolated from a murine adult thymus cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid
10 sequence of the encoded protein. L69_3 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "L69_3 protein").

The nucleotide sequence of the 5' portion of L69_3 as presently determined is reported in SEQ ID NO:43. What applicants presently believe is the proper reading frame for the coding region is indicated in SEQ ID NO:44. The predicted amino acid sequence
15 of the L69_3 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:44. Amino acids 7 to 19 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 20, or are a transmembrane domain. Additional nucleotide sequence from the 3' portion of L69_3, including the polyA tail, is reported in SEQ ID NO:45.

20 The EcoRI/NotI restriction fragment obtainable from the deposit containing clone L69_3 should be approximately 1200 bp.

The nucleotide sequence disclosed herein for L69_3 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. L69_3 demonstrated at least some similarity with sequences
25 identified as H35162 (EST108034 Rattus sp. cDNA similar to H.sapiens hypothetical protein (PIR:S25641)), U02442 (Cloning vector pADbeta, complete sequence), W74864 (md91b10.r1 Soares mouse embryo NbME13.5 14.5 Mus musculus cDNA), and X67698 (H.sapiens tissue specific mRNA). The predicted amino acid sequence disclosed herein for L69_3 was searched against the GenPept and GeneSeq amino acid sequence databases
30 using the BLASTX search protocol. The predicted L69_3 protein demonstrated at least some similarity to sequences identified as A18921 (tissue-specific secretory protein [unidentified]). Based upon sequence similarity, L69_3 proteins and each similar protein or peptide may share at least some activity.

Deposit of Clones

Clones AJ26_3, AJ172_2, AP224_2, BL89_10, BL341_4, BV239_2, CC25_16, CC397_11, D305_2, G55_1, K39_7, K330_3, K363_3, K446_3, K464_4, K483_1, and L69_3 were deposited on July 25, 1996 with the American Type Culture Collection as an original deposit under the Budapest Treaty and were given the accession number ATCC 98115, from which each clone comprising a particular polynucleotide is obtainable. Clones K39_7, K330_3, K363_3, K446_3, K464_4, and L69_3 were referred to as K39_2, K330_2, K363_2, K446_2, K464_3, and L69_2, respectively, when the July 25, 1996 deposit was made. An additional isolate of each of clones BL89_10, BV239_2, CC25_16, and CC397_11 (namely isolates BL89_13, BV239_3, CC25_17, and CC397_19, respectively) were deposited with the American Type Culture Collection on August 23, 1996 under accession number 98153, from which each clone comprising a particular polynucleotide is obtainable. All restrictions on the availability to the public of the deposited material will be irrevocably removed upon the granting of the patent, except for the requirements specified in 37 C.F.R. § 1.808(b).

Each clone has been transfected into separate bacterial cells (*E. coli*) in this composite deposit. Each clone can be removed from the vector in which it was deposited by performing an EcoRI/NotI digestion (5' site, EcoRI; 3' site, NotI) to produce the appropriate fragment for such clone. Each clone was deposited in either the pED6 or pNOTs vector depicted in Fig. 1. The pED6dpc2 vector ("pED6") was derived from pED6dpc1 by insertion of a new polylinker to facilitate cDNA cloning (Kaufman *et al.*, 1991, *Nucleic Acids Res.* 19: 4485-4490); the pNOTs vector was derived from pMT2 (Kaufman *et al.*, 1989, *Mol. Cell. Biol.* 9: 946-958) by deletion of the DHFR sequences, insertion of a new polylinker, and insertion of the M13 origin of replication in the ClaI site. In some instances, the deposited clone can become "flipped" (i.e., in the reverse orientation) in the deposited isolate. In such instances, the cDNA insert can still be isolated by digestion with EcoRI and NotI. However, NotI will then produce the 5' site and EcoRI will produce the 3' site for placement of the cDNA in proper orientation for expression in a suitable vector. The cDNA may also be expressed from the vectors in which they were deposited.

Bacterial cells containing a particular clone can be obtained from the composite deposit as follows:

An oligonucleotide probe or probes should be designed to the sequence that is known for that particular clone. This sequence can be derived from the sequences

provided herein, or from a combination of those sequences. The sequence of the oligonucleotide probe that was used to isolate each full-length clone is identified below, and should be most reliable in isolating the clone of interest.

| | <u>Clone</u> | <u>Probe Sequence</u> |
|----|--------------|-----------------------|
| 5 | AJ26_3 | SEQ ID NO:46 |
| | AJ172_2 | SEQ ID NO:47 |
| | AP224_2 | SEQ ID NO:48 |
| | BL89_13 | SEQ ID NO:49 |
| 10 | BL341_4 | SEQ ID NO:50 |
| | BV239_3 | SEQ ID NO:51 |
| | CC25_17 | SEQ ID NO:52 |
| | CC397_19 | SEQ ID NO:53 |
| | D305_2 | SEQ ID NO:54 |
| 15 | G55_1 | SEQ ID NO:55 |
| | K39_7 | SEQ ID NO:56 |
| | K330_3 | SEQ ID NO:57 |
| | K363_3 | SEQ ID NO:58 |
| | K446_3 | SEQ ID NO:59 |
| 20 | K464_4 | SEQ ID NO:60 |
| | K483_1 | SEQ ID NO:61 |
| | L69_3 | SEQ ID NO:62 |

In the sequences listed above which include an N at position 2, that position is occupied
 25 in preferred probes/primers by a biotinylated phosphoaramidite residue rather than a nucleotide (such as, for example, that produced by use of biotin phosphoramidite (1-dimethoxytryloxy-2-(N-biotinyl-4-aminobutyl)-propyl-3-O-(2-cyanoethyl)-(N,N-diisopropyl)-phosphoramidite) (Glen Research, cat. no. 10-1953)).

The design of the oligonucleotide probe should preferably follow these
 30 parameters:

- (a) It should be designed to an area of the sequence which has the fewest ambiguous bases ("N's"), if any;
- (b) It should be designed to have a T_m of approx. 80 ° C (assuming 2° for each A or T and 4 degrees for each G or C).

The oligonucleotide should preferably be labeled with g-³²P ATP (specific activity 6000 Ci/mmole) and T4 polynucleotide kinase using commonly employed techniques for labeling oligonucleotides. Other labeling techniques can also be used. Unincorporated label should preferably be removed by gel filtration chromatography or other established methods. The amount of radioactivity incorporated into the probe should be quantitated by measurement in a scintillation counter. Preferably, specific activity of the resulting probe should be approximately 4e+6 dpm/pmole.

The bacterial culture containing the pool of full-length clones should preferably be thawed and 100 µl of the stock used to inoculate a sterile culture flask containing 25 ml of sterile L-broth containing ampicillin at 100 µg/ml. The culture should preferably be grown to saturation at 37°C, and the saturated culture should preferably be diluted in fresh L-broth. Aliquots of these dilutions should preferably be plated to determine the dilution and volume which will yield approximately 5000 distinct and well-separated colonies on solid bacteriological media containing L-broth containing ampicillin at 100 µg/ml and agar at 1.5% in a 150 mm petri dish when grown overnight at 37°C. Other known methods of obtaining distinct, well-separated colonies can also be employed.

Standard colony hybridization procedures should then be used to transfer the colonies to nitrocellulose filters and lyse, denature and bake them.

The filter is then preferably incubated at 65°C for 1 hour with gentle agitation in 6X SSC (20X stock is 175.3 g NaCl/liter, 88.2 g Na citrate/liter, adjusted to pH 7.0 with NaOH) containing 0.5% SDS, 100 µg/ml of yeast RNA, and 10 mM EDTA (approximately 10 mL per 150 mm filter). Preferably, the probe is then added to the hybridization mix at a concentration greater than or equal to 1e+6 dpm/mL. The filter is then preferably incubated at 65°C with gentle agitation overnight. The filter is then preferably washed in 500 mL of 2X SSC/0.5% SDS at room temperature without agitation, preferably followed by 500 mL of 2X SSC/0.1% SDS at room temperature with gentle shaking for 15 minutes. A third wash with 0.1X SSC/0.5% SDS at 65°C for 30 minutes to 1 hour is optional. The filter is then preferably dried and subjected to autoradiography for sufficient time to visualize the positives on the X-ray film. Other known hybridization methods can also be employed.

The positive colonies are picked, grown in culture, and plasmid DNA isolated using standard procedures. The clones can then be verified by restriction analysis, hybridization analysis, or DNA sequencing.

Fragments of the proteins of the present invention which are capable of exhibiting biological activity are also encompassed by the present invention. Fragments of the protein may be in linear form or they may be cyclized using known methods, for example, as described in H.U. Saragovi, *et al.*, Bio/Technology 10, 773-778 (1992) and in R.S. McDowell, *et al.*, J. Amer. Chem. Soc. 114, 9245-9253 (1992), both of which are incorporated herein by reference. Such fragments may be fused to carrier molecules such as immunoglobulins for many purposes, including increasing the valency of protein binding sites. For example, fragments of the protein may be fused through "linker" sequences to the Fc portion of an immunoglobulin. For a bivalent form of the protein, such a fusion could be to the Fc portion of an IgG molecule. Other immunoglobulin isotypes may also be used to generate such fusions. For example, a protein - IgM fusion would generate a decavalent form of the protein of the invention.

The present invention also provides both full-length and mature forms of the disclosed proteins. The full-length form of the such proteins is identified in the sequence listing by translation of the nucleotide sequence of each disclosed clone. The mature form of such protein may be obtained by expression of the disclosed full-length polynucleotide (preferably those deposited with ATCC) in a suitable mammalian cell or other host cell. The sequence of the mature form of the protein may also be determinable from the amino acid sequence of the full-length form.

The present invention also provides genes corresponding to the cDNA sequences disclosed herein. "Corresponding genes" are the regions of the genome that are transcribed to produce the mRNAs from which the cDNA sequences are derived and any contiguous regions of the genome necessary for the regulated expression of such genes, including but not limited to coding sequences, 5' and 3' untranslated regions, alternatively spliced exons, introns, promoters, enhancers, and silencer or suppressor elements. The corresponding genes can be isolated in accordance with known methods using the sequence information disclosed herein. Such methods include the preparation of probes or primers from the disclosed sequence information for identification and/or amplification of genes in appropriate genomic libraries or other sources of genomic materials.

Where the protein of the present invention is membrane-bound (e.g., is a receptor), the present invention also provides for soluble forms of such protein. In such forms part or all of the intracellular and transmembrane domains of the protein are deleted such that the protein is fully secreted from the cell in which it is expressed. The intracellular and

transmembrane domains of proteins of the invention can be identified in accordance with known techniques for determination of such domains from sequence information.

Proteins and protein fragments of the present invention include proteins with amino acid sequence lengths that are at least 25% (more preferably at least 50%, and most preferably at least 75%) of the length of a disclosed protein and have at least 60% sequence identity (more preferably, at least 75% identity; most preferably at least 90% or 95% identity) with that disclosed protein, where sequence identity is determined by comparing the amino acid sequences of the proteins when aligned so as to maximize overlap and identity while minimizing sequence gaps. Also included in the present invention are proteins and protein fragments that contain a segment preferably comprising 8 or more (more preferably 20 or more, most preferably 30 or more) contiguous amino acids that shares at least 75% sequence identity (more preferably, at least 85% identity; most preferably at least 95% identity) with any such segment of any of the disclosed proteins.

Species homologs of the disclosed polynucleotides and proteins are also provided by the present invention. As used herein, a "species homologue" is a protein or polynucleotide with a different species of origin from that of a given protein or polynucleotide, but with significant sequence similarity to the given protein or polynucleotide, as determined by those of skill in the art. Species homologs may be isolated and identified by making suitable probes or primers from the sequences provided herein and screening a suitable nucleic acid source from the desired species.

The invention also encompasses allelic variants of the disclosed polynucleotides or proteins; that is, naturally-occurring alternative forms of the isolated polynucleotide which also encode proteins which are identical, homologous, or related to that encoded by the polynucleotides.

The invention also includes polynucleotides with sequences complementary to those of the polynucleotides disclosed herein.

The present invention also includes polynucleotides capable of hybridizing under reduced stringency conditions, more preferably stringent conditions, and most preferably highly stringent conditions, to polynucleotides described herein. Examples of stringency conditions are shown in the table below: highly stringent conditions are those that are at least as stringent as, for example, conditions A-F; stringent conditions are at least as stringent as, for example, conditions G-L; and reduced stringency conditions are at least as stringent as, for example, conditions M-R.

| Stringency Condition | Polynucleotide Hybrid | Hybrid Length (bp) [†] | Hybridization Temperature and Buffer [‡] | Wash Temperature and Buffer [‡] |
|----------------------|-----------------------|---------------------------------|---|--|
| 5 | A | ≥ 50 | 65°C; 1xSSC -or- 42°C; 1xSSC, 50% formamide | 65°C; 0.3xSSC |
| | B | <50 | T _B *; 1xSSC | T _B *; 1xSSC |
| | C | ≥ 50 | 67°C; 1xSSC -or- 45°C; 1xSSC, 50% formamide | 67°C; 0.3xSSC |
| | D | <50 | T _D *; 1xSSC | T _D *; 1xSSC |
| 10 | E | ≥ 50 | 70°C; 1xSSC -or- 50°C; 1xSSC, 50% formamide | 70°C; 0.3xSSC |
| | F | <50 | T _F *; 1xSSC | T _F *; 1xSSC |
| | G | ≥ 50 | 65°C; 4xSSC -or- 42°C; 4xSSC, 50% formamide | 65°C; 1xSSC |
| | H | <50 | T _H *; 4xSSC | T _H *; 4xSSC |
| 15 | I | ≥ 50 | 67°C; 4xSSC -or- 45°C; 4xSSC, 50% formamide | 67°C; 1xSSC |
| | J | <50 | T _J *; 4xSSC | T _J *; 4xSSC |
| | K | ≥ 50 | 70°C; 4xSSC -or- 50°C; 4xSSC, 50% formamide | 67°C; 1xSSC |
| | L | <50 | T _L *; 2xSSC | T _L *; 2xSSC |
| 20 | M | ≥ 50 | 50°C; 4xSSC -or- 40°C; 6xSSC, 50% formamide | 50°C; 2xSSC |
| | N | <50 | T _N *; 6xSSC | T _N *; 6xSSC |
| | O | ≥ 50 | 55°C; 4xSSC -or- 42°C; 6xSSC, 50% formamide | 55°C; 2xSSC |
| | P | <50 | T _P *; 6xSSC | T _P *; 6xSSC |
| 25 | Q | ≥ 50 | 60°C; 4xSSC -or- 45°C; 6xSSC, 50% formamide | 60°C; 2xSSC |
| | R | <50 | T _R *; 4xSSC | T _R *; 4xSSC |

[†]: The hybrid length is that anticipated for the hybridized region(s) of the hybridizing polynucleotides. When hybridizing a polynucleotide to a target polynucleotide of unknown sequence, the hybrid length is assumed to be that of the hybridizing polynucleotide. When polynucleotides of known sequence are hybridized, the hybrid length can be determined by aligning the sequences of the polynucleotides and identifying the region or regions of optimal sequence complementarity.

[‡]: SSPE (1xSSPE is 0.15M NaCl, 10mM NaH₂PO₄, and 1.25mM EDTA, pH 7.4) can be substituted for SSC (1xSSC is 0.15M NaCl and 15mM sodium citrate) in the hybridization and wash buffers; washes are performed for 15 minutes after hybridization is complete.

30 ^{*}T_B - T_R: The hybridization temperature for hybrids anticipated to be less than 50 base pairs in length should be 5-10°C less than the melting temperature (T_m) of the hybrid, where T_m is determined according to the following equations. For hybrids less than 18 base pairs in length, T_m(°C) = 2(# of A + T bases) + 4(# of G + C bases). For hybrids between 18 and 49 base pairs in length, T_m(°C) = 81.5 + 16.6(log₁₀[Na⁺]) + 0.41(%G+C) - (600/N), where N is the number of bases in the hybrid, and [Na⁺] is the concentration of sodium ions in the hybridization buffer ([Na⁺] for 1xSSC = 0.165 M).

Additional examples of stringency conditions for polynucleotide hybridization are provided in Sambrook, J., E.F. Fritsch, and T. Maniatis, 1989, *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, chapters 9 and 11, and *Current Protocols in Molecular Biology*, 1995, F.M. Ausubel et al., eds.,

5 John Wiley & Sons, Inc., sections 2.10 and 6.3-6.4, incorporated herein by reference.

Preferably, each such hybridizing polynucleotide has a length that is at least 25% (more preferably at least 50%, and most preferably at least 75%) of the length of the polynucleotide of the present invention to which it hybridizes, and has at least 60% sequence identity (more preferably, at least 75% identity; most preferably at least 90% or 10 95% identity) with the polynucleotide of the present invention to which it hybridizes, where sequence identity is determined by comparing the sequences of the hybridizing polynucleotides when aligned so as to maximize overlap and identity while minimizing sequence gaps.

The isolated polynucleotide of the invention may be operably linked to an 15 expression control sequence such as the pMT2 or pED expression vectors disclosed in Kaufman *et al.*, Nucleic Acids Res. 19, 4485-4490 (1991), in order to produce the protein recombinantly. Many suitable expression control sequences are known in the art. General methods of expressing recombinant proteins are also known and are exemplified in R. Kaufman, Methods in Enzymology 185, 537-566 (1990). As defined herein "operably 20 linked" means that the isolated polynucleotide of the invention and an expression control sequence are situated within a vector or cell in such a way that the protein is expressed by a host cell which has been transformed (transfected) with the ligated polynucleotide/expression control sequence.

A number of types of cells may act as suitable host cells for expression of the 25 protein. Mammalian host cells include, for example, monkey COS cells, Chinese Hamster Ovary (CHO) cells, human kidney 293 cells, human epidermal A431 cells, human Colo205 cells, 3T3 cells, CV-1 cells, other transformed primate cell lines, normal diploid cells, cell strains derived from *in vitro* culture of primary tissue, primary explants, HeLa cells, mouse L cells, BHK, HL-60, U937, HaK or Jurkat cells.

30 Alternatively, it may be possible to produce the protein in lower eukaryotes such as yeast or in prokaryotes such as bacteria. Potentially suitable yeast strains include *Saccharomyces cerevisiae*, *Schizosaccharomyces pombe*, *Kluyveromyces* strains, *Candida*, or any yeast strain capable of expressing heterologous proteins. Potentially suitable bacterial strains include *Escherichia coli*, *Bacillus subtilis*, *Salmonella typhimurium*, or any bacterial

strain capable of expressing heterologous proteins. If the protein is made in yeast or bacteria, it may be necessary to modify the protein produced therein, for example by phosphorylation or glycosylation of the appropriate sites, in order to obtain the functional protein. Such covalent attachments may be accomplished using known chemical or 5 enzymatic methods.

The protein may also be produced by operably linking the isolated polynucleotide of the invention to suitable control sequences in one or more insect expression vectors, and employing an insect expression system. Materials and methods for baculovirus/insect cell expression systems are commercially available in kit form from, 10 e.g., Invitrogen, San Diego, California, U.S.A. (the MaxBac® kit), and such methods are well known in the art, as described in Summers and Smith, Texas Agricultural Experiment Station Bulletin No. 1555 (1987), incorporated herein by reference. As used herein, an insect cell capable of expressing a polynucleotide of the present invention is "transformed."

15 The protein of the invention may be prepared by culturing transformed host cells under culture conditions suitable to express the recombinant protein. The resulting expressed protein may then be purified from such culture (i.e., from culture medium or cell extracts) using known purification processes, such as gel filtration and ion exchange chromatography. The purification of the protein may also include an affinity column 20 containing agents which will bind to the protein; one or more column steps over such affinity resins as concanavalin A-agarose, heparin-toyopearl® or Cibacrom blue 3GA Sepharose®; one or more steps involving hydrophobic interaction chromatography using such resins as phenyl ether, butyl ether, or propyl ether; or immunoaffinity chromatography.

25 Alternatively, the protein of the invention may also be expressed in a form which will facilitate purification. For example, it may be expressed as a fusion protein, such as those of maltose binding protein (MBP), glutathione-S-transferase (GST) or thioredoxin (TRX). Kits for expression and purification of such fusion proteins are commercially available from New England BioLab (Beverly, MA), Pharmacia (Piscataway, NJ) and 30 InVitrogen, respectively. The protein can also be tagged with an epitope and subsequently purified by using a specific antibody directed to such epitope. One such epitope ("Flag") is commercially available from Kodak (New Haven, CT).

Finally, one or more reverse-phase high performance liquid chromatography (RP-HPLC) steps employing hydrophobic RP-HPLC media, e.g., silica gel having pendant

methyl or other aliphatic groups, can be employed to further purify the protein. Some or all of the foregoing purification steps, in various combinations, can also be employed to provide a substantially homogeneous isolated recombinant protein. The protein thus purified is substantially free of other mammalian proteins and is defined in accordance
5 with the present invention as an "isolated protein."

The protein of the invention may also be expressed as a product of transgenic animals, e.g., as a component of the milk of transgenic cows, goats, pigs, or sheep which are characterized by somatic or germ cells containing a nucleotide sequence encoding the protein.

10 The protein may also be produced by known conventional chemical synthesis. Methods for constructing the proteins of the present invention by synthetic means are known to those skilled in the art. The synthetically-constructed protein sequences, by virtue of sharing primary, secondary or tertiary structural and/or conformational characteristics with proteins may possess biological properties in common therewith,
15 including protein activity. Thus, they may be employed as biologically active or immunological substitutes for natural, purified proteins in screening of therapeutic compounds and in immunological processes for the development of antibodies.

The proteins provided herein also include proteins characterized by amino acid sequences similar to those of purified proteins but into which modification are naturally
20 provided or deliberately engineered. For example, modifications in the peptide or DNA sequences can be made by those skilled in the art using known techniques. Modifications of interest in the protein sequences may include the alteration, substitution, replacement, insertion or deletion of a selected amino acid residue in the coding sequence. For example, one or more of the cysteine residues may be deleted or replaced with another
25 amino acid to alter the conformation of the molecule. Techniques for such alteration, substitution, replacement, insertion or deletion are well known to those skilled in the art (see, e.g., U.S. Patent No. 4,518,584). Preferably, such alteration, substitution, replacement, insertion or deletion retains the desired activity of the protein.

Other fragments and derivatives of the sequences of proteins which would be
30 expected to retain protein activity in whole or in part and may thus be useful for screening or other immunological methodologies may also be easily made by those skilled in the art given the disclosures herein. Such modifications are believed to be encompassed by the present invention.

USES AND BIOLOGICAL ACTIVITY

The polynucleotides and proteins of the present invention are expected to exhibit one or more of the uses or biological activities (including those associated with assays cited herein) identified below. Uses or activities described for proteins of the present invention may be provided by administration or use of such proteins or by administration or use of polynucleotides encoding such proteins (such as, for example, in gene therapies or vectors suitable for introduction of DNA).

Research Uses and Utilities

10 The polynucleotides provided by the present invention can be used by the research community for various purposes. The polynucleotides can be used to express recombinant protein for analysis, characterization or therapeutic use; as markers for tissues in which the corresponding protein is preferentially expressed (either constitutively or at a particular stage of tissue differentiation or development or in disease states); as molecular weight markers on Southern gels; as chromosome markers or tags (when labeled) to identify chromosomes or to map related gene positions; to compare with endogenous DNA sequences in patients to identify potential genetic disorders; as probes to hybridize and thus discover novel, related DNA sequences; as a source of information to derive PCR primers for genetic fingerprinting; as a probe to "subtract-out" known sequences in the process of discovering other novel polynucleotides; for selecting and making oligomers for attachment to a "gene chip" or other support, including for examination of expression patterns; to raise anti-protein antibodies using DNA immunization techniques; and as an antigen to raise anti-DNA antibodies or elicit another immune response. Where the polynucleotide encodes a protein which binds or potentially binds to another protein (such as, for example, in a receptor-ligand interaction), the polynucleotide can also be used in interaction trap assays (such as, for example, that described in Gyuris et al., Cell 75:791-803 (1993)) to identify polynucleotides encoding the other protein with which binding occurs or to identify inhibitors of the binding interaction.

15

20

25

30 The proteins provided by the present invention can similarly be used in assay to determine biological activity, including in a panel of multiple proteins for high-throughput screening; to raise antibodies or to elicit another immune response; as a reagent (including the labeled reagent) in assays designed to quantitatively determine levels of the protein (or its receptor) in biological fluids; as markers for tissues in which

the corresponding protein is preferentially expressed (either constitutively or at a particular stage of tissue differentiation or development or in a disease state); and, of course, to isolate correlative receptors or ligands. Where the protein binds or potentially binds to another protein (such as, for example, in a receptor-ligand interaction), the
5 protein can be used to identify the other protein with which binding occurs or to identify inhibitors of the binding interaction. Proteins involved in these binding interactions can also be used to screen for peptide or small molecule inhibitors or agonists of the binding interaction.

Any or all of these research utilities are capable of being developed into reagent
10 grade or kit format for commercialization as research products.

Methods for performing the uses listed above are well known to those skilled in the art. References disclosing such methods include without limitation "Molecular Cloning: A Laboratory Manual", 2d ed., Cold Spring Harbor Laboratory Press, Sambrook, J., E.F. Fritsch and T. Maniatis eds., 1989, and "Methods in Enzymology: Guide to
15 Molecular Cloning Techniques", Academic Press, Berger, S.L. and A.R. Kimmel eds., 1987.

Nutritional Uses

Polynucleotides and proteins of the present invention can also be used as nutritional sources or supplements. Such uses include without limitation use as a protein
20 or amino acid supplement, use as a carbon source, use as a nitrogen source and use as a source of carbohydrate. In such cases the protein or polynucleotide of the invention can be added to the feed of a particular organism or can be administered as a separate solid or liquid preparation, such as in the form of powder, pills, solutions, suspensions or capsules. In the case of microorganisms, the protein or polynucleotide of the invention
25 can be added to the medium in or on which the microorganism is cultured.

Cytokine and Cell Proliferation/Differentiation Activity

A protein of the present invention may exhibit cytokine, cell proliferation (either inducing or inhibiting) or cell differentiation (either inducing or inhibiting) activity or may
30 induce production of other cytokines in certain cell populations. Many protein factors discovered to date, including all known cytokines, have exhibited activity in one or more factor dependent cell proliferation assays, and hence the assays serve as a convenient confirmation of cytokine activity. The activity of a protein of the present invention is evidenced by any one of a number of routine factor dependent cell proliferation assays

for cell lines including, without limitation, 32D, DA2, DA1G, T10, B9, B9/11, BaF3, MC9/G, M+ (preB M+), 2E8, RB5, DA1, 123, T1165, HT2, CTLL2, TF-1, Mo7e and CMK.

The activity of a protein of the invention may, among other means, be measured
5 by the following methods:

Assays for T-cell or thymocyte proliferation include without limitation those described in: Current Protocols in Immunology, Ed by J. E. Coligan, A.M. Kruisbeek, D.H. Margulies, E.M. Shevach, W Strober, Pub. Greene Publishing Associates and Wiley-Interscience (Chapter 3, In Vitro assays for Mouse Lymphocyte Function 3.1-3.19; Chapter 10 7, Immunologic studies in Humans); Takai et al., J. Immunol. 137:3494-3500, 1986; Bertagnolli et al., J. Immunol. 145:1706-1712, 1990; Bertagnolli et al., Cellular Immunology 133:327-341, 1991; Bertagnolli, et al., J. Immunol. 149:3778-3783, 1992; Bowman et al., J. Immunol. 152: 1756-1761, 1994.

Assays for cytokine production and/or proliferation of spleen cells, lymph node 15 cells or thymocytes include, without limitation, those described in: Polyclonal T cell stimulation, Kruisbeek, A.M. and Shevach, E.M. In *Current Protocols in Immunology*. J.E.e.a. Coligan eds. Vol 1 pp. 3.12.1-3.12.14, John Wiley and Sons, Toronto. 1994; and Measurement of mouse and human Interferon γ , Schreiber, R.D. In *Current Protocols in Immunology*. J.E.e.a. Coligan eds. Vol 1 pp. 6.8.1-6.8.8, John Wiley and Sons, Toronto. 1994.

Assays for proliferation and differentiation of hematopoietic and lymphopoietic 20 cells include, without limitation, those described in: Measurement of Human and Murine Interleukin 2 and Interleukin 4, Bottomly, K., Davis, L.S. and Lipsky, P.E. In *Current Protocols in Immunology*. J.E.e.a. Coligan eds. Vol 1 pp. 6.3.1-6.3.12, John Wiley and Sons, Toronto. 1991; deVries et al., J. Exp. Med. 173:1205-1211, 1991; Moreau et al., Nature 25 336:690-692, 1988; Greenberger et al., Proc. Natl. Acad. Sci. U.S.A. 80:2931-2938, 1983; Measurement of mouse and human interleukin 6 - Nordan, R. In *Current Protocols in Immunology*. J.E.e.a. Coligan eds. Vol 1 pp. 6.6.1-6.6.5, John Wiley and Sons, Toronto. 1991; Smith et al., Proc. Natl. Acad. Sci. U.S.A. 83:1857-1861, 1986; Measurement of human Interleukin 11 - Bennett, F., Giannotti, J., Clark, S.C. and Turner, K. J. In *Current Protocols* 30 in *Immunology*. J.E.e.a. Coligan eds. Vol 1 pp. 6.15.1 John Wiley and Sons, Toronto. 1991; Measurement of mouse and human Interleukin 9 - Ciarletta, A., Giannotti, J., Clark, S.C. and Turner, K.J. In *Current Protocols in Immunology*. J.E.e.a. Coligan eds. Vol 1 pp. 6.13.1, John Wiley and Sons, Toronto. 1991.

Assays for T-cell clone responses to antigens (which will identify, among others, proteins that affect APC-T cell interactions as well as direct T-cell effects by measuring proliferation and cytokine production) include, without limitation, those described in: Current Protocols in Immunology, Ed by J. E. Coligan, A.M. Kruisbeek, D.H. Margulies,

5 E.M. Shevach, W Strober, Pub. Greene Publishing Associates and Wiley-Interscience (Chapter 3, In Vitro assays for Mouse Lymphocyte Function; Chapter 6, Cytokines and their cellular receptors; Chapter 7, Immunologic studies in Humans); Weinberger et al., Proc. Natl. Acad. Sci. USA 77:6091-6095, 1980; Weinberger et al., Eur. J. Immun. 11:405-411, 1981; Takai et al., J. Immunol. 137:3494-3500, 1986; Takai et al., J. Immunol.

10 140:508-512, 1988.

Immune Stimulating or Suppressing Activity

A protein of the present invention may also exhibit immune stimulating or immune suppressing activity, including without limitation the activities for which assays

15 are described herein. A protein may be useful in the treatment of various immune deficiencies and disorders (including severe combined immunodeficiency (SCID)), e.g., in regulating (up or down) growth and proliferation of T and/or B lymphocytes, as well as effecting the cytolytic activity of NK cells and other cell populations. These immune deficiencies may be genetic or be caused by viral (e.g., HIV) as well as bacterial or fungal

20 infections, or may result from autoimmune disorders. More specifically, infectious diseases causes by viral, bacterial, fungal or other infection may be treatable using a protein of the present invention, including infections by HIV, hepatitis viruses, herpesviruses, mycobacteria, Leishmania spp., malaria spp. and various fungal infections such as candidiasis. Of course, in this regard, a protein of the present invention may also

25 be useful where a boost to the immune system generally may be desirable, i.e., in the treatment of cancer.

Autoimmune disorders which may be treated using a protein of the present invention include, for example, connective tissue disease, multiple sclerosis, systemic lupus erythematosus, rheumatoid arthritis, autoimmune pulmonary inflammation,

30 Guillain-Barre syndrome, autoimmune thyroiditis, insulin dependent diabetes mellitus, myasthenia gravis, graft-versus-host disease and autoimmune inflammatory eye disease. Such a protein of the present invention may also be useful in the treatment of allergic reactions and conditions, such as asthma (particularly allergic asthma) or other respiratory problems. Other conditions, in which immune suppression is desired (including, for

example, organ transplantation), may also be treatable using a protein of the present invention.

Using the proteins of the invention it may also be possible to immune responses, in a number of ways. Down regulation may be in the form of inhibiting or blocking an

5 immune response already in progress or may involve preventing the induction of an immune response. The functions of activated T cells may be inhibited by suppressing T cell responses or by inducing specific tolerance in T cells, or both. Immunosuppression of T cell responses is generally an active, non-antigen-specific, process which requires continuous exposure of the T cells to the suppressive agent. Tolerance, which involves

10 inducing non-responsiveness or anergy in T cells, is distinguishable from immunosuppression in that it is generally antigen-specific and persists after exposure to the tolerizing agent has ceased. Operationally, tolerance can be demonstrated by the lack of a T cell response upon reexposure to specific antigen in the absence of the tolerizing agent.

15 Down regulating or preventing one or more antigen functions (including without limitation B lymphocyte antigen functions (such as, for example, B7)), e.g., preventing high level lymphokine synthesis by activated T cells, will be useful in situations of tissue, skin and organ transplantation and in graft-versus-host disease (GVHD). For example, blockage of T cell function should result in reduced tissue destruction in tissue

20 transplantation. Typically, in tissue transplants, rejection of the transplant is initiated through its recognition as foreign by T cells, followed by an immune reaction that destroys the transplant. The administration of a molecule which inhibits or blocks interaction of a B7 lymphocyte antigen with its natural ligand(s) on immune cells (such as a soluble, monomeric form of a peptide having B7-2 activity alone or in conjunction with a

25 monomeric form of a peptide having an activity of another B lymphocyte antigen (e.g., B7-1, B7-3) or blocking antibody), prior to transplantation can lead to the binding of the molecule to the natural ligand(s) on the immune cells without transmitting the corresponding costimulatory signal. Blocking B lymphocyte antigen function in this matter prevents cytokine synthesis by immune cells, such as T cells, and thus acts as an

30 immunosuppressant. Moreover, the lack of costimulation may also be sufficient to anergize the T cells, thereby inducing tolerance in a subject. Induction of long-term tolerance by B lymphocyte antigen-blocking reagents may avoid the necessity of repeated administration of these blocking reagents. To achieve sufficient immunosuppression or

tolerance in a subject, it may also be necessary to block the function of a combination of B lymphocyte antigens.

The efficacy of particular blocking reagents in preventing organ transplant rejection or GVHD can be assessed using animal models that are predictive of efficacy in humans. Examples of appropriate systems which can be used include allogeneic cardiac grafts in rats and xenogeneic pancreatic islet cell grafts in mice, both of which have been used to examine the immunosuppressive effects of CTLA4Ig fusion proteins *in vivo* as described in Lenschow *et al.*, Science 257:789-792 (1992) and Turka *et al.*, Proc. Natl. Acad. Sci USA, 89:11102-11105 (1992). In addition, murine models of GVHD (see Paul ed., Fundamental Immunology, Raven Press, New York, 1989, pp. 846-847) can be used to determine the effect of blocking B lymphocyte antigen function *in vivo* on the development of that disease.

Blocking antigen function may also be therapeutically useful for treating autoimmune diseases. Many autoimmune disorders are the result of inappropriate activation of T cells that are reactive against self tissue and which promote the production of cytokines and autoantibodies involved in the pathology of the diseases. Preventing the activation of autoreactive T cells may reduce or eliminate disease symptoms. Administration of reagents which block costimulation of T cells by disrupting receptor:ligand interactions of B lymphocyte antigens can be used to inhibit T cell activation and prevent production of autoantibodies or T cell-derived cytokines which may be involved in the disease process. Additionally, blocking reagents may induce antigen-specific tolerance of autoreactive T cells which could lead to long-term relief from the disease. The efficacy of blocking reagents in preventing or alleviating autoimmune disorders can be determined using a number of well-characterized animal models of human autoimmune diseases. Examples include murine experimental autoimmune encephalitis, systemic lupus erythematosus in MRL/lpr/lpr mice or NZB hybrid mice, murine autoimmune collagen arthritis, diabetes mellitus in NOD mice and BB rats, and murine experimental myasthenia gravis (see Paul ed., Fundamental Immunology, Raven Press, New York, 1989, pp. 840-856).

Upregulation of an antigen function (preferably a B lymphocyte antigen function), as a means of up regulating immune responses, may also be useful in therapy. Upregulation of immune responses may be in the form of enhancing an existing immune response or eliciting an initial immune response. For example, enhancing an immune response through stimulating B lymphocyte antigen function may be useful in cases of

viral infection. In addition, systemic viral diseases such as influenza, the common cold, and encephalitis might be alleviated by the administration of stimulatory forms of B lymphocyte antigens systemically.

Alternatively, anti-viral immune responses may be enhanced in an infected patient

5 by removing T cells from the patient, costimulating the T cells *in vitro* with viral antigen-pulsed APCs either expressing a peptide of the present invention or together with a stimulatory form of a soluble peptide of the present invention and reintroducing the *in vitro* activated T cells into the patient. Another method of enhancing anti-viral immune responses would be to isolate infected cells from a patient, transfet them with a nucleic

10 acid encoding a protein of the present invention as described herein such that the cells express all or a portion of the protein on their surface, and reintroduce the transfected cells into the patient. The infected cells would now be capable of delivering a costimulatory signal to, and thereby activate, T cells *in vivo*.

In another application, up regulation or enhancement of antigen function

15 (preferably B lymphocyte antigen function) may be useful in the induction of tumor immunity. Tumor cells (*e.g.*, sarcoma, melanoma, lymphoma, leukemia, neuroblastoma, carcinoma) transfected with a nucleic acid encoding at least one peptide of the present invention can be administered to a subject to overcome tumor-specific tolerance in the subject. If desired, the tumor cell can be transfected to express a combination of peptides.

20 For example, tumor cells obtained from a patient can be transfected *ex vivo* with an expression vector directing the expression of a peptide having B7-2-like activity alone, or in conjunction with a peptide having B7-1-like activity and/or B7-3-like activity. The transfected tumor cells are returned to the patient to result in expression of the peptides on the surface of the transfected cell. Alternatively, gene therapy techniques can be used

25 to target a tumor cell for transfection *in vivo*.

The presence of the peptide of the present invention having the activity of a B lymphocyte antigen(s) on the surface of the tumor cell provides the necessary costimulation signal to T cells to induce a T cell mediated immune response against the transfected tumor cells. In addition, tumor cells which lack MHC class I or MHC class II

30 molecules, or which fail to reexpress sufficient amounts of MHC class I or MHC class II molecules, can be transfected with nucleic acid encoding all or a portion of (*e.g.*, a cytoplasmic-domain truncated portion) of an MHC class I α chain protein and β_2 microglobulin protein or an MHC class II α chain protein and an MHC class II β chain protein to thereby express MHC class I or MHC class II proteins on the cell surface.

Expression of the appropriate class I or class II MHC in conjunction with a peptide having the activity of a B lymphocyte antigen (e.g., B7-1, B7-2, B7-3) induces a T cell mediated immune response against the transfected tumor cell. Optionally, a gene encoding an antisense construct which blocks expression of an MHC class II associated protein, such

5 as the invariant chain, can also be cotransfected with a DNA encoding a peptide having the activity of a B lymphocyte antigen to promote presentation of tumor associated antigens and induce tumor specific immunity. Thus, the induction of a T cell mediated immune response in a human subject may be sufficient to overcome tumor-specific tolerance in the subject.

10 The activity of a protein of the invention may, among other means, be measured by the following methods:

Suitable assays for thymocyte or splenocyte cytotoxicity include, without limitation, those described in: *Current Protocols in Immunology*, Ed by J. E. Coligan, A.M. Kruisbeek, D.H. Margulies, E.M. Shevach, W Strober, Pub. Greene Publishing Associates and Wiley-Interscience (Chapter 3, *In Vitro assays for Mouse Lymphocyte Function 3.1-3.19; Chapter 7, Immunologic studies in Humans*); Herrmann et al., Proc. Natl. Acad. Sci. USA 78:2488-2492, 1981; Herrmann et al., J. Immunol. 128:1968-1974, 1982; Handa et al., J. Immunol. 135:1564-1572, 1985; Takai et al., J. Immunol. 137:3494-3500, 1986; Takai et al., J. Immunol. 140:508-512, 1988; Herrmann et al., Proc. Natl. Acad. Sci. USA 78:2488-2492,

15 20 1981; Herrmann et al., J. Immunol. 128:1968-1974, 1982; Handa et al., J. Immunol. 135:1564-1572, 1985; Takai et al., J. Immunol. 137:3494-3500, 1986; Bowman et al., J. Virology 61:1992-1998; Takai et al., J. Immunol. 140:508-512, 1988; Bertagnolli et al., Cellular Immunology 133:327-341, 1991; Brown et al., J. Immunol. 153:3079-3092, 1994.

Assays for T-cell-dependent immunoglobulin responses and isotype switching

25 (which will identify, among others, proteins that modulate T-cell dependent antibody responses and that affect Th1/Th2 profiles) include, without limitation, those described in: Maliszewski, J. Immunol. 144:3028-3033, 1990; and Assays for B cell function: *In vitro antibody production*, Mond, J.J. and Brunswick, M. In *Current Protocols in Immunology*. J.E.e.a. Coligan eds. Vol 1 pp. 3.8.1-3.8.16, John Wiley and Sons, Toronto. 1994.

30 Mixed lymphocyte reaction (MLR) assays (which will identify, among others, proteins that generate predominantly Th1 and CTL responses) include, without limitation, those described in: *Current Protocols in Immunology*, Ed by J. E. Coligan, A.M. Kruisbeek, D.H. Margulies, E.M. Shevach, W Strober, Pub. Greene Publishing Associates and Wiley-Interscience (Chapter 3, *In Vitro assays for Mouse Lymphocyte Function 3.1-3.19; Chapter*

7, Immunologic studies in Humans); Takai et al., J. Immunol. 137:3494-3500, 1986; Takai et al., J. Immunol. 140:508-512, 1988; Bertagnolli et al., J. Immunol. 149:3778-3783, 1992.

Dendritic cell-dependent assays (which will identify, among others, proteins expressed by dendritic cells that activate naive T-cells) include, without limitation, those described in: Guery et al., J. Immunol. 134:536-544, 1995; Inaba et al., Journal of Experimental Medicine 173:549-559, 1991; Macatonia et al., Journal of Immunology 154:5071-5079, 1995; Porgador et al., Journal of Experimental Medicine 182:255-260, 1995; Nair et al., Journal of Virology 67:4062-4069, 1993; Huang et al., Science 264:961-965, 1994; Macatonia et al., Journal of Experimental Medicine 169:1255-1264, 1989; Bhardwaj et al., Journal of Clinical Investigation 94:797-807, 1994; and Inaba et al., Journal of Experimental Medicine 172:631-640, 1990.

Assays for lymphocyte survival/apoptosis (which will identify, among others, proteins that prevent apoptosis after superantigen induction and proteins that regulate lymphocyte homeostasis) include, without limitation, those described in: Darzynkiewicz et al., Cytometry 13:795-808, 1992; Górczyca et al., Leukemia 7:659-670, 1993; Górczyca et al., Cancer Research 53:1945-1951, 1993; Itoh et al., Cell 66:233-243, 1991; Zacharchuk, Journal of Immunology 145:4037-4045, 1990; Zamai et al., Cytometry 14:891-897, 1993; Górczyca et al., International Journal of Oncology 1:639-648, 1992.

Assays for proteins that influence early steps of T-cell commitment and development include, without limitation, those described in: Antica et al., Blood 84:111-117, 1994; Fine et al., Cellular Immunology 155:111-122, 1994; Galy et al., Blood 85:2770-2778, 1995; Toki et al., Proc. Nat. Acad Sci. USA 88:7548-7551, 1991.

Hematopoiesis Regulating Activity

A protein of the present invention may be useful in regulation of hematopoiesis and, consequently, in the treatment of myeloid or lymphoid cell deficiencies. Even marginal biological activity in support of colony forming cells or of factor-dependent cell lines indicates involvement in regulating hematopoiesis, e.g. in supporting the growth and proliferation of erythroid progenitor cells alone or in combination with other cytokines, thereby indicating utility, for example, in treating various anemias or for use in conjunction with irradiation/chemotherapy to stimulate the production of erythroid precursors and/or erythroid cells; in supporting the growth and proliferation of myeloid cells such as granulocytes and monocytes/macrophages (i.e., traditional CSF activity) useful, for example, in conjunction with chemotherapy to prevent or treat consequent

myelo-suppression; in supporting the growth and proliferation of megakaryocytes and consequently of platelets thereby allowing prevention or treatment of various platelet disorders such as thrombocytopenia, and generally for use in place of or complimentary to platelet transfusions; and/or in supporting the growth and proliferation of 5 hematopoietic stem cells which are capable of maturing to any and all of the above-mentioned hematopoietic cells and therefore find therapeutic utility in various stem cell disorders (such as those usually treated with transplantation, including, without limitation, aplastic anemia and paroxysmal nocturnal hemoglobinuria), as well as in repopulating the stem cell compartment post irradiation/chemotherapy, either *in-vivo* or 10 *ex-vivo* (i.e., in conjunction with bone marrow transplantation or with peripheral progenitor cell transplantation (homologous or heterologous)) as normal cells or genetically manipulated for gene therapy.

The activity of a protein of the invention may, among other means, be measured by the following methods:

15 Suitable assays for proliferation and differentiation of various hematopoietic lines are cited above.

Assays for embryonic stem cell differentiation (which will identify, among others, proteins that influence embryonic differentiation hematopoiesis) include, without limitation, those described in: Johansson et al. *Cellular Biology* 15:141-151, 1995; Keller et 20 al., *Molecular and Cellular Biology* 13:473-486, 1993; McClanahan et al., *Blood* 81:2903-2915, 1993.

Assays for stem cell survival and differentiation (which will identify, among others, proteins that regulate lympho-hematopoiesis) include, without limitation, those described in: Methylcellulose colony forming assays, Freshney, M.G. In *Culture of 25 Hematopoietic Cells*. R.I. Freshney, et al. eds. Vol pp. 265-268, Wiley-Liss, Inc., New York, NY. 1994; Hirayama et al., *Proc. Natl. Acad. Sci. USA* 89:5907-5911, 1992; Primitive hematopoietic colony forming cells with high proliferative potential, McNiece, I.K. and Briddell, R.A. In *Culture of Hematopoietic Cells*. R.I. Freshney, et al. eds. Vol pp. 23-39, Wiley-Liss, Inc., New York, NY. 1994; Neben et al., *Experimental Hematology* 22:353-359, 30 1994; Cobblestone area forming cell assay, Ploemacher, R.E. In *Culture of Hematopoietic Cells*. R.I. Freshney, et al. eds. Vol pp. 1-21, Wiley-Liss, Inc., New York, NY. 1994; Long term bone marrow cultures in the presence of stromal cells, Spooncer, E., Dexter, M. and Allen, T. In *Culture of Hematopoietic Cells*. R.I. Freshney, et al. eds. Vol pp. 163-179, Wiley-Liss, Inc., New York, NY. 1994; Long term culture initiating cell assay, Sutherland,

H.J. In *Culture of Hematopoietic Cells*. R.I. Freshney, et al. eds. Vol pp. 139-162, Wiley-Liss, Inc., New York, NY. 1994.

Tissue Growth Activity

5 A protein of the present invention also may have utility in compositions used for bone, cartilage, tendon, ligament and/or nerve tissue growth or regeneration, as well as for wound healing and tissue repair and replacement, and in the treatment of burns, incisions and ulcers.

A protein of the present invention, which induces cartilage and/or bone growth
10 in circumstances where bone is not normally formed, has application in the healing of bone fractures and cartilage damage or defects in humans and other animals. Such a preparation employing a protein of the invention may have prophylactic use in closed as well as open fracture reduction and also in the improved fixation of artificial joints. *De novo* bone formation induced by an osteogenic agent contributes to the repair of
15 congenital, trauma induced, or oncologic resection induced craniofacial defects, and also is useful in cosmetic plastic surgery.

A protein of this invention may also be used in the treatment of periodontal disease, and in other tooth repair processes. Such agents may provide an environment to attract bone-forming cells, stimulate growth of bone-forming cells or induce
20 differentiation of progenitors of bone-forming cells. A protein of the invention may also be useful in the treatment of osteoporosis or osteoarthritis, such as through stimulation of bone and/or cartilage repair or by blocking inflammation or processes of tissue destruction (collagenase activity, osteoclast activity, etc.) mediated by inflammatory processes.

25 Another category of tissue regeneration activity that may be attributable to the protein of the present invention is tendon/ligament formation. A protein of the present invention, which induces tendon/ligament-like tissue or other tissue formation in circumstances where such tissue is not normally formed, has application in the healing of tendon or ligament tears, deformities and other tendon or ligament defects in humans and
30 other animals. Such a preparation employing a tendon/ligament-like tissue inducing protein may have prophylactic use in preventing damage to tendon or ligament tissue, as well as use in the improved fixation of tendon or ligament to bone or other tissues, and in repairing defects to tendon or ligament tissue. *De novo* tendon/ligament-like tissue formation induced by a composition of the present invention contributes to the repair of

congenital, trauma induced, or other tendon or ligament defects of other origin, and is also useful in cosmetic plastic surgery for attachment or repair of tendons or ligaments. The compositions of the present invention may provide an environment to attract tendon- or ligament-forming cells, stimulate growth of tendon- or ligament-forming cells, induce 5 differentiation of progenitors of tendon- or ligament-forming cells, or induce growth of tendon/ligament cells or progenitors *ex vivo* for return *in vivo* to effect tissue repair. The compositions of the invention may also be useful in the treatment of tendinitis, carpal tunnel syndrome and other tendon or ligament defects. The compositions may also include an appropriate matrix and/or sequestering agent as a carrier as is well known in 10 the art.

The protein of the present invention may also be useful for proliferation of neural cells and for regeneration of nerve and brain tissue, *i.e.* for the treatment of central and peripheral nervous system diseases and neuropathies, as well as mechanical and traumatic disorders, which involve degeneration, death or trauma to neural cells or nerve 15 tissue. More specifically, a protein may be used in the treatment of diseases of the peripheral nervous system, such as peripheral nerve injuries, peripheral neuropathy and localized neuropathies, and central nervous system diseases, such as Alzheimer's, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, and Shy-Drager syndrome. Further conditions which may be treated in accordance with the present 20 invention include mechanical and traumatic disorders, such as spinal cord disorders, head trauma and cerebrovascular diseases such as stroke. Peripheral neuropathies resulting from chemotherapy or other medical therapies may also be treatable using a protein of the invention.

Proteins of the invention may also be useful to promote better or faster closure of 25 non-healing wounds, including without limitation pressure ulcers, ulcers associated with vascular insufficiency, surgical and traumatic wounds, and the like.

It is expected that a protein of the present invention may also exhibit activity for generation or regeneration of other tissues, such as organs (including, for example, pancreas, liver, intestine, kidney, skin, endothelium), muscle (smooth, skeletal or cardiac) 30 and vascular (including vascular endothelium) tissue, or for promoting the growth of cells comprising such tissues. Part of the desired effects may be by inhibition or modulation of fibrotic scarring to allow normal tissue to regenerate. A protein of the invention may also exhibit angiogenic activity.

A protein of the present invention may also be useful for gut protection or regeneration and treatment of lung or liver fibrosis, reperfusion injury in various tissues, and conditions resulting from systemic cytokine damage.

5 A protein of the present invention may also be useful for promoting or inhibiting differentiation of tissues described above from precursor tissues or cells; or for inhibiting the growth of tissues described above.

The activity of a protein of the invention may, among other means, be measured by the following methods:

Assays for tissue generation activity include, without limitation, those described
10 in: International Patent Publication No. WO95/16035 (bone, cartilage, tendon);
International Patent Publication No. WO95/05846 (nerve, neuronal); International Patent
Publication No. WO91/07491 (skin, endothelium).

Assays for wound healing activity include, without limitation, those described in:
Winter, Epidermal Wound Healing, pps. 71-112 (Maibach, HI and Rovee, DT, eds.), Year
15 Book Medical Publishers, Inc., Chicago, as modified by Eaglstein and Mertz, J. Invest.
Dermatol 71:382-84 (1978).

Activin/Inhibin Activity

A protein of the present invention may also exhibit activin- or inhibin-related
20 activities. Inhibins are characterized by their ability to inhibit the release of follicle stimulating hormone (FSH), while activins and are characterized by their ability to stimulate the release of follicle stimulating hormone (FSH). Thus, a protein of the present invention, alone or in heterodimers with a member of the inhibin α family, may be useful as a contraceptive based on the ability of inhibins to decrease fertility in female mammals
25 and decrease spermatogenesis in male mammals. Administration of sufficient amounts of other inhibins can induce infertility in these mammals. Alternatively, the protein of the invention, as a homodimer or as a heterodimer with other protein subunits of the inhibin- β group, may be useful as a fertility inducing therapeutic, based upon the ability of activin molecules in stimulating FSH release from cells of the anterior pituitary. See, for example,
30 United States Patent 4,798,885. A protein of the invention may also be useful for advancement of the onset of fertility in sexually immature mammals, so as to increase the lifetime reproductive performance of domestic animals such as cows, sheep and pigs.

The activity of a protein of the invention may, among other means, be measured by the following methods:

Assays for activin/inhibin activity include, without limitation, those described in: Vale et al., Endocrinology 91:562-572, 1972; Ling et al., Nature 321:779-782, 1986; Vale et al., Nature 321:776-779, 1986; Mason et al., Nature 318:659-663, 1985; Forage et al., Proc. Natl. Acad. Sci. USA 83:3091-3095, 1986.

5

Chemotactic/Chemokinetic Activity

A protein of the present invention may have chemotactic or chemokinetic activity (e.g., act as a chemokine) for mammalian cells, including, for example, monocytes, fibroblasts, neutrophils, T-cells, mast cells, eosinophils, epithelial and/or endothelial cells.

10 Chemotactic and chemokinetic proteins can be used to mobilize or attract a desired cell population to a desired site of action. Chemotactic or chemokinetic proteins provide particular advantages in treatment of wounds and other trauma to tissues, as well as in treatment of localized infections. For example, attraction of lymphocytes, monocytes or neutrophils to tumors or sites of infection may result in improved immune responses

15 against the tumor or infecting agent.

A protein or peptide has chemotactic activity for a particular cell population if it can stimulate, directly or indirectly, the directed orientation or movement of such cell population. Preferably, the protein or peptide has the ability to directly stimulate directed movement of cells. Whether a particular protein has chemotactic activity for a population

20 of cells can be readily determined by employing such protein or peptide in any known assay for cell chemotaxis.

The activity of a protein of the invention may, among other means, be measured by the following methods:

Assays for chemotactic activity (which will identify proteins that induce or prevent

25 chemotaxis) consist of assays that measure the ability of a protein to induce the migration of cells across a membrane as well as the ability of a protein to induce the adhesion of one cell population to another cell population. Suitable assays for movement and adhesion include, without limitation, those described in: Current Protocols in Immunology, Ed by J.E. Coligan, A.M. Kruisbeek, D.H. Margulies, E.M. Shevach, W. Strober, Pub. Greene

30 Publishing Associates and Wiley-Interscience (Chapter 6.12, Measurement of alpha and beta Chemokines 6.12.1-6.12.28; Taub et al. J. Clin. Invest. 95:1370-1376, 1995; Lind et al. APMIS 103:140-146, 1995; Muller et al Eur. J. Immunol. 25: 1744-1748; Gruber et al. J. of Immunol. 152:5860-5867, 1994; Johnston et al. J. of Immunol. 153: 1762-1768, 1994.

Hemostatic and Thrombolytic Activity

A protein of the invention may also exhibit hemostatic or thrombolytic activity. As a result, such a protein is expected to be useful in treatment of various coagulation disorders (including hereditary disorders, such as hemophilias) or to enhance coagulation 5 and other hemostatic events in treating wounds resulting from trauma, surgery or other causes. A protein of the invention may also be useful for dissolving or inhibiting formation of thromboses and for treatment and prevention of conditions resulting therefrom (such as, for example, infarction of cardiac and central nervous system vessels (e.g., stroke).

10 The activity of a protein of the invention may, among other means, be measured by the following methods:

Assay for hemostatic and thrombolytic activity include, without limitation, those described in: Linet et al., J. Clin. Pharmacol. 26:131-140, 1986; Burdick et al., Thrombosis Res. 45:413-419, 1987; Humphrey et al., Fibrinolysis 5:71-79 (1991); Schaub, Prostaglandins 15 35:467-474, 1988.

Receptor/Ligand Activity

A protein of the present invention may also demonstrate activity as receptors, receptor ligands or inhibitors or agonists of receptor/ligand interactions. Examples of 20 such receptors and ligands include, without limitation, cytokine receptors and their ligands, receptor kinases and their ligands, receptor phosphatases and their ligands, receptors involved in cell-cell interactions and their ligands (including without limitation, cellular adhesion molecules (such as selectins, integrins and their ligands) and receptor/ligand pairs involved in antigen presentation, antigen recognition and 25 development of cellular and humoral immune responses). Receptors and ligands are also useful for screening of potential peptide or small molecule inhibitors of the relevant receptor/ligand interaction. A protein of the present invention (including, without limitation, fragments of receptors and ligands) may themselves be useful as inhibitors of receptor/ligand interactions.

30 The activity of a protein of the invention may, among other means, be measured by the following methods:

Suitable assays for receptor-ligand activity include without limitation those described in: Current Protocols in Immunology, Ed by J.E. Coligan, A.M. Kruisbeek, D.H. Margulies, E.M. Shevach, W. Strober, Pub. Greene Publishing Associates and

Wiley-Interscience (Chapter 7.28, Measurement of Cellular Adhesion under static conditions 7.28.1-7.28.22), Takai et al., Proc. Natl. Acad. Sci. USA 84:6864-6868, 1987; Bierer et al., J. Exp. Med. 168:1145-1156, 1988; Rosenstein et al., J. Exp. Med. 169:149-160 1989; Stoltenborg et al., J. Immunol. Methods 175:59-68, 1994; Stitt et al., Cell 80:661-670, 5 1995.

Anti-Inflammatory Activity

Proteins of the present invention may also exhibit anti-inflammatory activity. The anti-inflammatory activity may be achieved by providing a stimulus to cells involved in 10 the inflammatory response, by inhibiting or promoting cell-cell interactions (such as, for example, cell adhesion), by inhibiting or promoting chemotaxis of cells involved in the inflammatory process, inhibiting or promoting cell extravasation, or by stimulating or suppressing production of other factors which more directly inhibit or promote an inflammatory response. Proteins exhibiting such activities can be used to treat 15 inflammatory conditions including chronic or acute conditions), including without limitation inflammation associated with infection (such as septic shock, sepsis or systemic inflammatory response syndrome (SIRS)), ischemia-reperfusion injury, endotoxin lethality, arthritis, complement-mediated hyperacute rejection, nephritis, cytokine or chemokine-induced lung injury, inflammatory bowel disease, Crohn's disease or resulting 20 from over production of cytokines such as TNF or IL-1. Proteins of the invention may also be useful to treat anaphylaxis and hypersensitivity to an antigenic substance or material.

Cadherin/Tumor Invasion Suppressor Activity

Cadherins are calcium-dependent adhesion molecules that appear to play major 25 roles during development, particularly in defining specific cell types. Loss or alteration of normal cadherin expression can lead to changes in cell adhesion properties linked to tumor growth and metastasis. Cadherin malfunction is also implicated in other human diseases, such as pemphigus vulgaris and pemphigus foliaceus (auto-immune blistering skin diseases), Crohn's disease, and some developmental abnormalities.

30 The cadherin superfamily includes well over forty members, each with a distinct pattern of expression. All members of the superfamily have in common conserved extracellular repeats (cadherin domains), but structural differences are found in other parts of the molecule. The cadherin domains bind calcium to form their tertiary structure and thus calcium is required to mediate their adhesion. Only a few amino acids in the

first cadherin domain provide the basis for homophilic adhesion; modification of this recognition site can change the specificity of a cadherin so that instead of recognizing only itself, the mutant molecule can now also bind to a different cadherin. In addition, some cadherins engage in heterophilic adhesion with other cadherins.

5 E-cadherin, one member of the cadherin superfamily, is expressed in epithelial cell types. Pathologically, if E-cadherin expression is lost in a tumor, the malignant cells become invasive and the cancer metastasizes. Transfection of cancer cell lines with polynucleotides expressing E-cadherin has reversed cancer-associated changes by returning altered cell shapes to normal, restoring cells' adhesiveness to each other and to
10 their substrate, decreasing the cell growth rate, and drastically reducing anchorage-independent cell growth. Thus, reintroducing E-cadherin expression reverts carcinomas to a less advanced stage. It is likely that other cadherins have the same invasion suppressor role in carcinomas derived from other tissue types. Therefore, proteins of the present invention with cadherin activity, and polynucleotides of the present invention
15 encoding such proteins, can be used to treat cancer. Introducing such proteins or polynucleotides into cancer cells can reduce or eliminate the cancerous changes observed
20 in these cells by providing normal cadherin expression.

Cancer cells have also been shown to express cadherins of a different tissue type than their origin, thus allowing these cells to invade and metastasize in a different tissue
20 in the body. Proteins of the present invention with cadherin activity, and polynucleotides of the present invention encoding such proteins, can be substituted in these cells for the inappropriately expressed cadherins, restoring normal cell adhesive properties and reducing or eliminating the tendency of the cells to metastasize.

Additionally, proteins of the present invention with cadherin activity, and
25 polynucleotides of the present invention encoding such proteins, can be used to generate antibodies recognizing and binding to cadherins. Such antibodies can be used to block the adhesion of inappropriately expressed tumor-cell cadherins, preventing the cells from forming a tumor elsewhere. Such an anti-cadherin antibody can also be used as a marker for the grade, pathological type, and prognosis of a cancer, i.e. the more progressed the
30 cancer, the less cadherin expression there will be, and this decrease in cadherin expression can be detected by the use of a cadherin-binding antibody.

Fragments of proteins of the present invention with cadherin activity, preferably a polypeptide comprising a decapeptide of the cadherin recognition site, and polynucleotides of the present invention encoding such protein fragments, can also be used

to block cadherin function by binding to cadherins and preventing them from binding in ways that produce undesirable effects. Additionally, fragments of proteins of the present invention with cadherin activity, preferably truncated soluble cadherin fragments which have been found to be stable in the circulation of cancer patients, and polynucleotides 5 encoding such protein fragments, can be used to disturb proper cell-cell adhesion.

Assays for cadherin adhesive and invasive suppressor activity include, without limitation, those described in: Hortsch et al. J Biol Chem 270 (32): 18809-18817, 1995; Miyaki et al. Oncogene 11: 2547-2552, 1995; Ozawa et al. Cell 63: 1033-1038, 1990.

10 Tumor Inhibition Activity

In addition to the activities described above for immunological treatment or prevention of tumors, a protein of the invention may exhibit other anti-tumor activities. A protein may inhibit tumor growth directly or indirectly (such as, for example, via ADCC). A protein may exhibit its tumor inhibitory activity by acting on tumor tissue or 15 tumor precursor tissue, by inhibiting formation of tissues necessary to support tumor growth (such as, for example, by inhibiting angiogenesis), by causing production of other factors, agents or cell types which inhibit tumor growth, or by suppressing, eliminating or inhibiting factors, agents or cell types which promote tumor growth.

20 Other Activities

A protein of the invention may also exhibit one or more of the following additional activities or effects: inhibiting the growth, infection or function of, or killing, infectious agents, including, without limitation, bacteria, viruses, fungi and other parasites; effecting (suppressing or enhancing) bodily characteristics, including, without limitation, height, 25 weight, hair color, eye color, skin, fat to lean ratio or other tissue pigmentation, or organ or body part size or shape (such as, for example, breast augmentation or diminution, change in bone form or shape); effecting biorhythms or circadian cycles or rhythms; effecting the fertility of male or female subjects; effecting the metabolism, catabolism, anabolism, processing, utilization, storage or elimination of dietary fat, lipid, protein, 30 carbohydrate, vitamins, minerals, cofactors or other nutritional factors or component(s); effecting behavioral characteristics, including, without limitation, appetite, libido, stress, cognition (including cognitive disorders), depression (including depressive disorders) and violent behaviors; providing analgesic effects or other pain reducing effects; promoting differentiation and growth of embryonic stem cells in lineages other than hematopoietic

lineages; hormonal or endocrine activity; in the case of enzymes, correcting deficiencies of the enzyme and treating deficiency-related diseases; treatment of hyperproliferative disorders (such as, for example, psoriasis); immunoglobulin-like activity (such as, for example, the ability to bind antigens or complement); and the ability to act as an antigen

5 in a vaccine composition to raise an immune response against such protein or another material or entity which is cross-reactive with such protein.

ADMINISTRATION AND DOSING

10 A protein of the present invention (from whatever source derived, including without limitation from recombinant and non-recombinant sources) may be used in a pharmaceutical composition when combined with a pharmaceutically acceptable carrier. Such a composition may also contain (in addition to protein and a carrier) diluents, fillers, salts, buffers, stabilizers, solubilizers, and other materials well known in the art. The term

15 "pharmaceutically acceptable" means a non-toxic material that does not interfere with the effectiveness of the biological activity of the active ingredient(s). The characteristics of the carrier will depend on the route of administration. The pharmaceutical composition of the invention may also contain cytokines, lymphokines, or other hematopoietic factors such as M-CSF, GM-CSF, TNF, IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11,

20 IL-12, IL-13, IL-14, IL-15, IFN, TNF₀, TNF₁, TNF₂, G-CSF, Meg-CSF, thrombopoietin, stem cell factor, and erythropoietin. The pharmaceutical composition may further contain other agents which either enhance the activity of the protein or compliment its activity or use in treatment. Such additional factors and/or agents may be included in the pharmaceutical composition to produce a synergistic effect with protein of the invention,

25 or to minimize side effects. Conversely, protein of the present invention may be included in formulations of the particular cytokine, lymphokine, other hematopoietic factor, thrombolytic or anti-thrombotic factor, or anti-inflammatory agent to minimize side effects of the cytokine, lymphokine, other hematopoietic factor, thrombolytic or anti-thrombotic factor, or anti-inflammatory agent.

30 A protein of the present invention may be active in multimers (e.g., heterodimers or homodimers) or complexes with itself or other proteins. As a result, pharmaceutical compositions of the invention may comprise a protein of the invention in such multimeric or complexed form.

The pharmaceutical composition of the invention may be in the form of a complex of the protein(s) of present invention along with protein or peptide antigens. The protein and/or peptide antigen will deliver a stimulatory signal to both B and T lymphocytes. B lymphocytes will respond to antigen through their surface immunoglobulin receptor. T 5 lymphocytes will respond to antigen through the T cell receptor (TCR) following presentation of the antigen by MHC proteins. MHC and structurally related proteins including those encoded by class I and class II MHC genes on host cells will serve to present the peptide antigen(s) to T lymphocytes. The antigen components could also be supplied as purified MHC-peptide complexes alone or with co-stimulatory molecules that 10 can directly signal T cells. Alternatively antibodies able to bind surface immunoglobulin and other molecules on B cells as well as antibodies able to bind the TCR and other molecules on T cells can be combined with the pharmaceutical composition of the invention.

The pharmaceutical composition of the invention may be in the form of a liposome 15 in which protein of the present invention is combined, in addition to other pharmaceutically acceptable carriers, with amphipathic agents such as lipids which exist in aggregated form as micelles, insoluble monolayers, liquid crystals, or lamellar layers in aqueous solution. Suitable lipids for liposomal formulation include, without limitation, monoglycerides, diglycerides, sulfatides, lysolecithin, phospholipids, saponin, bile acids, 20 and the like. Preparation of such liposomal formulations is within the level of skill in the art, as disclosed, for example, in U.S. Patent No. 4,235,871; U.S. Patent No. 4,501,728; U.S. Patent No. 4,837,028; and U.S. Patent No. 4,737,323, all of which are incorporated herein by reference.

As used herein, the term "therapeutically effective amount" means the total 25 amount of each active component of the pharmaceutical composition or method that is sufficient to show a meaningful patient benefit, i.e., treatment, healing, prevention or amelioration of the relevant medical condition, or an increase in rate of treatment, healing, prevention or amelioration of such conditions. When applied to an individual active ingredient, administered alone, the term refers to that ingredient alone. When applied to 30 a combination, the term refers to combined amounts of the active ingredients that result in the therapeutic effect, whether administered in combination, serially or simultaneously.

In practicing the method of treatment or use of the present invention, a therapeutically effective amount of protein of the present invention is administered to a mammal having a condition to be treated. Protein of the present invention may be

administered in accordance with the method of the invention either alone or in combination with other therapies such as treatments employing cytokines, lymphokines or other hematopoietic factors. When co-administered with one or more cytokines, lymphokines or other hematopoietic factors, protein of the present invention may be
5 administered either simultaneously with the cytokine(s), lymphokine(s), other hematopoietic factor(s), thrombolytic or anti-thrombotic factors, or sequentially. If administered sequentially, the attending physician will decide on the appropriate sequence of administering protein of the present invention in combination with cytokine(s), lymphokine(s), other hematopoietic factor(s), thrombolytic or anti-thrombotic
10 factors.

Administration of protein of the present invention used in the pharmaceutical composition or to practice the method of the present invention can be carried out in a variety of conventional ways, such as oral ingestion, inhalation, topical application or cutaneous, subcutaneous, intraperitoneal, parenteral or intravenous injection.
15

15 Intravenous administration to the patient is preferred.

When a therapeutically effective amount of protein of the present invention is administered orally, protein of the present invention will be in the form of a tablet, capsule, powder, solution or elixir. When administered in tablet form, the pharmaceutical composition of the invention may additionally contain a solid carrier such as a gelatin or
20 an adjuvant. The tablet, capsule, and powder contain from about 5 to 95% protein of the present invention, and preferably from about 25 to 90% protein of the present invention. When administered in liquid form, a liquid carrier such as water, petroleum, oils of animal or plant origin such as peanut oil, mineral oil, soybean oil, or sesame oil, or synthetic oils may be added. The liquid form of the pharmaceutical composition may further contain
25 physiological saline solution, dextrose or other saccharide solution, or glycols such as ethylene glycol, propylene glycol or polyethylene glycol. When administered in liquid form, the pharmaceutical composition contains from about 0.5 to 90% by weight of protein of the present invention, and preferably from about 1 to 50% protein of the present invention.

30 When a therapeutically effective amount of protein of the present invention is administered by intravenous, cutaneous or subcutaneous injection, protein of the present invention will be in the form of a pyrogen-free, parenterally acceptable aqueous solution. The preparation of such parenterally acceptable protein solutions, having due regard to pH, isotonicity, stability, and the like, is within the skill in the art. A preferred

pharmaceutical composition for intravenous, cutaneous, or subcutaneous injection should contain, in addition to protein of the present invention, an isotonic vehicle such as Sodium Chloride Injection, Ringer's Injection, Dextrose Injection, Dextrose and Sodium Chloride Injection, Lactated Ringer's Injection, or other vehicle as known in the art. The 5 pharmaceutical composition of the present invention may also contain stabilizers, preservatives, buffers, antioxidants, or other additives known to those of skill in the art.

The amount of protein of the present invention in the pharmaceutical composition of the present invention will depend upon the nature and severity of the condition being treated, and on the nature of prior treatments which the patient has undergone. 10 Ultimately, the attending physician will decide the amount of protein of the present invention with which to treat each individual patient. Initially, the attending physician will administer low doses of protein of the present invention and observe the patient's response. Larger doses of protein of the present invention may be administered until the optimal therapeutic effect is obtained for the patient, and at that point the dosage is not 15 increased further. It is contemplated that the various pharmaceutical compositions used to practice the method of the present invention should contain about 0.01 µg to about 100 mg (preferably about 0.1ng to about 10 mg, more preferably about 0.1 µg to about 1 mg) of protein of the present invention per kg body weight.

The duration of intravenous therapy using the pharmaceutical composition of the 20 present invention will vary, depending on the severity of the disease being treated and the condition and potential idiosyncratic response of each individual patient. It is contemplated that the duration of each application of the protein of the present invention will be in the range of 12 to 24 hours of continuous intravenous administration. Ultimately the attending physician will decide on the appropriate duration of intravenous 25 therapy using the pharmaceutical composition of the present invention.

Protein of the invention may also be used to immunize animals to obtain polyclonal and monoclonal antibodies which specifically react with the protein. Such antibodies may be obtained using either the entire protein or fragments thereof as an immunogen. The peptide immunogens additionally may contain a cysteine residue at the 30 carboxyl terminus, and are conjugated to a hapten such as keyhole limpet hemocyanin (KLH). Methods for synthesizing such peptides are known in the art, for example, as in R.P. Merrifield, J. Amer.Chem.Soc. 85, 2149-2154 (1963); J.L. Krstenansky, *et al.*, FEBS Lett. 211, 10 (1987). Monoclonal antibodies binding to the protein of the invention may be useful diagnostic agents for the immunodetection of the protein. Neutralizing monoclonal

antibodies binding to the protein may also be useful therapeutics for both conditions associated with the protein and also in the treatment of some forms of cancer where abnormal expression of the protein is involved. In the case of cancerous cells or leukemic cells, neutralizing monoclonal antibodies against the protein may be useful in detecting 5 and preventing the metastatic spread of the cancerous cells, which may be mediated by the protein.

For compositions of the present invention which are useful for bone, cartilage, tendon or ligament regeneration, the therapeutic method includes administering the composition topically, systematically, or locally as an implant or device. When 10 administered, the therapeutic composition for use in this invention is, of course, in a pyrogen-free, physiologically acceptable form. Further, the composition may desirably be encapsulated or injected in a viscous form for delivery to the site of bone, cartilage or tissue damage. Topical administration may be suitable for wound healing and tissue repair. Therapeutically useful agents other than a protein of the invention which may also 15 optionally be included in the composition as described above, may alternatively or additionally, be administered simultaneously or sequentially with the composition in the methods of the invention. Preferably for bone and/or cartilage formation, the composition would include a matrix capable of delivering the protein-containing composition to the site of bone and/or cartilage damage, providing a structure for the 20 developing bone and cartilage and optimally capable of being resorbed into the body. Such matrices may be formed of materials presently in use for other implanted medical applications.

The choice of matrix material is based on biocompatibility, biodegradability, mechanical properties, cosmetic appearance and interface properties. The particular 25 application of the compositions will define the appropriate formulation. Potential matrices for the compositions may be biodegradable and chemically defined calcium sulfate, tricalciumphosphate, hydroxyapatite, polylactic acid, polyglycolic acid and polyanhydrides. Other potential materials are biodegradable and biologically well-defined, such as bone or dermal collagen. Further matrices are comprised of pure proteins 30 or extracellular matrix components. Other potential matrices are nonbiodegradable and chemically defined, such as sintered hydroxapatite, bioglass, aluminates, or other ceramics. Matrices may be comprised of combinations of any of the above mentioned types of material, such as polylactic acid and hydroxyapatite or collagen and tricalciumphosphate. The bioceramics may be altered in composition, such as in calcium-

aluminate-phosphate and processing to alter pore size, particle size, particle shape, and biodegradability.

Presently preferred is a 50:50 (mole weight) copolymer of lactic acid and glycolic acid in the form of porous particles having diameters ranging from 150 to 800 microns.

5 In some applications, it will be useful to utilize a sequestering agent, such as carboxymethyl cellulose or autologous blood clot, to prevent the protein compositions from disassociating from the matrix.

A preferred family of sequestering agents is cellulosic materials such as alkylcelluloses (including hydroxyalkylcelluloses), including methylcellulose, 10 ethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, and carboxymethylcellulose, the most preferred being cationic salts of carboxymethylcellulose (CMC). Other preferred sequestering agents include hyaluronic acid, sodium alginate, poly(ethylene glycol), polyoxyethylene oxide, carboxyvinyl polymer and poly(vinyl alcohol). The amount of sequestering agent useful herein is 0.5-20 15 wt%, preferably 1-10 wt% based on total formulation weight, which represents the amount necessary to prevent desorption of the protein from the polymer matrix and to provide appropriate handling of the composition, yet not so much that the progenitor cells are prevented from infiltrating the matrix, thereby providing the protein the opportunity to assist the osteogenic activity of the progenitor cells.

20 In further compositions, proteins of the invention may be combined with other agents beneficial to the treatment of the bone and/or cartilage defect, wound, or tissue in question. These agents include various growth factors such as epidermal growth factor (EGF), platelet derived growth factor (PDGF), transforming growth factors (TGF- α and TGF- β), and insulin-like growth factor (IGF).

25 The therapeutic compositions are also presently valuable for veterinary applications. Particularly domestic animals and thoroughbred horses, in addition to humans, are desired patients for such treatment with proteins of the present invention.

The dosage regimen of a protein-containing pharmaceutical composition to be used in tissue regeneration will be determined by the attending physician considering 30 various factors which modify the action of the proteins, e.g., amount of tissue weight desired to be formed, the site of damage, the condition of the damaged tissue, the size of a wound, type of damaged tissue (e.g., bone), the patient's age, sex, and diet, the severity of any infection, time of administration and other clinical factors. The dosage may vary with the type of matrix used in the reconstitution and with inclusion of other proteins in

the pharmaceutical composition. For example, the addition of other known growth factors, such as IGF I (insulin like growth factor I), to the final composition, may also effect the dosage. Progress can be monitored by periodic assessment of tissue/bone growth and/or repair, for example, X-rays, histomorphometric determinations and tetracycline labeling.

Polynucleotides of the present invention can also be used for gene therapy. Such polynucleotides can be introduced either *in vivo* or *ex vivo* into cells for expression in a mammalian subject. Polynucleotides of the invention may also be administered by other known methods for introduction of nucleic acid into a cell or organism (including, without limitation, in the form of viral vectors or naked DNA).

Cells may also be cultured *ex vivo* in the presence of proteins of the present invention in order to proliferate or to produce a desired effect on or activity in such cells. Treated cells can then be introduced *in vivo* for therapeutic purposes.

Patent and literature references cited herein are incorporated by reference as if fully set forth.

What is claimed is:

1. A composition comprising an isolated polynucleotide selected from the group consisting of:
 - (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:1;
 - (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:1 from nucleotide 44 to nucleotide 1204;
 - (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:1 from nucleotide 1 to nucleotide 403;
 - (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone AJ26_3 deposited under accession number ATCC 98115;
 - (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone AJ26_3 deposited under accession number ATCC 98115;
 - (f) a polynucleotide comprising the nucleotide sequence of the mature protein coding sequence of clone AJ26_3 deposited under accession number ATCC 98115;
 - (g) a polynucleotide encoding the mature protein encoded by the cDNA insert of clone AJ26_3 deposited under accession number ATCC 98115;
 - (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:2;
 - (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:2 having biological activity;
 - (j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;
 - (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ; and
 - (l) a polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides specified in (a)-(i).
2. A composition of claim 1 wherein said polynucleotide is operably linked to at least one expression control sequence.
3. A host cell transformed with a composition of claim 2.
4. The host cell of claim 3, wherein said cell is a mammalian cell.
5. A process for producing a protein encoded by a composition of claim 2, which process comprises:
 - (a) growing a culture of the host cell of claim 3 in a suitable culture medium; and
 - (b) purifying said protein from the culture.

6. A protein produced according to the process of claim 5.

7. A composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:2;
- (b) the amino acid sequence of SEQ ID NO:2 from amino acid 1 to amino acid 120;
- (c) fragments of the amino acid sequence of SEQ ID NO:2; and
- (d) the amino acid sequence encoded by the cDNA insert of clone AJ26_3 deposited under accession number ATCC 98115;

the protein being substantially free from other mammalian proteins.

8. The composition of claim 7, wherein said protein comprises the amino acid sequence of SEQ ID NO:2.

9. The composition of claim 7, wherein said protein comprises the amino acid sequence of SEQ ID NO:2 from amino acid 1 to amino acid 120.

10. A composition of claim 7, further comprising a pharmaceutically acceptable carrier.

11. A method for preventing, treating or ameliorating a medical condition which comprises administering to a mammalian subject a therapeutically effective amount of a composition of claim 10.

12. An isolated gene corresponding to the cDNA sequence of SEQ ID NO:1.

13. A composition comprising an isolated polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:3;
- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:3 from nucleotide 928 to nucleotide 2541;
- (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:3 from nucleotide 988 to nucleotide 2541;
- (d) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:3 from nucleotide 684 to nucleotide 1128;
- (e) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone AJ172_2 deposited under accession number ATCC 98115;
- (f) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone AJ172_2 deposited under accession number ATCC 98115;

- (g) a polynucleotide comprising the nucleotide sequence of the mature protein coding sequence of clone AJ172_2 deposited under accession number ATCC 98115;
- (h) a polynucleotide encoding the mature protein encoded by the cDNA insert of clone AJ172_2 deposited under accession number ATCC 98115;
- (i) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:4;
- (j) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:4 having biological activity;
- (k) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(h) above;
- (l) a polynucleotide which encodes a species homologue of the protein of (i) or (j) above ; and
- (m) a polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides specified in (a)-(j).

14. A composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:4;
- (b) the amino acid sequence of SEQ ID NO:4 from amino acid 1 to amino acid 67;
- (c) fragments of the amino acid sequence of SEQ ID NO:4; and
- (d) the amino acid sequence encoded by the cDNA insert of clone AJ172_2 deposited under accession number ATCC 98115;

the protein being substantially free from other mammalian proteins.

15. An isolated gene corresponding to the cDNA sequence of SEQ ID NO:3.

16. A composition comprising an isolated polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:6;
- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:6 from nucleotide 185 to nucleotide 385;
- (c) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone AP224_2 deposited under accession number ATCC 98115;
- (d) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone AP224_2 deposited under accession number ATCC 98115;
- (e) a polynucleotide comprising the nucleotide sequence of the mature protein coding sequence of clone AP224_2 deposited under accession number ATCC 98115;

- (f) a polynucleotide encoding the mature protein encoded by the cDNA insert of clone AP224_2 deposited under accession number ATCC 98115;
- (g) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:7;
- (h) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:7 having biological activity;
- (i) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(f) above;
- (j) a polynucleotide which encodes a species homologue of the protein of (g) or (h) above ; and
- (k) a polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides specified in (a)-(h).

17. A composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:7;
- (b) the amino acid sequence of SEQ ID NO:7 from amino acid 1 to amino acid 28;
- (c) fragments of the amino acid sequence of SEQ ID NO:7; and
- (d) the amino acid sequence encoded by the cDNA insert of clone AP224_2 deposited under accession number ATCC 98115;

the protein being substantially free from other mammalian proteins.

18. An isolated gene corresponding to the cDNA sequences of SEQ ID NO:5, SEQ ID NO:6, and SEQ ID NO:8 .

19. A composition comprising an isolated polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:9;
- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:9 from nucleotide 6 to nucleotide 2408;
- (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:9 from nucleotide 1295 to nucleotide 1705;
- (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone BL89_13 deposited under accession number ATCC 98153;
- (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone BL89_13 deposited under accession number ATCC 98153;
- (f) a polynucleotide comprising the nucleotide sequence of the mature protein coding sequence of clone BL89_13 deposited under accession number ATCC 98153;

(g) a polynucleotide encoding the mature protein encoded by the cDNA insert of clone BL89_13 deposited under accession number ATCC 98153;

(h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:10;

(i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:10 having biological activity;

(j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;

(k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ; and

(l) a polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides specified in (a)-(i).

20. A composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

(a) the amino acid sequence of SEQ ID NO:10;

(b) the amino acid sequence of SEQ ID NO:10 from amino acid 431 to amino acid 567;

(c) fragments of the amino acid sequence of SEQ ID NO:10; and

(d) the amino acid sequence encoded by the cDNA insert of clone BL89_13 deposited under accession number ATCC 98153; the protein being substantially free from other mammalian proteins.

21. An isolated gene corresponding to the cDNA sequence of SEQ ID NO:9.

22. A composition comprising an isolated polynucleotide selected from the group consisting of:

(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:11;

(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:11 from nucleotide 2113 to nucleotide 2337;

(c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:11 from nucleotide 2036 to nucleotide 2316;

(d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone BL341_4 deposited under accession number ATCC 98115;

(e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone BL341_4 deposited under accession number ATCC 98115;

(f) a polynucleotide comprising the nucleotide sequence of the mature protein coding sequence of clone BL341_4 deposited under accession number ATCC 98115;

(g) a polynucleotide encoding the mature protein encoded by the cDNA insert of clone BL341_4 deposited under accession number ATCC 98115;

- (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:12;
- (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:12 having biological activity;
- (j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;
- (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ; and
- (l) a polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides specified in (a)-(i).

23. A composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:12;
- (b) the amino acid sequence of SEQ ID NO:12 from amino acid 1 to amino acid 68;
- (c) fragments of the amino acid sequence of SEQ ID NO:12; and
- (d) the amino acid sequence encoded by the cDNA insert of clone BL341_4 deposited under accession number ATCC 98115;

the protein being substantially free from other mammalian proteins.

24. An isolated gene corresponding to the cDNA sequence of SEQ ID NO:11.

25. A composition comprising an isolated polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:13;
- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:13 from nucleotide 1 to nucleotide 390;
- (c) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone BV239_3 deposited under accession number ATCC 98153;
- (d) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone BV239_3 deposited under accession number ATCC 98153;
- (e) a polynucleotide comprising the nucleotide sequence of the mature protein coding sequence of clone BV239_3 deposited under accession number ATCC 98153;
- (f) a polynucleotide encoding the mature protein encoded by the cDNA insert of clone BV239_3 deposited under accession number ATCC 98153;
- (g) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:14;
- (h) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:14 having biological activity;

- (i) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(f) above;
- (j) a polynucleotide which encodes a species homologue of the protein of (g) or (h) above ; and
- (k) a polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides specified in (a)-(h).

26. A composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:14;
- (b) the amino acid sequence of SEQ ID NO:14 from amino acid 50 to amino acid 130;
- (c) fragments of the amino acid sequence of SEQ ID NO:14; and
- (d) the amino acid sequence encoded by the cDNA insert of clone BV239_3 deposited under accession number ATCC 98153;

the protein being substantially free from other mammalian proteins.

27. An isolated gene corresponding to the cDNA sequence of SEQ ID NO:13.

28. A composition comprising an isolated polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:15;
- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:15 from nucleotide 144 to nucleotide 257;
- (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:15 from nucleotide 30 to nucleotide 271;
- (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone CC25_17 deposited under accession number ATCC 98153;
- (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone CC25_17 deposited under accession number ATCC 98153;
- (f) a polynucleotide comprising the nucleotide sequence of the mature protein coding sequence of clone CC25_17 deposited under accession number ATCC 98153;
- (g) a polynucleotide encoding the mature protein encoded by the cDNA insert of clone CC25_17 deposited under accession number ATCC 98153;
- (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:16;
- (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:16 having biological activity;

- (j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;
- (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ; and
- (l) a polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides specified in (a)-(i).

29. A composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:16;
- (b) fragments of the amino acid sequence of SEQ ID NO:16; and
- (c) the amino acid sequence encoded by the cDNA insert of clone CC25_17 deposited under accession number ATCC 98153;

the protein being substantially free from other mammalian proteins.

30. An isolated gene corresponding to the cDNA sequence of SEQ ID NO:15.

31. A composition comprising an isolated polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:17;
- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:17 from nucleotide 431 to nucleotide 520;
- (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:17 from nucleotide 266 to nucleotide 511;
- (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone CC397_19 deposited under accession number ATCC 98153;
- (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone CC397_19 deposited under accession number ATCC 98153;
- (f) a polynucleotide comprising the nucleotide sequence of the mature protein coding sequence of clone CC397_19 deposited under accession number ATCC 98153;
- (g) a polynucleotide encoding the mature protein encoded by the cDNA insert of clone CC397_19 deposited under accession number ATCC 98153;
- (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:18;
- (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:18 having biological activity;
- (j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;
- (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ; and

(l) a polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides specified in (a)-(i).

32. A composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:18;
- (b) the amino acid sequence of SEQ ID NO:18 from amino acid 1 to amino acid 27;
- (c) fragments of the amino acid sequence of SEQ ID NO:18; and
- (d) the amino acid sequence encoded by the cDNA insert of clone CC397_19 deposited under accession number ATCC 98153;

the protein being substantially free from other mammalian proteins.

33. An isolated gene corresponding to the cDNA sequence of SEQ ID NO:17.

34. A composition comprising an isolated polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:20;
- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:20 from nucleotide 253 to nucleotide 519;
- (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:20 from nucleotide 298 to nucleotide 519;
- (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone D305_2 deposited under accession number ATCC 98115;
- (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone D305_2 deposited under accession number ATCC 98115;
- (f) a polynucleotide comprising the nucleotide sequence of the mature protein coding sequence of clone D305_2 deposited under accession number ATCC 98115;
- (g) a polynucleotide encoding the mature protein encoded by the cDNA insert of clone D305_2 deposited under accession number ATCC 98115;
- (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:21;
- (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:21 having biological activity;
- (j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;
- (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ; and
- (l) a polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides specified in (a)-(i).

35. A composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:21;
- (b) fragments of the amino acid sequence of SEQ ID NO:21; and
- (c) the amino acid sequence encoded by the cDNA insert of clone

D305_2 deposited under accession number ATCC 98115;

the protein being substantially free from other mammalian proteins.

36. An isolated gene corresponding to the cDNA sequences of SEQ ID NO:19, SEQ ID NO:20, and SEQ ID NO:22 .

37. A composition comprising an isolated polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:23;
- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:23 from nucleotide 194 to nucleotide 622;
- (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:23 from nucleotide 524 to nucleotide 622;
- (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone G55_1 deposited under accession number ATCC 98115;
- (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone G55_1 deposited under accession number ATCC 98115;
- (f) a polynucleotide comprising the nucleotide sequence of the mature protein coding sequence of clone G55_1 deposited under accession number ATCC 98115;
- (g) a polynucleotide encoding the mature protein encoded by the cDNA insert of clone G55_1 deposited under accession number ATCC 98115;
- (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:24;
- (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:24 having biological activity;
- (j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;
- (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ; and
- (l) a polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides specified in (a)-(i).

38. A composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:24;

(b) the amino acid sequence of SEQ ID NO:24 from amino acid 1 to amino acid 32;

(c) fragments of the amino acid sequence of SEQ ID NO:24; and

(d) the amino acid sequence encoded by the cDNA insert of clone G55_1 deposited under accession number ATCC 98115;
the protein being substantially free from other mammalian proteins.

39. An isolated gene corresponding to the cDNA sequences of SEQ ID NO:23 and SEQ ID NO:25.

40. A composition comprising an isolated polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:26;
- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:26 from nucleotide 402 to nucleotide 533;
- (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:26 from nucleotide 447 to nucleotide 533;
- (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone K39_7 deposited under accession number ATCC 98115;
- (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone K39_7 deposited under accession number ATCC 98115;
- (f) a polynucleotide comprising the nucleotide sequence of the mature protein coding sequence of clone K39_7 deposited under accession number ATCC 98115;
- (g) a polynucleotide encoding the mature protein encoded by the cDNA insert of clone K39_7 deposited under accession number ATCC 98115;
- (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:27;
- (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:27 having biological activity;
- (j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;
- (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ; and
- (l) a polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides specified in (a)-(i).

41. A composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:27;
- (b) fragments of the amino acid sequence of SEQ ID NO:27; and

(c) the amino acid sequence encoded by the cDNA insert of clone K39_7 deposited under accession number ATCC 98115; the protein being substantially free from other mammalian proteins.

42. An isolated gene corresponding to the cDNA sequences of SEQ ID NO:26 and SEQ ID NO:28.

43. A composition comprising an isolated polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:29;
- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:29 from nucleotide 241 to nucleotide 525;
- (c) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone K330_3 deposited under accession number ATCC 98115;
- (d) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone K330_3 deposited under accession number ATCC 98115;
- (e) a polynucleotide comprising the nucleotide sequence of the mature protein coding sequence of clone K330_3 deposited under accession number ATCC 98115;
- (f) a polynucleotide encoding the mature protein encoded by the cDNA insert of clone K330_3 deposited under accession number ATCC 98115;
- (g) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:30;
- (h) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:30 having biological activity;
- (i) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(f) above;
- (j) a polynucleotide which encodes a species homologue of the protein of (g) or (h) above ; and
- (k) a polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides specified in (a)-(h).

44. A composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:30;
- (b) the amino acid sequence of SEQ ID NO:30 from amino acid 1 to amino acid 35;
- (c) fragments of the amino acid sequence of SEQ ID NO:30; and
- (d) the amino acid sequence encoded by the cDNA insert of clone K330_3 deposited under accession number ATCC 98115;

the protein being substantially free from other mammalian proteins.

45. An isolated gene corresponding to the cDNA sequences of SEQ ID NO:29 and SEQ ID NO:31.

46. A composition comprising an isolated polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:32;
- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:32 from nucleotide 158 to nucleotide 571;
- (c) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone K363_3 deposited under accession number ATCC 98115;
- (d) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone K363_3 deposited under accession number ATCC 98115;
- (e) a polynucleotide comprising the nucleotide sequence of the mature protein coding sequence of clone K363_3 deposited under accession number ATCC 98115;
- (f) a polynucleotide encoding the mature protein encoded by the cDNA insert of clone K363_3 deposited under accession number ATCC 98115;
- (g) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:33;
- (h) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:33 having biological activity;
- (i) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(f) above;
- (j) a polynucleotide which encodes a species homologue of the protein of (g) or (h) above ; and
- (k) a polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides specified in (a)-(h).

47. A composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:33;
- (b) the amino acid sequence of SEQ ID NO:33 from amino acid 24 to amino acid 96;
- (c) fragments of the amino acid sequence of SEQ ID NO:33; and
- (d) the amino acid sequence encoded by the cDNA insert of clone K363_3 deposited under accession number ATCC 98115;

the protein being substantially free from other mammalian proteins..

48. An isolated gene corresponding to the cDNA sequences of SEQ ID NO:32 and SEQ ID NO:34.

49. A composition comprising an isolated polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:35;
- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:35 from nucleotide 401 to nucleotide 526;
- (c) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone K446_3 deposited under accession number ATCC 98115;
- (d) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone K446_3 deposited under accession number ATCC 98115;
- (e) a polynucleotide comprising the nucleotide sequence of the mature protein coding sequence of clone K446_3 deposited under accession number ATCC 98115;
- (f) a polynucleotide encoding the mature protein encoded by the cDNA insert of clone K446_3 deposited under accession number ATCC 98115;
- (g) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:36;
- (h) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:36 having biological activity;
- (i) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(f) above;
- (j) a polynucleotide which encodes a species homologue of the protein of (g) or (h) above ; and
- (k) a polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides specified in (a)-(h).

50. A composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:36;
- (b) fragments of the amino acid sequence of SEQ ID NO:36; and
- (c) the amino acid sequence encoded by the cDNA insert of clone K446_3 deposited under accession number ATCC 98115;

the protein being substantially free from other mammalian proteins.

51. An isolated gene corresponding to the cDNA sequences of SEQ ID NO:35 and SEQ ID NO:37.

52. A composition comprising an isolated polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:38;

- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:38 from nucleotide 380 to nucleotide 535;
- (c) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone K464_4 deposited under accession number ATCC 98115;
- (d) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone K464_4 deposited under accession number ATCC 98115;
- (e) a polynucleotide comprising the nucleotide sequence of the mature protein coding sequence of clone K464_4 deposited under accession number ATCC 98115;
- (f) a polynucleotide encoding the mature protein encoded by the cDNA insert of clone K464_4 deposited under accession number ATCC 98115;
- (g) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:39;
- (h) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:39 having biological activity;
- (i) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(f) above;
- (j) a polynucleotide which encodes a species homologue of the protein of (g) or (h) above ; and
- (k) a polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides specified in (a)-(h).

53. A composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:39;
- (b) fragments of the amino acid sequence of SEQ ID NO:39; and
- (c) the amino acid sequence encoded by the cDNA insert of clone K464_4 deposited under accession number ATCC 98115;

the protein being substantially free from other mammalian proteins.

54. An isolated gene corresponding to the cDNA sequences of SEQ ID NO:38 and SEQ ID NO:40.

55. A composition comprising an isolated polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:41;
- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:41 from nucleotide 218 to nucleotide 1159;
- (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:41 from nucleotide 806 to nucleotide 1159;

- (d) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:41 from nucleotide 217 to nucleotide 517;
- (e) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone K483_1 deposited under accession number ATCC 98115;
- (f) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone K483_1 deposited under accession number ATCC 98115;
- (g) a polynucleotide comprising the nucleotide sequence of the mature protein coding sequence of clone K483_1 deposited under accession number ATCC 98115;
- (h) a polynucleotide encoding the mature protein encoded by the cDNA insert of clone K483_1 deposited under accession number ATCC 98115;
- (i) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:42;
- (j) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:42 having biological activity;
- (k) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(h) above;
- (l) a polynucleotide which encodes a species homologue of the protein of (i) or (j) above ; and
- (m) a polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides specified in (a)-(j).

56. A composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:42;
- (b) the amino acid sequence of SEQ ID NO:42 from amino acid 1 to amino acid 100;
- (c) fragments of the amino acid sequence of SEQ ID NO:42; and
- (d) the amino acid sequence encoded by the cDNA insert of clone K483_1 deposited under accession number ATCC 98115;

the protein being substantially free from other mammalian proteins.

57. An isolated gene corresponding to the cDNA sequence of SEQ ID NO:41.

58. A composition comprising an isolated polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:43;
- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:43 from nucleotide 446 to nucleotide 835;
- (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:43 from nucleotide 503 to nucleotide 835;

- (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone L69_3 deposited under accession number ATCC 98115;
- (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone L69_3 deposited under accession number ATCC 98115;
- (f) a polynucleotide comprising the nucleotide sequence of the mature protein coding sequence of clone L69_3 deposited under accession number ATCC 98115;
- (g) a polynucleotide encoding the mature protein encoded by the cDNA insert of clone L69_3 deposited under accession number ATCC 98115;
- (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:44;
- (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:44 having biological activity;
- (j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;
- (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ; and
- (l) a polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides specified in (a)-(i).


59. A composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:44;
- (b) the amino acid sequence of SEQ ID NO:44 from amino acid 1 to amino acid 93;
- (c) fragments of the amino acid sequence of SEQ ID NO:44; and
- (d) the amino acid sequence encoded by the cDNA insert of clone L69_3 deposited under accession number ATCC 98115;

the protein being substantially free from other mammalian proteins.

60. An isolated gene corresponding to the cDNA sequences of SEQ ID NO:43 and SEQ ID NO:45.

FIGURE 1A




Plasmid name: pED6dpc2

Plasmid size: 5374 bp

Comments/References: pED6dpc2 is derived from pED6dpc1 by insertion of a new polylinker to facilitate cDNA cloning. SST cDNAs are cloned between EcoRI and NotI. pED vectors are described in Kaufman et al.(1991), NAR 19: 4485-4490.

FIGURE 1B



Plasmid name: pNOTs
Plasmid size: 4529 bp

Comments/References: pNOTs is a derivative of pMT2 (Kaufman et al, 1989. Mol.Cell.Biol.9:1741-1750). DHFR was deleted and a new polylinker was inserted between EcoRI and HpaI. M13 origin of replication was inserted in the Clai site. SST cDNAs are cloned between EcoRI and NotI.

SEQUENCE LISTING

<110> Jacobs, Kenneth
McCoy, John M.
LaVallie, Edward R.
Collins-Racie, Lisa A.
Evans, Cheryl
Merberg, David
Treacy, Maurice
Genetics Institute, Inc.

<120> SECRETED PROTEINS AND POLYNUCLEOTIDES ENCODING THEM

<130> 6006B-PCT

<140>
<141>

<160> 62

<170> PatentIn Ver. 2.0

<210> 1
<211> 2166
<212> DNA
<213> Homo sapiens

<400> 1

ggcaagctac tggcacctgc tgctctcaac taacctccac acaatggtgt tcgcattttg 60
gaaggctttt ctgatcctaa gctgccttgc aggtcaggtt agtgtgggc aagtggccat 120
cccagacggt ttctgttaacg tgactgttg atctaatgtc actctcatct gcacatctacac 180
caccactgtg gcctcccgag aacagctttc catccagtgg tctttcttcc ataagaagga 240
gatggagcca atttcttattt actttctca aggtggacaa gctgttagcca tcgggcaatt 300
taaagatcga attacagggt ccaacgatcc aggttaatgca tctatcacta tctcgcataat 360
gcagccagca gacagtggaa ttatcatctg cgatgttaac aacccccccag actttctcg 420
ccaaaaccaa ggcacatcctca acgtcagtgt gtttagtggaaa ccttctaaac cccttcttag 480
cgttcaagga agaccagaaa ctggccacac tattttccctt tcctgtctct ctgcgtttgg 540
aacacccctcc cctgtgtact actggccataa acttgaggaa agagacatcg tgcaggatgaa 600
agaaaaacttc aaccccaacca cccggatttt ggtcattggaa aatctgacaa atttgaaca 660
agtttattac cagtgtactg cccatcaacag acttggcaat agttccctgcg aaatcgatct 720
cacttcttca catccagaag ttggaatcat tttttggggcc ttgattttgtt gccttggtagg 780
tgccgcctatc atcatctctg ttgtgtgtt cgcaggaaat aaggccaaaag caaaggccaaa 840
agaaagaaat tctaagacca tcgcggaaact tgagccaaatg acaaagataaa acccaagggg 900
agaaagcgaa gcaatgccaa gagaagacgc tacccaaacta gaagtaactc taccatcttc 960
cattcatgatg actggccctg ataccatcca agaaccagac tatgagccaa agcttactca 1020
ggagcctgcc ccagagcctg cccccaggatc agagcctatg gcagtgcctg accttgacat 1080
cgagctggag ctggagccag aaacgcagtc ggaatttggag ccagaggccag agccagagcc 1140
agagtcagag cctggggttt tagttgagcc cttaaatgtt gatggaaaagg gagttgtt 1200
ggcataggct ggtggctaa gtacagcattt aatcattaag gaaccatca ctgcattttg 1260
gaattcaat aacccaaatcc accctccaccc cctccttcca ttttgcacaa cttttcttca 1320
acaagggtctt cattctact atgaatcccg aataaaacacg ccaagataac agctaaatca 1380
gcaagggttc ctgttattacc aatatagaat actaacaatt ttactaaacac gtaagcataaa 1440
caaatgacag ggcaagtgtt tcttaactt gttgagttt gcaacagttt ctgtgttttt 1500
atttcagaaa atattatttc tctctttttt actactctt ttttttattt tagacagagt 1560
cgcttgcgtt caggagggtgg aggttgcagt gggccggat tttttttttt cactccaaacc 1620
tgggtgacag agtggatcc catctgaaaaa aaaaaaaaaa aaacagaaaaa caaacaacaa 1680
aaaaacaaaaa aatccccaca actttgtcaa ataatgtaca ggcaacact ttcaaatata 1740
atttccttca gtgaatacaa aatgttgata tcatacgatgt tttttttttt agtttgaat 1800
gagtttattt gttatctactg tttttttttt gaaaggcagt ccagaaaaatgt 1860
gttcttaatgtt aactttaatgtt gataattttca actaattttaa taacctgtttt 1920

tactgcctgt acattccaca ttaataaagc gataccaatc ttatatgaat gctaataatatta 1980
 ctaaaatgca ctgatatacac ttcttcctcc cctgttggaa agctttctca tgatcatatt 2040
 tcacccacat ctcacccatc agaaaacttac agtagactt acctttcac ttgtggatt 2100
 aatcatatcc aaatcttact ttaaggctca ataaataata ctcataaaaaaaa aaaaaaaaaa 2160
 aaaaaaa 2166

<210> 2
 <211> 387
 <212> PRT
 <213> Homo sapiens

<400> 2
 Met Val Phe Ala Phe Trp Lys Val Phe Leu Ile Leu Ser Cys Leu Ala
 1 5 10 15
 Gly Gln Val Ser Val Val Gln Val Thr Ile Pro Asp Gly Phe Val Asn
 20 25 30
 Val Thr Val Gly Ser Asn Val Thr Leu Ile Cys Ile Tyr Thr Thr Thr
 35 40 45
 Val Ala Ser Arg Glu Gln Leu Ser Ile Gln Trp Ser Phe Phe His Lys
 50 55 60
 Lys Glu Met Glu Pro Ile Ser Ile Tyr Phe Ser Gln Gly Gly Gln Ala
 65 70 75 80
 Val Ala Ile Gly Gln Phe Lys Asp Arg Ile Thr Gly Ser Asn Asp Pro
 85 90 95
 Gly Asn Ala Ser Ile Thr Ile Ser His Met Gln Pro Ala Asp Ser Gly
 100 105 110
 Ile Tyr Ile Cys Asp Val Asn Asn Pro Pro Asp Phe Leu Gly Gln Asn
 115 120 125
 Gln Gly Ile Leu Asn Val Ser Val Leu Val Lys Pro Ser Lys Pro Leu
 130 135 140
 Cys Ser Val Gln Gly Arg Pro Glu Thr Gly His Thr Ile Ser Leu Ser
 145 150 155 160
 Cys Leu Ser Ala Leu Gly Thr Pro Ser Pro Val Tyr Tyr Trp His Lys
 165 170 175
 Leu Glu Gly Arg Asp Ile Val Pro Val Lys Glu Asn Phe Asn Pro Thr
 180 185 190
 Thr Gly Ile Leu Val Ile Gly Asn Leu Thr Asn Phe Glu Gln Gly Tyr
 195 200 205
 Tyr Gln Cys Thr Ala Ile Asn Arg Leu Gly Asn Ser Ser Cys Glu Ile
 210 215 220
 Asp Leu Thr Ser Ser His Pro Glu Val Gly Ile Ile Val Gly Ala Leu
 225 230 235 240
 Ile Gly Ser Leu Val Gly Ala Ala Ile Ile Ser Val Val Cys Phe
 245 250 255

Ala Arg Asn Lys Ala Lys Ala Lys Glu Arg Asn Ser Lys Thr
 260 265 270

Ile Ala Glu Leu Glu Pro Met Thr Lys Ile Asn Pro Arg Gly Glu Ser
 275 280 285

Glu Ala Met Pro Arg Glu Asp Ala Thr Gln Leu Glu Val Thr Leu Pro
 290 295 300

Ser Ser Ile His Glu Thr Gly Pro Asp Thr Ile Gln Glu Pro Asp Tyr
 305 310 315 320

Glu Pro Lys Pro Thr Gln Glu Pro Ala Pro Glu Pro Ala Pro Gly Ser
 325 330 335

Glu Pro Met Ala Val Pro Asp Leu Asp Ile Glu Leu Glu Leu Glu Pro
 340 345 350

Glu Thr Gln Ser Glu Leu Glu Pro Glu Pro Glu Pro Glu Pro Glu Ser
 355 360 365

Glu Pro Gly Val Val Val Glu Pro Leu Ser Glu Asp Glu Lys Gly Val
 370 375 380

Val Lys Ala
 385

<210> 3
<211> 2946
<212> DNA
<213> Homo sapiens

<400> 3
tcgggctgcc ttatcgccaa gtccttcag gagaacaaag aacaggccat taccctggag 60
aagactggca actgatttt cccacaagcc caaaccttcag ggatttcagt atctactagt 120
ctgggttagat actttcactgg gttgggcaga ggccttcccc tgttaggacag aaaaggccca 180
agaggtataa aaggcactag ttcatgaaat aattcccaaga ttccggacttc cccgaggctt 240
acagagtgc aatagccctg ctttccaggg cacagtaacc caggggagtat cccaggcggtt 300
aggatacga tatcacttac actgcgcctg aaggccacag tcctcaggga aggtcgagaa 360
aatgaatgaa acactcaaag gacatctaaa aaagcaaaacc caggaaaccc acctcacatg 420
gcctgctctg ttgcctatag ccttaaaaag aatctgcaac ttccccaaaa aacgcaggact 480
tagcccatac gaaatgctgt atggaagccc cttcataaacc aatgacacctg tgcttgaccc 540
aagacagcca acttagttgc agacatcacc tccttagcca aatatcaaca agttcttaaa 600
acattacaag gaaccttatcc ctgagaagag gaaaaagaac tattccaccc ttgtgacatg 660
gtattagtca agtcccttcc ctctaattcc ccattccctg atacatccctg ggaaggaccc 720
tacccagtc ttttatctac cccaaactgctg gttaaaagtgg ctggagtgga gtcttgata 780
catcacactt gagtccaaatc ctggatactg cccaaaggaaac ctgaaaatcc aggagacaaac 840
gctagctatt cctgtgaacc tctagaggat ttgcgcctgc tcttcaaaaca acaacccagga 900
ggaaaagtaac taaaatcata aatcccattt gcctccctt atcatatttt tctctttact 960
gttcttttac cctctttcac tctcactgca cccctccat gccgctgtat gaccagtagc 1020
tcccttacc aagagttttct atggagaatg cagcgtcccg gaaatattga tgccccatcg 1080
tataaggatc tttctaaaggaa aaccccccacc ttcactgccc acacccatat gccccgcac 1140
tgcataactt ctgcacttgc ttgcactgcat gcaaaatactt attattggac agggaaaaatg 1200
attaatccta gttgtccctgg aggacttgaa gtcactgtct gttggacttta cttcacccaa 1260
actggatgtctgatgggggg tggagttcaa gatcaggcaaa gggaaaaatc tgaaaaagaa 1320
gtaatctccc aactcaccgg ggtacatggc acctcttagcc cctacaaagg actagatctc 1380
tcaaaaactac atgaaacccctt cctgaccat actcgcctgg taagcctatt taataccacc 1440
ctcaactgggc tccatgaggtt ctcggcccaa aaccctacta actgttggat atgcctcccc 1500
ctgaacttca ggccatatgt ttcaatccct gtacactgaaatggaaacaa cttcagcaca 1560

gaaataaaaca ccacttccgt ttttagtagga cctcttgaaa ccaatctggaa aataaccat 1620
 acctcaaacc tcacccgtgt aaaatttgc aataactacat acacaaccaa ctcccaatgc 1680
 atcagggtggg taactcctcc cacacaaata gtctgcctac cctcaggaaat atttttgtc 1740
 tgggtaccc cagccatcg ttgtttgaat ggcttcctcg aatctatgtc cttccctctca 1800
 ttcttagtgc cccctatgac catctacact gaacaagag tatacaatta tgtcatatct 1860
 aagccccgca aaaaaagagt acccattttt cctttgtta taggaggcagg agtgcgttgt 1920
 gcactaggtt ctggcattgg cggtatcaca acctctactc agttctacta caaactatct 1980
 caagaactaa atggggacat ggaacgggtc gcccactccc tggtcacccctt gcaagatcaa 2040
 cttaactccc tagcagcagt agtcctcaa aatcgaagag cttagactt gctaaccgct 2100
 gaaagagggg gAACCTGTTT attttttaggg gaagaatgct gttattatgt taatcaatcc 2160
 ggaatcgtca ctgagaaagt taaagaaatt cgagatcgaa tacaacgttag agcagaggg 2220
 cttcgaaaca ctggaccctg gggcctcctc agccaatggaa tgccctggat tctccccc 2280
 ttaggacctc tagcagctat aatattgcta ctcctttt gaccctgtat cttaacctc 2340
 ctgtttaact ttgtctcttc cagaatcgaa gctgtaaaac tacaaatggaa gccccaaatgg 2400
 cagtccttccaa ctaagatctt ccgcagaccc ctggaccggc ctgctagccc acgatctgat 2460
 gttaatgaca tcaaaaggcac ccctccctgag gaaatctcgat ctgcacaacc tctactacgc 2520
 cccaaattcg caggaaggcag ttagagcggt cgtcggccaa cctcccccac agcacttagg 2580
 tttccctgtt gagatggggg actgagagac aggactagct ggatttccta ggctgactaa 2640
 gaatccctaa gcctagctgg gaagggtgacc acatccaccc ttaaacacgg ggcttgcac 2700
 ttagctcaca cctgaccaat cagagagctc actaaaatgc taattaggca aaaacaggag 2760
 gtaaagaaat agccaatcat ctattgcctg agagcacagc aggagggaca atgatcggg 2820
 tataaaccctt agtcttcgag ccggcaacgg caacccctt tgggtccctt ccctttgtat 2880
 gggagctctg ttttcatgct atttactctt attaaatctt gcaactgcaa aaaaaaaaaa 2940
 aaaaaa 2946

<210> 4

<211> 538

<212> PRT

<213> Homo sapiens

<400> 4

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Met | Ala | Leu | Pro | Tyr | His | Ile | Phe | Leu | Phe | Thr | Val | Leu | Leu | Pro | Ser |
| 1 | | | | | | | | | | 10 | | | | | 15 |

| | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Phe | Thr | Leu | Thr | Ala | Pro | Pro | Cys | Arg | Cys | Met | Thr | Ser | Ser | Ser |
| | | | | | | | | | | 20 | | | | 30 |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Pro | Tyr | Gln | Glu | Phe | Leu | Trp | Arg | Met | Gln | Arg | Pro | Gly | Asn | Ile | Asp |
| | | | | | | | | | 35 | | | | 40 | | 45 |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Ala | Pro | Ser | Tyr | Arg | Ser | Leu | Ser | Lys | Gly | Thr | Pro | Thr | Phe | Thr | Ala |
| | | | | | | | | | 50 | | | | 55 | | 60 |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| His | Thr | His | Met | Pro | Arg | Asn | Cys | Tyr | His | Ser | Ala | Thr | Leu | Cys | Met |
| | | | | | | | | | 65 | | | | 70 | | 75 |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| His | Ala | Asn | Thr | His | Tyr | Trp | Thr | Gly | Lys | Met | Ile | Asn | Pro | Ser | Cys |
| | | | | | | | | | 85 | | | | 90 | | 95 |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Pro | Gly | Gly | Leu | Gly | Val | Thr | Val | Cys | Trp | Thr | Tyr | Phe | Thr | Gln | Thr |
| | | | | | | | | | 100 | | | | 105 | | 110 |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Gly | Met | Ser | Asp | Gly | Gly | Val | Gln | Asp | Gln | Ala | Arg | Glu | Lys | His | |
| | | | | | | | | | 115 | | | | 120 | | 125 |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Val | Lys | Glu | Val | Ile | Ser | Gln | Leu | Thr | Arg | Val | His | Gly | Thr | Ser | Ser |
| | | | | | | | | | 130 | | | | 135 | | 140 |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Pro | Tyr | Lys | Gly | Leu | Asp | Leu | Ser | Lys | Leu | His | Glu | Thr | Leu | Arg | Thr |
| | | | | | | | | | 145 | | | | 150 | | 155 |

His Thr Arg Leu Val Ser Leu Phe Asn Thr Thr Leu Thr Gly Leu His
 165 170 175

 Glu Val Ser Ala Gln Asn Pro Thr Asn Cys Trp Ile Cys Leu Pro Leu
 180 185 190

 Asn Phe Arg Pro Tyr Val Ser Ile Pro Val Pro Glu Gln Trp Asn Asn
 195 200 205

 Phe Ser Thr Glu Ile Asn Thr Thr Ser Val Leu Val Gly Pro Leu Val
 210 215 220

 Ser Asn Leu Glu Ile Thr His Thr Ser Asn Leu Thr Cys Val Lys Phe
 225 230 235 240

 Ser Asn Thr Thr Tyr Thr Asn Ser Gln Cys Ile Arg Trp Val Thr
 245 250 255

 Pro Pro Thr Gln Ile Val Cys Leu Pro Ser Gly Ile Phe Phe Val Cys
 260 265 270

 Gly Thr Ser Ala Tyr Arg Cys Leu Asn Gly Ser Ser Glu Ser Met Cys
 275 280 285

 Phe Leu Ser Phe Leu Val Pro Pro Met Thr Ile Tyr Thr Glu Gln Asp
 290 295 300

 Leu Tyr Asn Tyr Val Ile Ser Lys Pro Arg Asn Lys Arg Val Pro Ile
 305 310 315 320

 Leu Pro Phe Val Ile Gly Ala Gly Val Leu Gly Ala Leu Gly Thr Gly
 325 330 335

 Ile Gly Gly Ile Thr Thr Ser Thr Gln Phe Tyr Tyr Lys Leu Ser Gln
 340 345 350

 Glu Leu Asn Gly Asp Met Glu Arg Val Ala Asp Ser Leu Val Thr Leu
 355 360 365

 Gln Asp Gln Leu Asn Ser Leu Ala Ala Val Val Leu Gln Asn Arg Arg
 370 375 380

 Ala Leu Asp Leu Leu Thr Ala Glu Arg Gly Gly Thr Cys Leu Phe Leu
 385 390 395 400

 Gly Glu Glu Cys Cys Tyr Tyr Val Asn Gln Ser Gly Ile Val Thr Glu
 405 410 415

 Lys Val Lys Glu Ile Arg Asp Arg Ile Gln Arg Arg Ala Glu Glu Leu
 420 425 430

 Arg Asn Thr Gly Pro Trp Gly Leu Leu Ser Gln Trp Met Pro Trp Ile
 435 440 445

 Leu Pro Phe Leu Gly Pro Leu Ala Ala Ile Ile Leu Leu Leu Phe
 450 455 460

 Gly Pro Cys Ile Phe Asn Leu Leu Val Asn Phe Val Ser Ser Arg Ile
 465 470 475 480

Glu Ala Val Lys Leu Gln Met Glu Pro Lys Met Gln Ser Lys Thr Lys
485 490 495

Ile Tyr Arg Arg Pro Leu Asp Arg Pro Ala Ser Pro Arg Ser Asp Val
500 505 510

Asn Asp Ile Lys Gly Thr Pro Pro Glu Glu Ile Ser Ala Ala Gln Pro
515 520 525

Leu Leu Arg Pro Asn Ser Ala Gly Ser Ser
530 535

<210> 5
<211> 338
<212> DNA
<213> Homo sapiens

<220>
<221> unsure
<222> (259)

<220>
<221> unsure
<222> (261)

<220>
<221> unsure
<222> (282)

<220>
<221> unsure
<222> (285)

<220>
<221> unsure
<222> (312)

<220>
<221> unsure
<222> (334)

<400> 5
agccggccgcg ccatccccat caagcagggg atcctgctaa agcggagcg 60
aacaaggagt ggaagaagaaa gtatgtacg ctctgtgaca acgggctgct caccttatcac 120
cccagcctgc atcttgggtgc gctgtctgtg ccctctgcca acagtggagg cagcgaggat 180
gaagaggagt ggcaaggggt gtcttgatg tggaaaaaaaa tgtgggttgt ggggttggc 240
tgggttttgg ttcagtana ngaaacacag ccagctggag ancanaactc acgggggttg 300
gtggcttttc anaatcaccc ggctggtggc tganctaa 338

<210> 6
<211> 387
<212> DNA
<213> Homo sapiens

<220>
<221> unsure
<222> (30)

<220>
 <221> unsure
 <222> (163)

<400> 6
 aagtaggcaa gggataataa ccaaagaagn aaatttcatg aagactagac atcataaaagc 60
 ataattttaa tagtcactca accaagtatt ttttattttt tatggatact ctgaatggca 120
 attaaatgtg aaacctcagg tcttggccaa gtcaaattst ggnatcacat ccacctaata 180
 taaaatgact agctcgatt ttccccatct tcaagttca catcctggtc ataaaaagac 240
 tcgacagcaa gacttagaat gmaaaaagggt acttggat attaatattt ttacttgaa 300
 cacgtgttagc ttgcagcagg ttcttgatga atgtgctttg tgtccaaaat gcctcccat 360
 tgtacacagg tgtacaccat gcatgca 387

<210> 7
 <211> 67
 <212> PRT
 <213> Homo sapiens

<220>
 <221> UNSURE
 <222> (26)

<400> 7
 Met Thr Ser Ser Tyr Phe Pro His Leu Gln Val Ser His Pro Gly His
 1 5 10 15

Gln Lys Thr Arg Gln Gln Asp Leu Glu Xaa Lys Arg Val Leu Val Tyr
 20 25 30

Ile Asn Ile Phe Tyr Leu Asn Thr Cys Ser Leu Gln Gln Val Leu Asp
 35 40 45

Glu Cys Ala Leu Cys Pro Lys Cys Leu Pro Ile Val His Arg Cys Thr
 50 55 60

Pro Cys Met
 65

<210> 8
 <211> 348
 <212> DNA
 <213> Homo sapiens

<220>
 <221> unsure
 <222> (59)

<220>
 <221> unsure
 <222> (70)

<220>
 <221> unsure
 <222> (72)

<220>
 <221> unsure
 <222> (87)

<220>
<221> unsure
<222> (89)

<220>
<221> unsure
<222> (92)

<220>
<221> unsure
<222> (94)

<220>
<221> unsure
<222> (134)

<220>
<221> unsure
<222> (138)

<220>
<221> unsure
<222> (202)

<220>
<221> unsure
<222> (216)

<220>
<221> unsure
<222> (223)

<220>
<221> unsure
<222> (303)

<400> 8

caaaccctaa accctggcag gaagcatgtc gaggaggag ttccggcaac tccagaggnt 60
ccgacagaan tntgggctga gcctggntnt cntntccagc aagggtttcg cctgagcccc 120
aagggcatcg ggantggnga ctcacctatg gatgggggcc ggggagacag gacacacaga 180
agatgagttt gtggggccagc cntgagcccc gcgcengatt ttngccggcc caagagagcc 240
cgccgcagct tccccattt tgccagccagc ggagccattc acacaatcac cttctgttaa 300
ttntatctgc aacatcaatt aaattgtttg tagaaaactaa aaaaaaaaaa 348

<210> 9

<211> 3153

<212> DNA

<213> Homo sapiens

<400> 9

taatcatgcc tcttggaaagt aagttaacgg gcgtgattgt ggaaaatgar aatattacca 60
aagaagggtgg cttaktggac atggccaaga aaaaaaatga cttaaatgcg gagcccaatt 120
taaagcagac aattaaagca acagtagara atggcaagaa ggatggcatt gctgttgatc 180
atgttgttagg cctgaataaca gaaaaatatg ctgaaaactgt cmaacttaag cataaaagaa 240
sccccaggtaa agtaaaagac atwtcmattt atgttggaaag aaggaatgaa aacagtgg 300
tagacaccag tgcttggaaagt ggctctgcac cctctgtttt acacccaaagg aacggacaaa 360
ctgaggatgt ggcaactggg cctaggagag cagaaaaagac ttctgttgcc actagtactg 420
aagggaagga caaagatgtc accttaagt cagtgaaggc tgggcctgccc acaaccactt 480
cttcagaaac aagacaaaagt gaggtggctt tgccctgcac cagcattgaag gcagatgaag 540
gcctcataat aggaacacat tccagaaata atcccttca tgggggtgca gaagccagt 600

aatgtcactgt ttttgcgtca gctgaaaaag gtggggctgt tgcacagag ggatttgctg 660
aaagtgaaac cttccatcaca agcactaagg aaggggaaag tggggagtgt gcttgctg 720
aatctgagga cagagcagca gacctactgg ctgtcatgc agttaaaatc gaagccaatg 780
taaatagcgt tgtgacagag gaaaaggatg atgctgtaac cagtgcaggg tctgaagaaa 840
aatgtgatgg ttctttaagt agagactcg aaatagttga aggaactatt acttttatta 900
gtgaagttga aagtgtatggc gcagttacaa gtgctggAAC agagataaga gcaggatcta 960
taagcagtga agaggtggat ggctcccagg gaaatatgtat gagaatgggt cccaaaaaaag 1020
aaacagaggg cactgtgaca tgacaggag cagaaggcag aagtgataac tttgtgatct 1080
gctcagtaac tggagcaggg cccggggagg tggggatcaa tgatgcacca ccaggaacaa 1140
atgatggta agaagggttag agtgcagtca ccagcacggg gataacagaa gatggagagg 1200
ggccagcaag ttgcacaggt tcagaagatw gcakcgaagg ctttgcata agttctgaat 1260
cggaagaaaa tggagagagt gcaatggaca cattagttgc tgctgtcct tigtatgtat 1320
aggaagacga ggaaggggag gatgttgta atgcttcaac ttgtacaggg ttaggagaag 1380
cagaaggggaa cagtcagatt ggtactgtgg ccacatgaa tgcaaatgaa aataatgtt 1440
aagacacaga tatctgctcc agtgcmaaaag ggattgtaga aagcagtgtg accagtgcag 1500
tctcaggaaa ggatgaaagtg acaccagttc caggaggtg tgagggcct atgactagt 1560
ctgcacatcga tcaaagtgc agtcagctcg ggcctggtcgg gggtagttac gatgttctt 1620
ctcacatcacc aacaaatgaa aaagaagatg agtgtgatgg tttcatggca actacagcc 1680
cagggggtaa aaatcaagggc aaagttttga cccctcaggt aagcgaatt acagatgtgg 1740
aagaaaaat ggaagggttac agatgtacca cagtcctcagg agatgcacgc caactcact 1800
ccatgatttca cacaagcata ggggaagaat tcaagtgtc tgaaagttc agccgggtgc 1860
agtcttgcata agcaccggcg actttgaggg aagtccctt gcctcaacca gcaaggagga 1920
catagcagaa gaatgtgagg ctctgttgc agctggcaca gtcatggaa aaaaagacgg 1980
agactgttag gggccagtgt ccagtgtgt accagcgaa gagatgggtg acaccgcat 2040
agcagtcatg attgggtctg tctccaggaa tgaatgttgc gatgttgcata ctttttccac 2100
agacttggcaca gtcatggaa aaaaagacgg agactgttag gggccagtgt ccagtgtgt 2160
accagcgaa gagatgggtg acaccgcat gatgttgcata ctttttccac 2220
agcagtcatg attgggtctg tctccaggaa tgaatgttgc gatgttgcata ctttttccac 2280
agacttggcaca gtcatggaa aaaaagacgg agactgttag gggccagtgt ccagtgtgt 2340
accagcgaa gagatgggtg acaccgcat gatgttgcata ctttttccac 2400
agcagtcatg attgggtctg tctccaggaa tgaatgttgc gatgttgcata ctttttccac 2460
agacttggcaca gtcatggaa aaaaagacgg agactgttag gggccagtgt ccagtgtgt 2520
accagcgaa gagatgggtg acaccgcat gatgttgcata ctttttccac 2580
agcagtcatg attgggtctg tctccaggaa tgaatgttgc gatgttgcata ctttttccac 2640
agacttggcaca gtcatggaa aaaaagacgg agactgttag gggccagtgt ccagtgtgt 2700
accagcgaa gagatgggtg acaccgcat gatgttgcata ctttttccac 2760
agcagtcatg attgggtctg tctccaggaa tgaatgttgc gatgttgcata ctttttccac 2820
agacttggcaca gtcatggaa aaaaagacgg agactgttag gggccagtgt ccagtgtgt 2880
accagcgaa gagatgggtg acaccgcat gatgttgcata ctttttccac 2940
agacttggcaca gtcatggaa aaaaagacgg agactgttag gggccagtgt ccagtgtgt 3000
accagcgaa gagatgggtg acaccgcat gatgttgcata ctttttccac 3060
agcagtcatg attgggtctg tctccaggaa tgaatgttgc gatgttgcata ctttttccac 3120
agacttggcaca gtcatggaa aaaaagacgg agactgttag gggccagtgt ccagtgtgt 3180
accagcgaa gagatgggtg acaccgcat gatgttgcata ctttttccac 3153

<210> 10
<211> 800
<212> PRT
<213> *Homo sapiens*

<220>
<221> UNSURE
<222> (24)

<220>
<221> UNSURE
<222> (73)

<220>
<221> UNSURE
<222> (79)

<220>

<221> UNSURE

<222> (429)..(430)

<400> 10

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Met | Pro | Leu | Gly | Ser | Lys | Leu | Thr | Gly | Val | Ile | Val | Glu | Asn | Glu | Asn |
| 1 | | | | | 5 | | | | 10 | | | 15 | | | |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Ile | Thr | Lys | Glu | Gly | Gly | Leu | Xaa | Asp | Met | Ala | Lys | Lys | Glu | Asn | Asp |
| | | | | | | 20 | | | 25 | | | 30 | | | |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Leu | Asn | Ala | Glu | Pro | Asn | Leu | Lys | Gln | Thr | Ile | Lys | Ala | Thr | Val | Glu |
| | | | | | | 35 | | 40 | | | 45 | | | | |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Asn | Gly | Lys | Lys | Asp | Gly | Ile | Ala | Val | Asp | His | Val | Val | Gly | Leu | Asn |
| | | | | | | 50 | | 55 | | 60 | | | | | |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Thr | Glu | Lys | Tyr | Ala | Glu | Thr | Val | Xaa | Leu | Lys | His | Lys | Arg | Xaa | Pro |
| | | | | | | 65 | | 70 | | 75 | | 80 | | | |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Gly | Lys | Val | Lys | Asp | Ile | Ser | Ile | Asp | Val | Glu | Arg | Arg | Asn | Glu | Asn |
| | | | | | | 85 | | | 90 | | | 95 | | | |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Ser | Glu | Val | Asp | Thr | Ser | Ala | Gly | Ser | Gly | Ser | Ala | Pro | Ser | Val | Leu |
| | | | | | | 100 | | 105 | | | 110 | | | | |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| His | Gln | Arg | Asn | Gly | Gln | Thr | Glu | Asp | Val | Ala | Thr | Gly | Pro | Arg | Arg |
| | | | | | | 115 | | 120 | | | 125 | | | | |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Ala | Glu | Lys | Thr | Ser | Val | Ala | Thr | Ser | Thr | Glu | Gly | Lys | Asp | Lys | Asp |
| | | | | | | 130 | | 135 | | 140 | | | | | |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Val | Thr | Leu | Ser | Pro | Val | Lys | Ala | Gly | Pro | Ala | Thr | Thr | Thr | Ser | Ser |
| | | | | | | 145 | | 150 | | 155 | | 160 | | | |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Glu | Thr | Arg | Gln | Ser | Glu | Val | Ala | Leu | Pro | Cys | Thr | Ser | Ile | Glu | Ala |
| | | | | | | 165 | | 170 | | | 175 | | | | |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Asp | Glu | Gly | Leu | Ile | Ile | Gly | Thr | His | Ser | Arg | Asn | Asn | Pro | Leu | His |
| | | | | | | 180 | | 185 | | | 190 | | | | |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Val | Gly | Ala | Glu | Ala | Ser | Glu | Cys | Thr | Val | Phe | Ala | Ala | Ala | Glu | Lys |
| | | | | | | 195 | | 200 | | | 205 | | | | |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Gly | Gly | Ala | Val | Val | Thr | Glu | Gly | Phe | Ala | Glu | Ser | Glu | Thr | Phe | Leu |
| | | | | | | 210 | | 215 | | 220 | | | | | |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Thr | Ser | Thr | Lys | Glu | Gly | Glu | Ser | Gly | Glu | Cys | Ala | Val | Ala | Glu | Ser |
| | | | | | | 225 | | 230 | | 235 | | 240 | | | |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Glu | Asp | Arg | Ala | Ala | Asp | Leu | Leu | Ala | Val | His | Ala | Val | Lys | Ile | Glu |
| | | | | | | 245 | | 250 | | | 255 | | | | |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Ala | Asn | Val | Asn | Ser | Val | Val | Thr | Glu | Glu | Lys | Asp | Asp | Ala | Val | Thr |
| | | | | | | 260 | | 265 | | 270 | | | | | |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Ser | Ala | Gly | Ser | Glu | Glu | Lys | Cys | Asp | Gly | Ser | Leu | Ser | Arg | Asp | Ser |
| | | | | | | 275 | | 280 | | 285 | | | | | |

Glu Ile Val Glu Gly Thr Ile Thr Phe Ile Ser Glu Val Glu Ser Asp
 290 295 300

 Gly Ala Val Thr Ser Ala Gly Thr Glu Ile Arg Ala Gly Ser Ile Ser
 305 310 315 320

 Ser Glu Glu Val Asp Gly Ser Gln Gly Asn Met Met Arg Met Gly Pro
 325 330 335

 Lys Lys Glu Thr Glu Gly Thr Val Thr Cys Thr Gly Ala Glu Gly Arg
 340 345 350

 Ser Asp Asn Phe Val Ile Cys Ser Val Thr Gly Ala Gly Pro Arg Glu
 355 360 365

 Glu Arg Met Val Thr Gly Ala Gly Val Val Leu Gly Asp Asn Asp Ala
 370 375 380

 Pro Pro Gly Thr Ser Ala Ser Gln Glu Gly Asp Gly Ser Val Asn Asp
 385 390 395 400

 Gly Thr Glu Gly Glu Ser Ala Val Thr Ser Thr Gly Ile Thr Glu Asp
 405 410 415

 Gly Glu Gly Pro Ala Ser Cys Thr Gly Ser Glu Asp Xaa Xaa Glu Gly
 420 425 430

 Phe Ala Ile Ser Ser Glu Ser Glu Asn Gly Glu Ser Ala Met Asp
 435 440 445

 Ser Thr Val Ala Lys Glu Gly Thr Asn Val Pro Leu Val Ala Ala Gly
 450 455 460

 Pro Cys Asp Asp Glu Gly Ile Val Thr Ser Thr Gly Ala Lys Glu Glu
 465 470 475 480

 Asp Glu Glu Gly Glu Asp Val Val Thr Ser Thr Gly Arg Gly Asn Glu
 485 490 495

 Ile Gly His Ala Ser Thr Cys Thr Gly Leu Gly Glu Glu Ser Glu Gly
 500 505 510

 Val Leu Ile Cys Glu Ser Ala Glu Gly Asp Ser Gln Ile Gly Thr Val
 515 520 525

 Val Glu His Val Glu Ala Glu Ala Gly Ala Ala Ile Met Asn Ala Asn
 530 535 540

 Glu Asn Asn Val Asp Ser Met Ser Gly Thr Glu Lys Gly Ser Lys Asp
 545 550 555 560

 Thr Asp Ile Cys Ser Ser Ala Lys Gly Ile Val Glu Ser Ser Val Thr
 565 570 575

 Ser Ala Val Ser Gly Lys Asp Glu Val Thr Pro Val Pro Gly Gly Cys
 580 585 590

 Glu Gly Pro Met Thr Ser Ala Ala Ser Asp Gln Ser Asp Ser Gln Leu
 595 600 605

Glu Lys Val Glu Asp Thr Thr Ile Ser Thr Gly Leu Val Gly Gly Ser
 610 615 620

Tyr Asp Val Leu Val Ser Gly Glu Val Pro Glu Cys Glu Val Ala His
 625 630 635 640

Thr Ser Pro Ser Glu Lys Glu Asp Glu Asp Ile Ile Thr Ser Val Glu
 645 650 655

Asn Glu Glu Cys Asp Gly Phe Met Ala Thr Thr Ala Ser Gly Asp Ile
 660 665 670

Thr Asn Gln Asn Ser Leu Ala Gly Gly Lys Asn Gln Gly Lys Val Leu
 675 680 685

Ile Ile Ser Thr Ser Thr Asn Asp Tyr Thr Pro Gln Val Ser Ala
 690 695 700

Ile Thr Asp Val Glu Gly Leu Ser Asp Ala Leu Arg Thr Glu Glu
 705 710 715 720

Asn Met Glu Gly Thr Arg Val Thr Thr Glu Glu Phe Glu Ala Pro Met
 725 730 735

Pro Ser Ala Val Ser Gly Asp Asp Ser Gln Leu Thr Ala Ser Arg Ser
 740 745 750

Glu Glu Lys Asp Glu Cys Ala Met Ile Ser Thr Ser Ile Gly Glu Glu
 755 760 765

Phe Glu Leu Pro Ile Ser Ser Ala Thr Thr Ile Lys Cys Ala Glu Ser
 770 775 780

Phe Ser Arg Leu Leu Gln Gln Trp Lys Lys Gly Leu Gln Val Gln Ser
 785 790 795 800

<210> 11

<211> 2426

<212> DNA

<213> Homo sapiens

<400> 11

tctgttcccc agctggagct gcgttgggac ccgtcgatc gtaaatccca tgtaaggat 60
 ctgcgcgtcg aagatttcaa ctttctaatt ggacaccta caccacagt cctccaggtg 120
 ggtcttaagg atcttaggag caacgatggg gggctctaag ccaggggggg atgagggct 180
 ggctctcaagt ccccgcctcg cggggagtgc ctccccccctc tgcgatgggg gtcctaagag 240
 ccagtgggg aaccaggggc tggctctcag tcctgcctc gcgggggggtg cttccccccc 300
 tgtgtatgggg gtactaacag ccagggccgg aagagggat agctctcaagt ccccaccc 360
 ggggggggtg cttccccccctc gtgcgatggg ggtctctaaga tccagggggga gaagaggac 420
 tggctctcag tccctgcctc ggggggggtg cttccccccccc tgcgatgggg gtactcacag 480
 ccaggggtgg aagagggat agctctcaagt ccccaactctc gtgggggggtg cttcccccc 540
 ctgcgatgggg ggtctcaga gccgggggg aagagggat ggctctcaagt aatcccacgt 600
 aaggtaacctg ctgtcgaaat tttaactt tctacttggaa caactaacac ccacagtcc 660
 ccaggtgggt cctaaggatc ttaggatcaa tgatgggggg tccataagccg gtgggggaag 720
 agggcttggc tctcagtccc cgcctcgccgg ggggtgcctc cccctctgc gatgggggtc 780
 ctaagagcca gtgggggaac caggggtctgg ctctcaatcc tcgcctcgcc ggggttactc 840
 ccccccctcg ccatgggggtt accaacagcc agggccggaa gaggggatag ctctcagtcc 900
 ccacccctcg ggggttgctt ccccccctcg cgatgggggtt cctaagatcc tggggagggaa 960
 gagggactgg ctctcagtaa tcccaacctaa ggtacctgcc gtcggaaat ttgaacttcc 1020

tacttggaca actaacaccc acagtccctcc aggtgggtcc taaggatctt aggatcaatg 1080
 atggggggc ctaagccagg ggggaagagg gtctggcaact cagtccctgc ctgcggggg 1140
 gtgcctccgc ccccagcgtat ggggttccta agagcaaagg ggggaagagg ggctccctct 1200
 cagtccccgc gtcgcggagg gtgcctccccc ccctgcgtatg cggtgcataa gagccagggg 1260
 agggaaagagg gaggttcgca gtcccccgcct cgccggatt gcctcccccc ctgtatgg 1320
 ggtcccaaga gccagggggg gaagagggggt tggctcgatg tcccccgcctc gcgggggggt 1380
 cctccccccc tgcgatggga gtcccaagag ccagggggtta agaggggtatg gatctcagcc 1440
 atcacaaaat gggggggcct tatgttcagg ttttacccaa gaatcagtt atttgcttct 1500
 tgtacttagca gggcagtgc tgccaaggcc ctcaaatagg ggggccatcc ttagcaacc 1560
 ctgtcttagtt gtttagagac gttagctacg ggccctcagcc agggccccac agtttgggtt 1620
 aaaagtccag ctgcccattt ttctctctct gacgcataca atggaaaagg ctttgtcagg 1680
 tcgggtggc tgccagaaga ttttctgtt actcatgaaa aacttgcgtt tggtggatc 1740
 cccatccaa aagttccggg tcccccggcc atttgcacc tcatacaag gcttggctaa 1800
 tactgcagtt tggatccac agcctacaaa accccacagc tcctaagaat tctctcacct 1860
 gccttctgc cttaaagtc ggttagattgc aaataacctg ctttcttct gttcccgagc 1920
 tttgttcgga cccgtcgat cgtaaatccc acgttaaggc ggaagattt aactttctac 1980
 ttggacacct aacacccaca gtcctccagg tacctgcgtt cggaaagattt gaacgttcta 2040
 cttggacaac taacacccac agtcctccag acagaaagac aacaggtaca aagccctaag 2100
 gattataaaag gtatgtctgtt taccatcatc ttagtgc accgcagcga gctgtttctg 2160
 taccttggaa cagtcttccc tgacaagcca gagaacagtg ataaagccac cagccttggg 2220
 atcaggactg aaaaggcaag agtgcgttgcg atttctctgtt cgctaaagcca agagaaggtt 2280
 tcagcacttc agacagctcc caccgaagta gcccgcgtcc cagctgcgtt cagatgttga 2340
 aaaggaaagc ctcggtttgtt cttgaggttg tcagcaggtt caagacacgt aataaaatgc 2400
 aatgtttcc taaaaaaaaaaaaaaa 2426

<210> 12

<211> 75

<212> PRT

<213> Homo sapiens

<400> 12

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Met | Leu | Leu | Thr | Ile | Ile | Leu | Val | Thr | Lys | Ala | Ala | Lys | Leu | Phe | Leu |
| 1 | | | | | | | | 10 | | | | | | | 15 |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Tyr | Leu | Gly | Thr | Val | Phe | Pro | Asp | Lys | Pro | Glu | Asn | Ser | Asp | Lys | Ala |
| | | | | | | | | 20 | | | | 25 | | | 30 |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Thr | Ser | Leu | Gly | Ile | Arg | Thr | Glu | Lys | Ala | Arg | Val | Met | Glu | Ile | Ser |
| | | | | | | | | 35 | | | | 40 | | | 45 |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Pro | Ala | Leu | Ser | Gln | Glu | Lys | Val | Ser | Ala | Leu | Gln | Thr | Ala | Pro | Thr |
| | | | | | | | | 50 | | | 55 | | | 60 | |

| | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|--|--|----|
| Glu | Val | Ala | Ala | Leu | Pro | Ala | Ala | Cys | Arg | Cys | | | |
| | | | | | | | | 65 | | 70 | | | 75 |

<210> 13

<211> 429

<212> DNA

<213> Homo sapiens

<220>

<221> unsure

<222> (10)

<220>

<221> unsure

<222> (18)...(19)

<220>
 <221> unsure
 <222> (24)

<220>
 <221> unsure
 <222> (97)

<220>
 <221> unsure
 <222> (117)

<220>
 <221> unsure
 <222> (142)..(143)

<400> 13
 ctgggtccan ttggtttnt tcgnntcccc ctttttcttc cccttggttt tctttttttt 60
 cgggcaacaa tattttccaa ggctaatacc aaggcanacc aattcaactc ccaaggmtcg 120
 ggaatttta accttttaat tnnatggccc ctcccactcc tttctacgg cgatttgct 180
 gtgtctggcc cccacccact gcccattcccc catgttgtc tggatgtggt tctatttttt 240
 atcggtctcc ttcccccetcc tccccgttct cgcggccgccc ccacccctcg ctcccactac 300
 cctttgtctc ttgctcttc ttgggcttct gtacaactca acttgtatac actgtgtaca 360
 cacaaccagc caaacgaaaa cccaacggcr aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 420
 aaaaaaaaaa 429

<210> 14
 <211> 130
 <212> PRT
 <213> Homo sapiens

<220>
 <221> UNSURE
 <222> (4)

<220>
 <221> UNSURE
 <222> (6)..(7)

<220>
 <221> UNSURE
 <222> (33)

<220>
 <221> UNSURE
 <222> (48)

<400> 14
 Leu Gly Pro Xaa Gly Xaa Xaa Arg Phe Pro Leu Phe Leu Pro Leu Gly
 1 5 10 15

Phe Leu Phe Phe Arg Ala Thr Ile Phe Ser Lys Ala Asn Thr Lys Ala
 20 25 30

Xaa Gln Phe Asn Ser Gln Gly Ser Gly Ile Phe Asn Leu Leu Ile Xaa
 35 40 45

Trp Pro Leu Pro Leu Leu Phe Tyr Gly Asp Leu Ser Val Ser Gly Pro
 50 55 60

His Pro Leu Pro Ile Pro His Cys Cys Leu Asp Val Val Leu Phe Phe
 65 70 75 80

Ile Gly Leu Leu Ser Pro Pro Pro Arg Ser Arg Pro Arg Pro Thr Pro
 85 90 95

Cys Ser His Tyr Pro Leu Ser Leu Ala Leu Ser Trp Ala Ser Val Gln
 100 105 110

Leu Asn Leu Tyr Thr Leu Cys Thr His Asn Gln Pro Asn Glu Asn Pro
 115 120 125

Thr Ala
 130

<210> 15
<211> 271
<212> DNA
<213> Homo sapiens

<400> 15
gccccttcca ccttttcc tatgacttkg aggactcctc cctgtccacc aaggagaagg 60
aagcagatc ccagaaggaa aacagataca gcaattttgg caataactct tattacttct 120
caagaccctc atctggatcc agtgtgccca ccaccccccac atcatccgtc tcaccccccac 180
aggaggccag gttggaaaagg tcatcacccga gtggcttct cacatcatcc ttcaaggcagc 240
accaagatgc, actggcaaaa aaaaaaaaaa a 271

<210> 16
<211> 38
<212> PRT
<213> Homo sapiens

<400> 16
Val Pro Thr Thr Pro Thr Ser Ser Val Ser Pro Pro Gln Glu Ala Arg
 1 5 10 15

Leu Glu Arg Ser Ser Pro Ser Gly Leu Leu Thr Ser Ser Phe Arg Gln
 20 25 30

His Gln Glu Ser Leu Ala
 35

<210> 17
<211> 1630
<212> DNA
<213> Homo sapiens

<220>
<221> unsure
<222> (1622)

<400> 17
cctgaccta ggtgatctgc cggcctcgcc ctctgaaagt gctgggattta taggcatttag 60
ccaaacatgcc tgacctgtta tttattttaa attatatcag gaatacacac acacacacac 120
acacacacac acacacacac acaacttata aagataatgg ttccttggc actcccccac 180
accaccccat ccaaatttac acaagtaaat ctgtatcaa ttgggtttaga agggatttat 240
tttaatattt ttggggattt cttatgtgc agtataattt ttagttatat tagtagtaat 300
tggaaatgtg tattttgtg actgaagtca cttctaaat aatttctaga ataaaattt 360

tatattgaag aagttggctc taaccatttt ttttcagga gcatgcatt tgaaatcatt 420
 ctgtggaaag atgaaaacaa atttagttct atgtctcccc ttttagaga tggtgacact 480
 ttccctaaat gtaccatgca tgattttct accaccctt tagcttgtta tacttaaattc 540
 ccagatctct gtctcccat ttcagttct ctagaatttc tggctgcttc caatgggtca 600
 aatttatgag tgaaccattn agaatcactt agtgtagaaa taaaccatgg gttaggagtt 660
 tgaacactgc ctaggttctg tttctgattt gattatgact cagctgtgt gccttggaa 720
 accaccttac tggtatccct atccttgcag aagaagaga gtaatgatg gttgactaa 780
 tctttgtgg ttattatgaa gatcagataa gatacattaa cacatttgc caactgaatt 840
 aggttattta tttacatgtg tgcatgga cctgggatc aggtgctatg tctcagcctt 900
 atctttgttt ttaatcctgt gtctctaatt gtgttgtca gttaaggagt gagtcattha 960
 atggttgcta gatgtttgag taaaacaaac aagcaacaa atggtaaattt agtactattt 1020
 cttttaaaaa aattttttt tacattttaa aaattataga taaatacaga gatgaggatct 1080
 caccatgttgc cccagtcgg tttcaactc ctaaactcaa gtgatcctct ctcctcagcc 1140
 tcccaagtg ctaggattac aggctgtgagc caccatgcct ggccagtagt actatccc 1200
 tggaaaata ttttagtagt gtcaacaaag ttgagcatac tgcgttgc cagttttgat 1260
 gctaagtawa taccacaaac aaatgcaac atatacttac caaaactcat gtccaaagaaat 1320
 attcgttagaa gcacaatttct tatgatagca aaaaggtaga aaacaacyta aatgttta 1380
 agcagtagca taagagtaat accgtgtggt ttgttatac agtgagatcc tgcacagcca 1440
 tggaaaagac caaaatattc cctgttaacaa tgagaatgaa tctctgtgc ttgcttcggc 1500
 agcacataca cttaaattgg aacgatacag agatttagcat ggccctgtg caaggagaat 1560
 gaatyttcgat aatgttcagc aaaagaagcc agatataaat gaatattcca ttttataaaa 1620
 anaaaaaaaaa 1630

<210> 18
 <211> 30
 <212> PRT
 <213> Homo sapiens

<400> 18
 Met Lys Thr Asn Leu Val Leu Cys Leu Pro Phe Leu Glu Met Leu Thr
 1 5 10 15
 Leu Ser Leu Asn Val Pro Cys Met Ile Cys Leu Pro Pro Phe
 20 25 30

<210> 19
 <211> 456
 <212> DNA
 <213> Homo sapiens

<400> 19
 aagaaggaga ctgttaagctt gtttgcacaa aaacatacca tacagagaaa gctgaagaca 60
 aacaaaagtt agaattcttgg aaaaaaagca tggatttgaa ttatcaacat cactggattt 120
 tggataatat gcctgttaacg tgggttacg atgttgaaga tggcaggtt ctgttaatcct 180
 ggatttccta ttggctgtta cattacagat aaaggccatg caaaagatgc ctgtgttatt 240
 agttcagatt tccatgaaag agatacattt tacatcttca accatgttga cataaaaata 300
 tactatcatg ttgttgaac tgggtccatg ggagcaagat tagtggctgc taaaacttcaa 360
 ccgaaaagct tcaaacatac ccatatagat aaaccagact gtcaggggcc ccccatggac 420
 ataagtaaca aggcttctgg ggagataaaa attgca 456

<210> 20
 <211> 519
 <212> DNA
 <213> Homo sapiens

<220>
 <221> unsure
 <222> (4)

<220>
<221> unsure
<222> (12)

<220>
<221> unsure
<222> (28)

<220>
<221> unsure
<222> (35) .. (36)

<220>
<221> unsure
<222> (51)

<220>
<221> unsure
<222> (63) .. (65)

<220>
<221> unsure
<222> (90)

<220>
<221> unsure
<222> (111) .. (112)

<220>
<221> unsure
<222> (123)

<220>
<221> unsure
<222> (136)

<220>
<221> unsure
<222> (148)

<220>
<221> unsure
<222> (157)

<220>
<221> unsure
<222> (161)

<220>
<221> unsure
<222> (204)

<220>
<221> unsure
<222> (239)

<220>
<221> unsure
<222> (305)

<400> 20
caantaataa anctttgtt tccctcgncat ttgtnttcgt tcccctgtcc ngccttgaaa 60
ccnnngtcct gcaccaatat ttccaaaccn aatacccaag catacaatcc nnactccaag 120
ctnggaattc gccccanagag accgtcgngg gaagaanttg nctggaaact tggtcatgg 180
gatataatacc gtcctccaag aaangggatg ctgctatcg tcttctagg agccgggana 240
cagatattaa ttatgacctt tgtgactcta ttttcgcctt gcctgggagt tttgtcacct 300
cccancggag gagcgctgat gacgtgtgct gtggcctgt gggcgctgct gggcaccct 360
gcaggctatg tttctgccag attctataag tccttggag gtgagaagtg gaaaacaaat 420
gttttattaa catcattct ttgtccctggg attgtattt ctgacttctt tataatgaat 480
ctgatcctctt ggtcaacggc ctctttggcc ctgcagaca 519

<210> 21
<211> 89
<212> PRT
<213> Homo sapiens

<220>
<221> UNSURE
<222> (18)

<400> 21
Met Thr Phe Val Thr Leu Phe Phe Ala Cys Leu Gly Val Leu Ser Pro
1 5 10 15

Pro Xaa Arg Gly Ala Leu Met Thr Cys Ala Val Val Leu Trp Val Leu
20 25 30

Leu Gly Thr Pro Ala Gly Tyr Val Ser Ala Arg Phe Tyr Lys Ser Phe
35 40 45

Gly Gly Glu Lys Trp Lys Thr Asn Val Leu Leu Thr Ser Phe Leu Cys
50 55 60

Pro Gly Ile Val Phe Ala Asp Phe Phe Ile Met Asn Leu Ile Leu Trp
65 70 75 80

Ser Thr Ala Ser Leu Ala Leu Glu Thr
85

<210> 22
<211> 507
<212> DNA
<213> Homo sapiens

<400> 22
ttcttccat acacctttcc cccataagat gtgtcttcaa cactataaag catttgtatt 60
gtgatttgat taagtatata ttgggtgtt ctcaatgaag agcaaattta aatattatgt 120
gcattttgtaa atacagttagc tataaaattt tccataacttc taatggcaga atagaggagg 180
ccatattaaa taatactgtat gaaaggcagg acactgcatt gttaatagga ttttcttaggc 240
tcggtaggca gaaagaattt tttttctttt aagaaataa ctttttatca tggtaatttt 300
gaaggatgat tcctatgtat tggtcaccag gggaatgtgg cttttaaaga aaatcttcta 360
ttggttgtaa ctgttcatat cttcttactt ttctgtgttg acttcattat tcccatggta 420
ttggccctttt aaactatgtg cctctgagtc ttcaatatta taaatttgta tcttaataaa 480
tattataaaa atgaaaaaaaaaaaaaaa 507

<210> 23
<211> 622
<212> DNA
<213> Homo sapiens

<220>
 <221> unsure
 <222> (32)

<220>
 <221> unsure
 <222> (57)

<220>
 <221> unsure
 <222> (66)

<220>
 <221> unsure
 <222> (72)

<220>
 <221> unsure
 <222> (105)

<400> 23

ggttttcg gacacccgtg gatggacacg gnaaggaaac accagggcaa ccacagntgtt 60
 ggatanaata gnacaaccac accctggcgt ccagggcctc ccagnctgtg ccccggtctta 120
 gtaccaccag caaccatcaa tcccgttcc teetgcetcc tctcctgcaa tecacccgc 180
 cacgactatc gccatggcaag ccctgatcgc agagaacttc cgcttcctgt cactttttt 240
 caagagcaag gatgtgatga ttttcaacgg cctgggtggca ctggggcacgg tgggcagcca 300
 ggagctgttc tctgtgggtgg ctttccactg cccctgctcg cggggccggaa actacctgtta 360
 cgggctggcg gccatcgccg tgccccccct ggtgtcttc atcattggca tcatacctcaa 420
 caaccacacc tggAACCTCG tggccgagtg ccagcacccgg aggaccaaga actgctccgc 480
 cggccccacc ttccctcttc taagctccat cctgggacgt gcggctgtgg cccctgtcac 540
 ctggctgttc atccctctgc tgctgggtga ggcttatgtc tgtgtctca gtgagttcgt 600
 ggacccttcc tcactcacgg cc 622

<210> 24

<211> 143
 <212> PRT
 <213> Homo sapiens

<400> 24

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Met | Ala | Ala | Leu | Ile | Ala | Glu | Asn | Phe | Arg | Phe | Leu | Ser | Leu | Phe | Phe |
| 1 | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | 15 | |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Lys | Ser | Lys | Asp | Val | Met | Ile | Phe | Asn | Gly | Leu | Val | Ala | Leu | Gly | Thr |
| | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | 30 | |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Val | Gly | Ser | Gln | Glu | Leu | Phe | Ser | Val | Val | Ala | Phe | His | Cys | Pro | Cys |
| | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | 45 | |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Ser | Pro | Ala | Arg | Asn | Tyr | Leu | Tyr | Gly | Leu | Ala | Ala | Ile | Gly | Val | Pro |
| | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | 50 | |
| | | | | | | | | | | | | | | 55 | |
| | | | | | | | | | | | | | | 60 | |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Ala | Leu | Val | Leu | Phe | Ile | Ile | Gly | Ile | Ile | Leu | Asn | Asn | His | Thr | Trp |
| | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | 65 | |
| | | | | | | | | | | | | | | 70 | |
| | | | | | | | | | | | | | | 75 | |
| | | | | | | | | | | | | | | 80 | |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Asn | Leu | Val | Ala | Glu | Cys | Gln | His | Arg | Arg | Thr | Lys | Asn | Cys | Ser | Ala |
| | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | 85 | |
| | | | | | | | | | | | | | | 90 | |
| | | | | | | | | | | | | | | 95 | |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|--|
| Ala | Pro | Thr | Phe | Leu | Leu | Ser | Ser | Ile | Leu | Gly | Arg | Ala | Ala | Val | |
| | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | 100 | |
| | | | | | | | | | | | | | | 105 | |
| | | | | | | | | | | | | | | 110 | |

Ala Pro Val Thr Trp Ser Val Ile Ser Leu Leu Arg Gly Glu Ala Tyr
115 120 125

Val Cys Ala Leu Ser Glu Phe Val Asp Pro Ser Ser Leu Thr Ala
130 135 140

<210> 25
<211> 314
<212> DNA
<213> Homo sapiens

<220>
<221> unsure
<222> (38)

<220>
<221> unsure
<222> (50)

<220>
<221> unsure
<222> (58)

<220>
<221> unsure
<222> (63)

<220>
<221> unsure
<222> (65)

<220>
<221> unsure
<222> (70)

<220>
<221> unsure
<222> (77)

<220>
<221> unsure
<222> (82)

<220>
<221> unsure
<222> (84)

<220>
<221> unsure
<222> (94)

<220>
<221> unsure
<222> (113)

<220>
<221> unsure
<222> (132)

<220>
<221> unsure
<222> (144)

<220>
<221> unsure
<222> (155)

<220>
<221> unsure
<222> (165)

<220>
<221> unsure
<222> (171)

<220>
<221> unsure
<222> (183)

<220>
<221> unsure
<222> (198)

<220>
<221> unsure
<222> (216)

<220>
<221> unsure
<222> (234)

<220>
<221> unsure
<222> (249)

<220>
<221> unsure
<222> (254)

<220>
<221> unsure
<222> (256)

<400> 25
ttttaaaaaa ctttatctt cttggccagg gaaaaggnc cccaggcaan ctgggtntg 60
ganancacca naaaacnatg gnancccaa ccancaggc cagttacag tgnaactccc 120
cagtggcccc ctttatggg ctcnattcag ttaanattta tctancttca nagggacacc 180
canccaaca gttcccnct ggggatggc ccccanttca acctctggcc ttantttaaa 240
aaataaaant ttttcttac taaaaggaa aaaaaaaaaa aaaaaaaaaa 300
aaaaaaaaa aaaa 314

<210> 26
<211> 533
<212> DNA
<213> *Mus musculus*

<220>
<221> unsure

<222> (32)

<220>

<221> unsure
<222> (38)

<400> 26

gggatatatccc atacaggat gaaaaaaccc cntatgtnat agtgttctat agcacacaat 60
 accttatgaa ggaagggtt satgaataca tggcagaaga caatcatgaa agamttatyt 120
 tgaggggyta gaartaatga gtttggaggt gtccccctta gtcctgtart gtcctggat 180
 ccctmacccc taatttctc cccaragcat yatccctctc cagtattggt actacatgat 240
 tgaactttcc ttctastggt ccctgytctt cagcattgcc tctgtatgtcw agcgaaagga 300
 ttttaaggaa cagatcatcc accatgtggc cactatcatt ctccctgtct ttcctgttt 360
 tgccaattac gtccgggcag ggaccctcat catggctctg catgacgctt ctgactacct 420
 gctggagtct gccaagatgt ttaactacgc gggatggaag aacacctgca acaacctt 480
 cattgtgttc gccatcgtt tcatcatcac tcggctggtt atcatgcctt tct 533

<210> 27

<211> 44

<212> PRT

<213> Mus musculus

<400> 27

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Met | Thr | Leu | Leu | Thr | Thr | Cys | Trp | Ser | Leu | Pro | Arg | Cys | Leu | Thr | Thr |
| 1 | | | | | | | | | 10 | | | | | 15 | |
| Arg | Asp | Gly | Arg | Thr | Pro | Ala | Thr | Thr | Ser | Ser | Leu | Cys | Ser | Pro | Ser |
| | | | | | | | | | 25 | | | | | 30 | |
| Phe | Ser | Ser | Ser | Leu | Gly | Trp | Leu | Ser | Cys | Leu | Ser | | | | |
| | | | | | | | | | 40 | | | | | | |

<210> 28

<211> 313

<212> DNA

<213> Mus musculus

<220>

<221> unsure

<222> (4)

<220>

<221> unsure

<222> (33)

<220>

<221> unsure

<222> (35)

<220>

<221> unsure

<222> (94)

<220>

<221> unsure

<222> (226)

<400> 28

aaanacaagt caatgaagt aaggaggta tgnanacatg cccctcacca taccccaggg 60

accatggttc ctaggatctc actgcctccc tttntggcct tcctgtcccc tcccttcagc 120
 tatgacagct ggtgtggagt agaaggcaaa ctatgttgc tatatttattga acatttgggg 180
 tttcagttgt aaagccacaaa ctacaggttag gacctgatat ttcggngagg gaccattca 240
 gacccaaatg tactgttaat ttttttaat taaagtataat taaagggttaa ataaaaaaaaa 300
 aaaaaaaaaa aaa 313

<210> 29
 <211> 525
 <212> DNA
 <213> Mus musculus

<220>
 <221> unsure
 <222> (22)

<220>
 <221> unsure
 <222> (52)

<220>
 <221> unsure
 <222> (55)

<220>
 <221> unsure
 <222> (59)

<400> 29
 aaagacatcc actttgcctt tntctccaca ggtgtccact cccaggtcca antgnagng 60
 agcctgaatt cgccaaaga ggcctaatta caatcatcatttca aattttcaa ttttaagtt 120
 gatgggctct taagtggtcc gttctgaata raaaccaatt tgcttagttc gggtttgttt 180
 tggtttgttt tggtttgttt ttttaaggaa tcagatagcc agaaaaaaaaa 240
 atgctattgc ttgtttcat gaacttcagt tgctctttt tagtaaaccc agtacttcc 300
 acaaagtctt ctctgacctt ccccatcact ggacggttca cccatcttct tctccaagtg 360
 tttatccccc agcccaagcc tttcctgctg caagccaagc ctgctacatt tgttacagac 420
 caagcttata cacagctcga caactgcact cccactgttag gctccgggtgt gtactcttgt 480
 cttgtgttgg gaaggggaag tgaagtgata agccagaatt ttttt 525

<210> 30
 <211> 95
 <212> PRT
 <213> Mus musculus

<400> 30
 Met Leu Leu Leu Val Phe Met Asn Phe Ser Cys Leu Phe Leu Val Asn
 1 5 10 15

Pro Val Leu Ser Thr Lys Ser Ser Leu Thr Phe Pro Ile Thr Gly Arg
 20 25 30

Phe Thr His Leu Leu Leu Gln Val Phe Ile Pro Gln Pro Lys Pro Phe
 35 40 45

Leu Leu Gln Ala Lys Pro Ala Thr Phe Val Thr Asp Gln Ala Tyr Thr
 50 55 60

Gln Leu Asp Asn Cys Thr Pro Thr Val Gly Ser Gly Val Tyr Ser Cys
 65 70 75 80

Leu Val Leu Gly Arg Gly Ser Glu Val Ile Ser Gln Asn Phe Phe

85

90

95

<210> 31
<211> 270
<212> DNA
<213> Mus musculus

<220>
<221> unsure
<222> (47)

<220>
<221> unsure
<222> (71)

<220>
<221> unsure
<222> (91)

<220>
<221> unsure
<222> (94)

<220>
<221> unsure
<222> (105)

<220>
<221> unsure
<222> (170)

<220>
<221> unsure
<222> (189)

<220>
<221> unsure
<222> (192)

<220>
<221> unsure
<222> (210)

<220>
<221> unsure
<222> (246)..(247)

<400> 31
aggtttcttg ggaacagctc agcagattt tgagaccaat caaatgncc tattaagaac 60
tttatctgtt nggaaacatg gtttccttcc nggntctgct aaacngaaag ctcatttttt 120
gttgctgttg ttgttgtttt tttgtccatt tctctttaat tctaattgttn acatcatgttc 180
gtgctgtang antctagaaa gccttaattn acttccacca agaaataaag caatatgttg 240
gtaatnngaa aaaaaaaaaaaaaaaa aaaaaaaaaaaa 270

<210> 32
<211> 574
<212> DNA
<213> Mus musculus

<220>
<221> unsure
<222> (9)

<220>
<221> unsure
<222> (29)

<220>
<221> unsure
<222> (37)

<220>
<221> unsure
<222> (53)

<220>
<221> unsure
<222> (56)

<220>
<221> unsure
<222> (68)

<220>
<221> unsure
<222> (72)

<220>
<221> unsure
<222> (85)

<220>
<221> unsure
<222> (118)

<220>
<221> unsure
<222> (131)

<220>
<221> unsure
<222> (169)..(170)

<220>
<221> unsure
<222> (172)

<220>
<221> unsure
<222> (180)

<220>
<221> unsure
<222> (253)

<220>
<221> unsure
<222> (448)

<220>
<221> unsure
<222> (452)

<220>
<221> unsure
<222> (455)

<220>
<221> unsure
<222> (457)

<220>
<221> unsure
<222> (459)

<220>
<221> unsure
<222> (475)

<220>
<221> unsure
<222> (550)

<220>
<221> unsure
<222> (572)

<400> 32
tttggtcana aaagacaatt tttttgtnt caagctngag gtgtggcagg ctnganattt 60
ggccaaanaa tngagggaca aaganatcca ctttgccctt ttttccacag gtgtccantc 120
ccaggtccaa ntgcaggcgg gtccacaggc cgccagccatg gtagccgnn tntcccagn 180
ggarttcgaa tgggytaca cggaccarcc ccacgccc cggcgcaagg agatcttagc 240
aaagtatcca ganatcaagt ctttgatgaa acctgaccac aatctgatct ggattttagc 300
catgatgctt ctcgtccagc tggcttcatt ttacttagtc aaagatttgg actggaaatg 360
ggtcataattt tggtcctatg tctttggcag ctgccttaac cactccatga ctctggctat 420
ccatgagatt tcccacaatt tcccctngg cnccncnang gcctgtggaa cccgnggtt 480
ggaatgttg ctaacctctc tctccgaatg gcctactcca tttcctttaa aaaaaacaca 540
tggatcaccn ccggtaactcc gaacggataa antr 574

<210> 33
<211> 138
<212> PRT
<213> *Mus musculus*

<220>
<221> UNSURE
<222> (5)

<220>
<221> UNSURE
<222> (8)

<220>
<221> UNSURE
<222> (32)

<220>
<221> UNSURE
<222> (97)

<220>

<221> UNSURE

<222> (99)..(101)

<400> 33

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Met | Gly | Ser | Arg | Xaa | Ser | Arg | Xaa | Glu | Phe | Glu | Trp | Val | Tyr | Thr | Asp |
| 1 | | | | 5 | | | | | 10 | | | | 15 | | |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Gln | Pro | His | Ala | Ala | Arg | Arg | Lys | Glu | Ile | Leu | Ala | Lys | Tyr | Pro | Xaa |
| | | | | 20 | | | | 25 | | | | 30 | | | |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Ile | Lys | Ser | Leu | Met | Lys | Pro | Asp | His | Asn | Leu | Ile | Trp | Ile | Val | Ala |
| | | | | 35 | | | 40 | | | | 45 | | | | |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Met | Met | Leu | Leu | Val | Gln | Leu | Ala | Ser | Phe | Tyr | Leu | Val | Lys | Asp | Leu |
| | | | | 50 | | | 55 | | | | 60 | | | | |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Asp | Trp | Lys | Trp | Val | Ile | Phe | Trp | Ser | Tyr | Val | Phe | Gly | Ser | Cys | Leu |
| | 65 | | | 70 | | | | 75 | | | | 80 | | | |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Asn | His | Ser | Met | Thr | Leu | Ala | Ile | His | Glu | Ile | Ser | His | Asn | Phe | Pro |
| | 85 | | | | 90 | | | | | | 95 | | | | |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Xaa | Gly | Xaa | Xaa | Xaa | Ala | Cys | Gly | Thr | Ala | Gly | Leu | Glu | Cys | Leu | Leu |
| | | | | 100 | | | 105 | | | | 110 | | | | |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Thr | Ser | Leu | Ser | Glu | Trp | Pro | Thr | Pro | Phe | Pro | Leu | Lys | Lys | Thr | His |
| | | | | 115 | | | 120 | | | | 125 | | | | |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|--|--|--|--|--|--|
| Gly | Ser | Pro | Pro | Val | Leu | Arg | Thr | Asp | Lys | | | | | | |
| | | | | 130 | | | 135 | | | | | | | | |

<210> 34

<211> 216

<212> DNA

<213> Mus musculus

<220>

<221> unsure

<222> (69)

<220>

<221> unsure

<222> (86)

<220>

<221> unsure

<222> (114)

<220>

<221> unsure

<222> (116)

<220>

<221> unsure

<222> (119)

<220>

<221> unsure
<222> (142)

<400> 34
atgaagtgc ttttggagga gctttgttt agtccaacag gagtccaagg atgcagatta 60
gagtttngng agtttgctc ccttgnntggg ctaggcattt cattgttcta actncntcng 120
agtaactgat gatcctataaa gnaaccccaa taaatttttt gtttactaa aaaaaaaaaa 180
aaaaaaaaaaa aaaaaaaaaaaa aaaaaaaaaa aaaaaaa 216

<210> 35
<211> 526
<212> DNA
<213> *Mus musculus*

<220>
<221> unsure
<222> (6)

<220>
<221> unsure
<222> (25)

<220>
<221> unsure
<222> (53)

<400> 35
acagggngtcc aatcccaggc ccaantgcag gggagcctga attcggccaa agnggcctag 60
cctcccaagt gstgggatta aaggsgtgtg ccaccatgcc ccacttcata tgatatattt 120
ttaatgaata aagagtggaa aaattatgtt tcacatgtgt taatttgggg agaagcgctt 180
tataacagag ggcttactyt caatcaaaga gaacaaggr aaatgtgtty tacaggcagt 240
gtataccctt gacctctgaa aaaacctata tagttctcc tacagacacc ttgccagtaa 300
ccttacaggt cttataggag agcagatcca agttgccagg ctgatctgca agcacaaaaca 360
tttgtcaagg gaaagcacag gtcgttactt tcagtagaaa atggttcttt gctatggatg 420
gattctcttc ttcttgcccc atgtcctgtt cccaggacc gacttcctgc agcaactgtgg 480
tggactcttc tatgaggaga caacatctgg gccttattca atagcc 526

<210> 36
<211> 42
<212> PRT
<213> *Mus musculus*

<400> 36
Met Val Leu Cys Tyr Gly Trp Ile Leu Phe Phe Leu Pro His Val Leu
1 5 10 15

Phe Pro Arg Thr Asp Phe Leu Gln His Cys Gly Gly Leu Phe Tyr Glu
20 25 30

Glu Thr Thr Ser Gly Pro Tyr Ser Ile Ala
35 40

<210> 37
<211> 208
<212> DNA
<213> *Mus musculus*

<220>
<221> unsure

<222> (8)

<220>
<221> unsure
<222> (29)

<220>
<221> unsure
<222> (31)

<220>
<221> unsure
<222> (42)

<220>
<221> unsure
<222> (55)

<220>
<221> unsure
<222> (65)

<220>
<221> unsure
<222> (75)

<220>
<221> unsure
<222> (86)

<220>
<221> unsure
<222> (91)

<220>
<221> unsure
<222> (98)

<220>
<221> unsure
<222> (100)..(101)

<220>
<221> unsure
<222> (113)

<220>
<221> unsure
<222> (119)

<220>
<221> unsure
<222> (121)

<220>
<221> unsure
<222> (128)

<220>
<221> unsure

<222> (130)..(131)

<220>
<221> unsure
<222> (133)

<220>
<221> unsure
<222> (137)

<220>
<221> unsure
<222> (161)

<400> 37
tttggaaangg caacagaaaat atttttgna ntagaaaaag gnatggAACG tggtnccaat 60
tgttnatttt ccttnattta ttcccngtaa ntttgcngn ngataaattg aanataacng 120
ngattaangn ntnatgntaa aaaaaaaaaa aaaaaaaaaa naaaaaaaaaa aaaaaaaaaa 180
aaaaaaaaaa aaaaaaaaaa aaaaaaaaa 208

<210> 38
<211> 535
<212> DNA
<213> *Mus musculus*

<220>
<221> unsure
<222> (6)

<220>
<221> unsure
<222> (30)

<220>
<221> unsure
<222> (60)

<220>
<221> unsure
<222> (67)

<220>
<221> unsure
<222> (83)

<220>
<221> unsure
<222> (99)

<220>
<221> unsure
<222> (115)

<220>
<221> unsure
<222> (145)

<220>
<221> unsure
<222> (160)

<220>
 <221> unsure
 <222> (165)

<400> 38
 atttgntcag aaaagacaat tttttgttn tcaagcttga ggtgtggcag gcttgagatn 60
 tgcccanaca cttgaggac aangacatcc aataaaccnt tctctccaca ggtgnccact 120
 cccaggtcca actgcaggcg agccngaatt cggccaaagn gccnaagat cagtagctc 180
 cctgggttcg aacaagggtga aaagcagctt tcttgctttt gaaatcatyt ttgtgacaag 240
 gacacatggg gtcagggttag ggtgtccart taaaatagtg tcactgctta gaaagggwa 300
 ctggattcc ttttagttagc ttagcttgt ctctgtttc ataaaacaca ctgggttaga 360
 ataraggctc ctgcattaca tggtttgtgt cactgtttt tggttgggtt tctttttgtt 420
 ttttcgagac agggttctc tgtatacgccc tggctgtcct araactcact ctgttagacca 480
 ggctggcctc gaactcagaa atctgcccgc ttctgcctcc caagtgctgg gatta 535

<210> 39
 <211> 52
 <212> PRT
 <213> Mus musculus

<220>
 <221> UNSURE
 <222> (28)

<400> 39
 Met Val Cys Val Thr Val Phe Cys Trp Val Phe Phe Leu Val Phe Arg
 1 5 10 15

Asp Arg Val Ser Leu Tyr Ser Pro Gly Cys Pro Xaa Thr His Ser Val
 20 25 30

Asp Gln Ala Gly Leu Glu Leu Arg Asn Leu Pro Ala Ser Ala Ser Gln
 35 40 45

Val Leu Gly Leu
 50

<210> 40
 <211> 308
 <212> DNA
 <213> Mus musculus

<220>
 <221> unsure
 <222> (43)

<220>
 <221> unsure
 <222> (115)

<220>
 <221> unsure
 <222> (134)

<400> 40
 ggattaaagg catgtgtcac gttttaatt gatagttata acntcgatgc cacgaatcct 60
 gcagtttctc ctgtgctct ttctttgtgt cagatgggtt aagggttatac agttngggta 120
 agaattgtcc ttgnaccccc tggaaattatt tttctcaaaa atccaagact ccaaagaaca 180

tggaaaaat ttttctgtcc acttttgacg ttgaagat~~t~~ tggtatcct tttcgta~~c~~t 240
 tctatgtatt ttctatgtaa aattttacac aattaaaaat gttttttgt ctagtaaaaa 300
 aaaaaaaaaa 308

<210> 41
 <211> 1351
 <212> DNA
 <213> Mus musculus

<220>
 <221> unsure
 <222> (134)

<400> 41
 cagcgcgcgg agccggcg~~c~~ ccgttggcgc gctctggcct ggcttcgggt cg~~tc~~cgcttc~~g~~ 60
 gcccggagga gcegc~~t~~cg~~c~~ gtctccggag cggccggagag gatgg~~t~~gc~~g~~ ggcagcc~~g~~ 120
 ggcccggcgc g~~c~~gc~~c~~ccggc~~c~~ gagtgaacag ggccaggccg cgggc~~t~~ccg cgggc~~t~~car 180
 cccggc~~a~~gtct g~~c~~ggggc~~g~~ggt tgccgcttgt gggaa~~g~~catg tt~~c~~ag~~t~~atca accccct~~g~~ga 240
 gaac~~c~~ctgaag ctgtacatca gc~~a~~gcccggcc gccc~~t~~ttgg~~t~~ gtttttatga tc~~a~~gtgt~~c~~ag 300
 cgccatggcc atcg~~c~~ttcc tcacc~~c~~ttgg ctacttcttc aagatcaagg agattaagtc 360
 cccagaaaat~~t~~ gctgaggatt ggaatacttt tctgctccgg ttaatgatt tggactt~~t~~g 420
 t~~g~~tatc~~g~~aa aacgagacac tgaagcatct ctccaac~~g~~at accaccacac cagagacac 480
 catgaccg~~t~~c gggcagg~~c~~ca gat~~c~~gtctac ccagccgccc c~~a~~gtccct~~g~~ aggagg~~t~~cagg 540
 ccccatcaat atttc~~g~~at~~t~~g ccattac~~c~~tt gac~~c~~ttggac cctctca~~g~~ac cctt~~t~~ggagg 600
 gtactctc~~g~~a aat~~t~~gttacac ac~~t~~gtactc caccatc~~c~~tc gggcatcaga ttggatt~~t~~tc 660
 agg~~c~~agg~~g~~aa gcccac~~g~~agg agatcaacat cac~~c~~tc~~c~~acc ctgc~~c~~ctg~~c~~ctg cctggaac~~g~~c 720
 cgat~~t~~gactgt gccc~~t~~ccat~~g~~ g~~c~~ca~~t~~gt~~t~~ga gc~~a~~ggc~~g~~gt~~t~~ ttc~~a~~c~~g~~at~~c~~ gcatgac~~c~~ct 780
 cac~~a~~g~~t~~gc~~c~~ cccggagg~~t~~ct tcccc~~t~~ca~~c~~ tg~~t~~c~~a~~g~~c~~ca cctc~~a~~ct~~t~~ga tcccc~~g~~ac~~a~~c 840
 atacagcaac g~~c~~ca~~c~~g~~t~~ct~~c~~ ggtacaagat cttcacaact gccagagat~~g~~ ccaacac~~g~~aa 900
 atat~~t~~ctcaa~~t~~ gactacaat~~c~~ ctttct~~t~~gt~~t~~ ttataagg~~g~~gt g~~c~~catt~~t~~gg~~a~~ aagtctac~~ca~~ 960
 tgctttaat~~t~~ cccaaact~~c~~ ctgtt~~t~~gt~~t~~ tcc~~a~~gat~~t~~gac gacc~~g~~ct~~c~~at taataaaac~~c~~t 1020
 gcat~~t~~ctat~~g~~ cac~~a~~ccagg~~t~~t actt~~c~~ct~~t~~tt c~~g~~t~~g~~at~~t~~gt~~t~~ ataac~~g~~at~~t~~g tctg~~c~~tat~~g~~c 1080
 agt~~c~~at~~c~~aaa~~t~~ ggc~~a~~g~~c~~ccca g~~c~~aa~~a~~ct~~t~~g~~c~~ g~~c~~ag~~a~~caat c~~ct~~g~~a~~at~~t~~tt g~~c~~cmt~~g~~ag~~a~~aa 1140
 ggtggyt~~c~~ g~~c~~t~~g~~ac~~g~~c~~c~~ aat~~c~~ct~~a~~ca~~t~~ g~~c~~ccccat~~t~~tt tyt~~g~~ag~~a~~gac caagaaccat 1200
 gat~~c~~att~~g~~cc~~t~~ tg~~t~~ct~~a~~at~~g~~ g~~c~~agg~~g~~cc~~t~~ g~~c~~cc~~a~~ct~~t~~g~~t~~ tgaat~~a~~cat~~g~~t atctt~~g~~caat 1260
 gttgg~~t~~tt~~t~~ tcc~~a~~g~~c~~aaa~~t~~ gac~~a~~tt~~c~~aa~~t~~ g~~t~~gc~~c~~ct~~g~~ta~~t~~ ctg~~a~~ttt~~g~~tc catat~~t~~tata 1320
 aac~~a~~ct~~g~~at~~c~~ tggnaaaaaa aaaaaaaaaa a 1351

<210> 42
 <211> 314
 <212> PRT
 <213> Mus musculus

<220>
 <221> UNSURE
 <222> (306)

<220>
 <221> UNSURE
 <222> (310)

<400> 42
 Met Phe Ser Ile Asn Pro Leu Glu Asn Leu Lys Leu Tyr Ile Ser Ser
 1 5 10 15

Arg Pro Pro Leu Val Val Phe Met Ile Ser Val Ser Ala Met Ala Ile
 20 25 30

Ala Phe Leu Thr Leu Gly Tyr Phe Phe Lys Ile Lys Glu Ile Lys Ser
 35 40 45

Pro Glu Met Ala Glu Asp Trp Asn Thr Phe Leu Leu Arg Phe Asn Asp
 50 55 60

Leu Asp Leu Cys Val Ser Glu Asn Glu Thr Leu Lys His Leu Ser Asn
 65 70 75 80

Asp Thr Thr Thr Pro Glu Ser Thr Met Thr Val Gly Gln Ala Arg Ser
 85 90 95

Ser Thr Gln Pro Pro Gln Ser Leu Glu Glu Ser Gly Pro Ile Asn Ile
 100 105 110

Ser Val Ala Ile Thr Leu Thr Leu Asp Pro Leu Lys Pro Phe Gly Gly
 115 120 125

Tyr Ser Arg Asn Val Thr His Leu Tyr Ser Thr Ile Leu Gly His Gln
 130 135 140

Ile Gly Leu Ser Gly Arg Glu Ala His Glu Glu Ile Asn Ile Thr Phe
 145 150 155 160

Thr Leu Pro Ala Ala Trp Asn Ala Asp Asp Cys Ala Leu His Gly His
 165 170 175

Cys Glu Gln Ala Val Phe Thr Ala Cys Met Thr Leu Thr Ala Ala Pro
 180 185 190

Gly Val Phe Pro Val Thr Val Gln Pro Pro His Cys Ile Pro Asp Thr
 195 200 205

Tyr Ser Asn Ala Thr Leu Trp Tyr Lys Ile Phe Thr Thr Ala Arg Asp
 210 215 220

Ala Asn Thr Lys Tyr Ala Gln Asp Tyr Asn Pro Phe Trp Cys Tyr Lys
 225 230 235 240

Gly Ala Ile Gly Lys Val Tyr His Ala Leu Asn Pro Lys Leu Thr Val
 245 250 255

Val Val Pro Asp Asp Arg Ser Leu Ile Asn Leu His Leu Met His
 260 265 270

Thr Ser Tyr Phe Leu Phe Val Met Val Ile Thr Met Phe Cys Tyr Ala
 275 280 285

Val Ile Lys Gly Arg Pro Ser Lys Leu Arg Gln Ser Asn Pro Glu Phe
 290 295 300

Cys Xaa Glu Lys Val Xaa Leu Ala Asp Ala
 305 310

<210> 43
 <211> 848
 <212> DNA
 <213> Mus musculus

<220>
 <221> unsure

<222> (11)

<220>
<221> unsure
<222> (30)

<220>
<221> unsure
<222> (137)

<220>
<221> unsure
<222> (183)

<220>
<221> unsure
<222> (370)

<220>
<221> unsure
<222> (649)

<220>
<221> unsure
<222> (712)

<220>
<221> unsure
<222> (725)

<220>
<221> unsure
<222> (727)

<220>
<221> unsure
<222> (729)

<220>
<221> unsure
<222> (746)

<220>
<221> unsure
<222> (760)

<220>
<221> unsure
<222> (840)

<400> 43

agctgttggg ntgcgggttg aggacaatn ttgcgggtct ttccagtatt cttggatcgg 60
aaacccgtcg gcttccgaac ggtactccgc caccgaggga cctgagcgag tccgcatacg 120
ccggatcgga aaacctntcg actgttgggg tgagtactcc ctctcaaaaag cgggcatacg 180
ttntgcgcta agattgtcaag ttccaaaaa cgaggaggat ttgatattca cctggcccg 240
ggtgatgcct ttgaggggtgg ccgegtccat ctggtcagaa aagacaatct ttttgttgc 300
aagcttgagg tgtggcaggc ttgagatctg gccataact tgagtgacaa tgacatccac 360
tttgccttn tctccacagg tgtccactcc caggccaac tgcaacttgc 420
aaagaggccct actttcatat ccacgtcg ttttctggcc gccacgttgc tgctgtggc 480
gctggtcgtt gcccaggccct gcacttcaag gactgcggct ctaagggtggg 540

agtataaaag gaggtgaatg tgagccatg tcccaccatc ccctgtcagc tgcacaaagg 600
 ccagtctac agtgtcaaca tcaccttac cagggact cagtccana acagcacggc 660
 cttggtccac ggcattcctgg aaggatccg ggtcccccttc cctattcctg ancctgacgg 720
 ttgtanant ggaatcaact gccccntcca gaaagacaan gtctacagct acctgaataa 780
 gctccggtg aaaaatgaat accccttat aaaactggtg gtggaatgga aactttgaan 840
 atgacaaa 848

<210> 44
 <211> 130
 <212> PRT
 <213> Mus musculus

<220>
 <221> UNSURE
 <222> (68)

<220>
 <221> UNSURE
 <222> (89)

<220>
 <221> UNSURE
 <222> (94)...(95)

<220>
 <221> UNSURE
 <222> (101)

<220>
 <221> UNSURE
 <222> (105)

<400> 44

Met Arg Phe Leu Ala Ala Thr Ile Leu Leu Leu Ala Leu Val Ala Ala
 1 5 10 15

Ser Gln Ala Glu Pro Leu His Phe Lys Asp Cys Gly Ser Lys Val Gly
 20 25 30

Val Ile Lys Glu Val Asn Val Ser Pro Cys Pro Thr Asp Pro Cys Gln
 35 40 45

Leu His Lys Gly Gln Ser Tyr Ser Val Asn Ile Thr Phe Thr Ser Gly
 50 55 60

Thr Gln Ser Xaa Asn Ser Thr Ala Leu Val His Gly Ile Leu Glu Gly
 65 70 75 80

Ile Arg Val Pro Phe Pro Ile Pro Xaa Pro Asp Gly Cys Xaa Xaa Gly
 85 90 95

Ile Asn Cys Pro Xaa Gln Lys Asp Xaa Val Tyr Ser Tyr Leu Asn Lys
 100 105 110

Leu Pro Val Lys Asn Glu Tyr Pro Ser Ile Lys Leu Val Val Glu Trp
 115 120 125

Lys Leu
 130

<210> 45
<211> 265
<212> DNA
<213> *Mus musculus*

<220>
<221> unsure
<222> (2)

<220>
<221> unsure
<222> (67)

<220>
<221> unsure
<222> (75)

<220>
<221> unsure
<222> (79)

<220>
<221> unsure
• <222> (101)

<220>
<221> unsure
<222> (104)

<220>
<221> unsure
<222> (111)

<220>
<221> unsure
<222> (121)

<220>
<221> unsure
<222> (133)

<220>
<221> unsure
<222> (136)

<220>
<221> unsure
<222> (157)

<220>
<221> unsure
<222> (162)

<220>
<221> unsure
<222> (164)

<220>
<221> unsure

<222> (172)

<220>
<221> unsure
<222> (175)

<220>
<221> unsure
<222> (183)

<220>
<221> unsure
<222> (187)

<220>
<221> unsure
<222> (192)

<220>
<221> unsure
<222> (199)..(200)

<220>
<221> unsure
<222> (208)

<220>
<221> unsure
<222> (211)

<220>
<221> unsure
<222> (223)

<220>
<221> unsure
<222> (225)

<220>
<221> unsure
<222> (227)

<220>
<221> unsure
<222> (243)..(244)

<220>
<221> unsure
<222> (246)

<400> 45
gngttacctc ccctgtttct aagtgcctcc tgagtccccca gcccctggct tatcagtcag 60
atgagtncc ttggnagcnt ctggcccatc gcttcagcag nagngactag ntccctcgg 120
natccagact ggntgngggg cagtctgccc cagaaanttg tntntgagtg gntgngtctt 180
tgnggtnagc tntcggtcn nnntgatntt nattaaagcc aanantnggt tgcaaaaaaa 240
aanngnaaaa aaaaaaaaaa aaaaa 265

<210> 46
<211> 29
<212> DNA

<213> Artificial Sequence

<220>

<223> oligonucleotide

<220>

<221> misc_feature

<222> (2)

<223> biotinylated phosphoamidite residue

<400> 46

ttagatccaa cagtcacgtt cacgaaacc

29

<210> 47

<211> 29

<212> DNA

<213> Artificial Sequence

<220>

<223> oligonucleotide

<220>

<221> misc_feature

<222> (2)

<223> biotinylated phosphoamidite residue

<400> 47

cntcctggtt gttgtttgaa gagcaggcg

29

<210> 48

<211> 29

<212> DNA

<213> Artificial Sequence

<220>

<223> oligonucleotide

<220>

<221> misc_feature

<222> (2)

<223> biotinylated phosphoamidite residue

<400> 48

tngcccaaga aactgggtt cacattaa

29

<210> 49

<211> 29

<212> DNA

<213> Artificial Sequence

<220>

<223> oligonucleotide

<220>

<221> misc_feature

<222> (2)

<223> biotinylated phosphoamidite residue

<400> 49

gntgaagcat gcccaatttc atttcctct

29

<210> 50
<211> 29
<212> DNA
<213> Artificial Sequence

<220>
<223> oligonucleotide

<220>
<221> misc_feature
<222> (2)
<223> biotinylated phosphoamidite residue

<400> 50
antgttctct ggcttgcag ggaagactg 29

<210> 51
<211> 29
<212> DNA
<213> Artificial Sequence

<220>
<223> oligonucleotide

<220>
<221> misc_feature
<222> (2)
<223> biotinylated phosphoamidite residue

<400> 51
tncaagttga gttgtacaga agcccaaga 29

<210> 52
<211> 29
<212> DNA
<213> Artificial Sequence

<220>
<223> oligonucleotide

<220>
<221> misc_feature
<222> (2)
<223> biotinylated phosphoamidite residue

<400> 52
gntgtgagaa gaccactcgg tgatgacct 29

<210> 53
<211> 29
<212> DNA
<213> Artificial Sequence

<220>
<223> oligonucleotide

<220>
<221> misc_feature
<222> (2)

<223> biotinylated phosphoamidite residue

<400> 53

tngagtctgg gtggtagaca aatcatgca

29

<210> 54

<211> 29

<212> DNA

<213> Artificial Sequence

<220>

<223> oligonucleotide

<220>

<221> misc_feature

<222> (2)

<223> biotinylated phosphoamidite residue

<400> 54

anggacggta tatatcacca tgaacaagt

29

<210> 55

<211> 29

<212> DNA

<213> Artificial Sequence

<220>

<223> oligonucleotide

<220>

<221> misc_feature

<222> (2)

<223> biotinylated phosphoamidite residue

<400> 55

anaggcagga ggagacggga ttgatggtt

29

<210> 56

<211> 29

<212> DNA

<213> Artificial Sequence

<220>

<223> oligonucleotide

<220>

<221> misc_feature

<222> (2)

<223> biotinylated phosphoamidite residue

<400> 56

anaagcgtca tgcagagcca tgatgaggg

29

<210> 57

<211> 29

<212> DNA

<213> Artificial Sequence

<220>

<223> oligonucleotide

<220>
<221> misc_feature
<222> (2)
<223> biotinylated phosphoaramidite residue

<400> 57
anaaatgtag caggcttggc ttgcagcag 29

<210> 58
<211> 29
<212> DNA
<213> Artificial Sequence

<220>
<223> oligonucleotide

<220>
<221> misc_feature
<222> (2)
<223> biotinylated phosphoaramidite residue

<400> 58
angacccatt tccagtccaa atctttgac 29

<210> 59
<211> 28
<212> DNA
<213> Artificial Sequence

<220>
<223> oligonucleotide

<220>
<221> misc_feature
<222> (2)
<223> biotinylated phosphoaramidite residue

<400> 59
gncaagggt ctgttaggaga aactatat 28

<210> 60
<211> 29
<212> DNA
<213> Artificial Sequence

<220>
<223> oligonucleotide

<220>
<221> misc_feature
<222> (2)
<223> biotinylated phosphoaramidite residue

<400> 60
anccagggt atacagagaaa accctgtct 29

<210> 61
<211> 29
<212> DNA

<213> Artificial Sequence

<220>

<223> oligonucleotide

<220>

<221> misc_feature

<222> (2)

<223> biotinylated phosphoaramidite residue

<400> 61

gntcttgaag aagttagccca gggtgaggga

29

<210> 62

<211> 29

<212> DNA

<213> Artificial Sequence

<220>

<223> oligonucleotide

<220>

<221> misc_feature

<222> (2)

<223> biotinylated phosphoaramidite residue

<400> 62

cnggtaaagg tgatgttgac actgttagga

29

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US98/24614

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) :Please See Extra Sheet.
US CL :Please See Extra Sheet.

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : US 530/300, 350; 536/23.1, 23.5; 435/69.1, 320.1, 325, 252.3, 254.11; 512/2, 12

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

APS, WPIDS

search terms: kenneth jabocs, aj26?

C. DOCUMENTS CONSIDERED TO BE RELEVANT

| Category* | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|-----------|---|-----------------------|
| X,P | US 5,708,157 A (JACOBS et al.) 13 January 1998, especially claims. | 1-11 |
| X | Database GenBank, National Library of Medicine, Bethesda, Maryland USA. MARRA et al. Accession Number AA497966, 'vi69e01.rl Stratagene mouse testis (#937308) Mus musculus cDNA clone 917496 5' similar to TR:G1297304 G1297304 CTX', 01 July 1997. | 1-3 |
| X | EP 0 606 734 A1 (FOLDES ROBERT L.) 20 July 1994, especially Figure 1, page 10, lines 1-4 and 27-30, and page 11, lines 3-9 and 34-37. | 1-7, 10-11 |
| A | JACOBS et al. A genetic selection for isolating cDNAs encoding secreted proteins. Gene. 01 October 1997, Vol. 198, pages 289-296, entire document. | 1-12 |

Further documents are listed in the continuation of Box C.

See patent family annex.

| | | |
|---|-----|--|
| * Special categories of cited documents: | "T" | later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention |
| "A" document defining the general state of the art which is not considered to be of particular relevance | "X" | document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone |
| "E" earlier document published on or after the international filing date | "Y" | document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art |
| "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) | "&" | document member of the same patent family |
| "O" document referring to an oral disclosure, use, exhibition or other means | | |
| "P" document published prior to the international filing date but later than the priority date claimed | | |

Date of the actual completion of the international search

05 FEBRUARY 1999

Date of mailing of the international search report

25 FEB 1999

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Faxsimile No. (703) 305-3230

Authorized officer

CLAIRES M. KAUFMAN

Telephone No. (703) 308-0196

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US98/24614

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:

2. Claims Nos.: because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

Please See Extra Sheet.

1. As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:

4. No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.: 1 - 12

Remark on Protest

The additional search fees were accompanied by the applicant's protest.

No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

In. national application No.
PCT/US98/24614

A. CLASSIFICATION OF SUBJECT MATTER:
IPC (6):

C07K 14/47, 14/00, 7/00; C12N 5/10, 15/10, 15/11, 15/12, 15/63; A61K 38/00

A. CLASSIFICATION OF SUBJECT MATTER:
US CL :

US 530/300, 350; 536/23.1, 23.5; 435/69.1, 320.1, 325, 252.3, 254.11; 512/2, 12

BOX II. OBSERVATIONS WHERE UNITY OF INVENTION WAS LACKING

This ISA found multiple inventions as follows:

This application contains the following inventions or groups of inventions which are not so linked as to form a single inventive concept under PCT Rule 13.1.

Group I, claim(s) 1-12, drawn to polynucleotide of clone AJ26_3, protein, method of making the protein, method comprising administration of the protein, and gene.

Group II, claim(s) 13-15, drawn to polynucleotide of clone AJ172_2, protein and gene.

Group III, claim(s) 16-18, drawn to polynucleotide of clone AP224_2, protein and gene.

Group IV, claim(s) 19-21, drawn to polynucleotide of clone BL89_13, protein and gene.

Group V, claim(s) 22-24, drawn to polynucleotide of clone BL341_4, protein and gene.

Group VI, claim(s) 25-27, drawn to polynucleotide of clone BV239_3, protein and gene.

Group VII, claim(s) 28-30, drawn to polynucleotide of clone CC25_17, protein and gene.

Group VIII, claim(s) 31-33, drawn to polynucleotide of clone CC397_19, protein and gene.

Group IX, claim(s) 34-36, drawn to polynucleotide of clone D305_2, protein and gene.

Group X, claim(s) 37-39, drawn to polynucleotide of clone G55_1, protein and gene.

Group XI, claim(s) 40-42, drawn to polynucleotide of clone K39_7, protein and gene.

Group XII, claim(s) 43-45, drawn to polynucleotide of clone K330_3, protein and gene.

Group XIII, claim(s) 46-48, drawn to polynucleotide of clone K363_3, protein and gene.

Group XIV, claim(s) 49-51, drawn to polynucleotide of clone K446_3, protein and gene.

Group XV, claim(s) 52-54, drawn to polynucleotide of clone K464_4, protein and gene.

Group XVI, claim(s) 55-57, drawn to polynucleotide of clone K483_1, protein and gene.

Group XVII, claim(s) 58-60, drawn to polynucleotide of clone KL69_3, protein and gene.

The inventions listed as Groups I-XVI do not relate to a single inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: the main invention in the instant application comprises the first-recited product and the method of using the product, as well as products produced by the method and method of using the products. Further, pursuant to 37 CFR 1.475(b)-(d), the ISA/US considers that each group is drawn to a different polynucleotide and related protein and gene, so the groups lack the same or corresponding special technical feature within the meaning of PCT Rule 13.2, and thus do not relate to a single general inventive concept within the meaning of PCT Rule 13.1.